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Chemotherapeutics are potent molecules capable of systematically treating cancer. As healthy 
tissues contain features also inherent to cancer cells, treatment often results in unwanted side-
effect. As chemotherapeutic side-effect produces significant harm and often limits optimal drug 
dosing, new strategies must be developed to improve treatment selectivity. A prodrug strategy 
provides one option to improve the selectivity of an established chemotherapeutic. By 
modifying a pharmaceutically active drug, interaction with biology may be functionally masked. 
Subsequent ‘un-masking’ the prodrug exclusively at the intended treatment site may direct 
treatment only to where the anticancer effect is required.  
 
This thesis progresses the novel approach of bioorthogonal organometallic (BOOM) prodrug 
activation. A metal catalyst and masked chemotherapeutic constitute reaction partners to 
provide a new strategy for intratumoural prodrug activation. Whereby the prodrug and metal 
catalyst are independently non-cytotoxic, in combination the prodrug undergoes catalytic 
activation to deliver an anticancer affect. By positioning the metal catalyst within a tumour (i.e. 
by microsurgery), an administered masked prodrug sensitive to catalyst-mediated activation 
could allow for ‘targeted’ chemotherapy localised to the tumour site.  
 
The design, synthesis and study of new BOOM prodrug candidates are reported herein. Novel 
protecting groups are developed to enhance drug masking to biology and subsequent catalyst-
mediated activation. Prodrug screening studies are carried out in cancer cell culture models, 
with zebrafish and in ex vivo rodent model tumour explants. The catalyst, a palladium (Pd0) 
functionalised bead system, is optimised for enhanced activation, drug release and in vivo 
implantation. The potentially infinite generation of active chemotherapeutics exclusively in 
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Improving methods for the study and modification of biomolecules in their native environment 
is a key frontier in chemical biology. Genetic engineering and bioconjugation has allowed for 
key advances in the understanding of biology and the development of new medicines. In this 
introductory chapter the caveats of classical biochemical methodologies will be briefly explored. 
Bioorthogonal chemistry strategies will be examined that may solve such caveats. New ways 
to form and break covalent bonds orthogonal to living systems will also be described.  
 
1.1 The Bioorthogonal Chemistry Horizon 
By utilising synthetic gene reporting systems that express modified variants of a molecule of 
interest, the expression and localisation of specific proteins in vitro1 and in vivo2 is now a 
standard technique in biological sciences. Synthetic gene reporting was established by the 
discovery and characterisation of green fluorescent protein (GFP), now a commercialised 
fluorescent probe. GFP is a protein composed of 238 amino acid residues first isolated from 
the jellyfish Aequorea victoria3, and is recognised as a key reagent for the native study of 
biomolecules4. By attaching a GFP genetic sequence to a regulatory gene of interest, co-
expression of GFP bound to a target protein allows for protein tracking and quantitative protein 
expression in a living system. Significant limitations exist however in utilising GFP proteins to 
study biomolecules in living systems. As the function of GFP is dependent upon its co-
expression with a gene of interest, GFP and variants are unable to study biomolecules not 
encoded for by DNA. This precludes GFP based studies on lipids, nucleic acids, glycans and 
metabolites within the cell (fig 1.1).  
 
Although sequence optimisation has expanded the repertoire of fluorescent protein tags to 
include emission wavelengths across the entire visible spectrum5, other imaging modalities 
are still inaccessible. Perhaps most importantly, the structural perturbation imposed by 
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genetically engineering a large synthetic protein to covalently bond to its target alters the native 
function of the molecule of interest.  
 
Another established method to study living systems is to covalently couple molecules of 
interest to target native amino acids through key functional groups. This is a process known 
as bioconjugation. Unlike GFP based strategies, a diverse range of small molecules may be 
synthetically coupled to a target, including fluorescent dyes, biotin and polymers, drug 
conjugates, nanoparticles and surfaces6,7. Traditional bioconjugation reactions rely on 
chemistry specific to functional groups present on native amino acid residues. Frequently, 
targeted functional groups for bioconjugation include the N- and C- end termini and the R 
groups of lysine, cysteine, tyrosine and tryptophan. Whilst this methodology expands the 
position and number of sites available for protein modification, these key functional groups are 
ubiquitous to biology, and off target modification is inevitable (fig 1.1).  
 
 
Figure 1.1 Conventional methods for studying biomolecules in native environments. 
Target proteins may be studied by synthetically modifying the gene sequence of a target 
protein to include a gene encoding green fluorescent protein (GFP). GFP imposes structural 
perturbation, is only visualised by fluorescence microscopy and is not applicable to 
biomolecules that are not genetically encoded for. Target biomolecules (including proteins, 
lipids, glycans and DNA) may be studied by traditional bioconjugation reactions, where probes 
are attached to functional groups on native amino acids. Chemoselectivity to the target amino 
acid hinders the specificity of this approach. Image adapted from open source database 




Chemoselectivity remains an intractable limitation on the efficiency of native residue based 
covalent bonding strategies, and biology imposes complex demands on target specificity. 
Perturbational and chemoselective disadvantages in genetic engineering and bioconjugation 
have led to new methods that increase the scope of biomolecule investigation with retained 
control of target specificity and reduced effect on the surrounding environment. Covalent 
bonding chemistry conducted ‘orthogonal’ to a living system was initially validated with 
bespoke chemical strategies capable of bond ligation in situ10–12. Tsien and colleagues first 
reported the development of a dye that would fluoresce in vitro when attached to cysteine rich 
positions of a recombinant protein by rapid covalent bond formation between an organoarsenic 
group and a di-thiol10. This strategy was validated in living cells by labelling expressed proteins 
containing a CCXXCC motif (fig 1.2). For the first time selective reversible fluorescence in a 
living system was possible with the use of a small molecule reporter. Shortly after, Bertozzi 
described the use of a biocompatible Staudinger ligation on the surface of live cells11. This 





Figure 1.2 Fluorescent labelling of a specific recombinant protein molecule in live cells. 
One step synthesis of 4’,5’-bis(1,3,2-dithioarsolan-2-yl)fluorescein (FLASH) followed by 
FLASH fluorescent labelling of a recombinant protein containing four cysteines at the i, i+1, 
i+4, and i+5 positions of an α helix (core motif CCXXCC) in living cells. Image reprinted and 
adapted with permission from reference10, copyright (1998), Science. 
 
Formally, bioorthogonal chemistry describes the subset of synthetic chemical reactions 
between chemospecific partners occurring in a biological environment without perturbation. 
The reaction must form (ligate) or break (cleave) stable covalent bond(s) between bioinert 
functional groups at physiological pH and temperature, with sufficient kinetic rate that the 
product is formed rapidly, even when reactants are present in low concentration.  
 
Although the term for bioorthogonal chemistry was formally coined in 200311, the first truly 
biorthogonal ligation reaction proceeded it’s definition. In 1986 Rideout and colleagues 
demonstrated that two biologically inert molecular building blocks (an aldehyde and a 
hydrazine) were capable of self-assembling into cytotoxic hydrazones in vitro by hydrazone 
condensation12. Later, Bertozzi delivered seminal work on the use of a Staudinger ligation 
between a biotin conjugated phosphine and a cell surface bound azido sialic acid to produce 





Figure 1.3 Staudinger Azide Ligation on cell surface. Bioorthogonal ligation reaction 
between a water-soluble biotinylated phosphine and a cell surface covalently bound azido 
sialic acid. The azido sialic acid was introduced onto a glycosylated protein (purple, green) on 
cellular surfaces (orange) by incubating Jurkat cells with N-azidoacetylmannosamine. Water-
soluble biotinylated phosphine was added, and biotinylation was monitored by flow cytometry. 
Reprinted and adapted with permission from reference13, copyright (2000) Science. 
 
A range of ligation reactions have since developed to meet the strict definition of bioorthogonal 
chemistry (fig 1.4). Looking to overcome slow kinetics associated with Staudinger ligation 
chemistry, a Copper(Cu)(I)-catalyzed azide alkyne cycloaddition (CuAAC) ‘click reaction’ with 
fast reaction kinetics and non-toxic reaction partners was reported14,15. Cu(I) catalysts are 
limited however by cytotoxicity, and the reaction rate drops considerably when catalyst 
concentration is decreased. Three concerted strategies have been able to overcome this. First, 
libraries of Cu(I) stabilizing ligands have reduced cytotoxicity whilst boosting reactivity in living 
systems16. Second, different metal catalysts such as Palladium (Pd) and Ruthenium (Ru) and 
their associated ligands have been designed for bioorthogonal cross coupling and olefin 
metathesis reactions respectively17. Third, innovative ‘metal-free’ versions of click chemistry 
have made significant progress beyond CuAAC. The strain-promoted azide-alkyne 
cycloaddition (SPAAC)18 and inverse electron-demand Diels-Alder (IED-DA)19 reactions 
display superior biocompatibility and comparative reaction kinetics to metal catalysed 
equivalents. The field of bioorthogonal ligation has rapidly grown to include a diverse range of 
strategies including exotic strained, cyclic and ‘traceless’ (producing only gaseous by-products 





Figure 1.4 Bioorthogonal ligation reactions. A representative collection of three widely used 
bioorthogonal ligation strategies that have been developed over the last few decades including 
(i) prototypical Staudinger ligation; Metal-triggered (ii) copper-mediated azide-alkyne 
cycloaddition (CuAAC), (iii) palladium-mediated Suzuki cross-coupling, (iv) ruthenium-
mediated olefin metathesis; and Strain promoted (v) azide-alkyne cycloaddition (SPAAC) 
and (vi) inverse electron-demand Diels-Alder reaction (IED-DA).  
 
1.2 Bioorthogonal Cleavage Reactions in Biological Systems 
Just as biorthogonal ligation was developed to overcome challenges in bioconjugation, 
biorthogonal cleavage reactions were conceived to improve molecular decaging reactions in 
living systems. Photo-decaging (or photo-deprotection) describes the selective cleavage of 
bioinert, Ultra Violet (UV)-sensitive functional groups by UV irradiation in biological systems. 
The o-nitrobenzylic derivative is a widely used photo-decaging group readily cleaved when 
irradiated by UV light. Time resolved spectroscopy has revealed that upon irradiation, 
hydrogen transfer from the o-alkyl substituent to the nitro group results in an aci-nitro tautomer 
in the ground state20,21. If a leaving group is attached at the benzylic position, aci-nitro 
intermediates will readily release the leaving group during flash photolysis. Originally 
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developed as a tool for organic synthesis22, o-nitrobenzylic variants were first repurposed to 
‘cage’ and release Adenosine Triphosphate (ATP) selectively in human red blood cells by 
Kaplan in 197823 (fig 1.5). The o-nitrobenzylic group remains a popular photo-decaging moiety. 
 
 
Figure 1.5 Prototype bioorthogonal cleavage: photolytic release of ATP in a human red 
blood cell. 2-nitrobenzyl phosphate and 1-(2-nitro)phenylethyl phosphate were attached to 
the terminal phosphate of adenosine 5-triphosphate. The ‘caged-ATP’ product was 
incorporated into resealed human red blood cells starved of ATP. Whilst the caged-ATP was 
unable to activate an ATP dependant Na:K pump, photolysis at 340 nm for 30 s liberated ATP 
to activate the pump. This figure illustrates the original strategy proposed by Kaplan et al. 
Biochemistry (1978)23. 
 
As a bond cleavage strategy, photo-decaging has a number of practical limitations for use in 
living systems. Nitrobenzylic caged compounds are readily metabolized by nitroreductases, 
an enzyme class conserved across mammalian and bacterial cells24,25. Whilst UV-triggered 
reactions are high yielding and rapid in controlled environments, sophisticated instrumentation 
limits the ability to develop high throughput or clinically relevant photo-decaging methodologies. 
Furthermore UV light has low penetrance and both the method of irradiation and the formation 
of nitrobenzylic by-products is perturbing to biology. 
 
Seeking to overcome these problems, scientists have looked to small molecule reaction 
partners capable of controlled non-perturbing covalent bond cleavage in the living system. 
Taking photo-induced decaging as the prototype reaction, a number of small molecule 
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deprotection strategies have been advanced around freeing hydroxy and amine functional 
groups (fig 1.8).  
 
As with bioorthogonal ligation chemistry, metal catalysts were first investigated to break 
chemical bonds in accordance with the stringent requirements imposed by bioorthogonal 
chemistry. Conceptually, metal based de-caging strategies pair tolerated metal catalyst 
species with protecting groups that are biologically inert and selectively cleavable with fast 
kinetics in homeostatic conditions. Allyloxycarbonyl (Alloc) and propargyloxycarbonyl (Poc) 
are standard protecting groups that are readily cleaved by a range of metal catalysts in peptide 
synthesis26–28. Furthermore, bioorthogonal ligation reactions regularly utilize both Alloc and 
Poc reaction handles, further evidence of their stability to enzymatic processing. 
 
Encouraged by evidence that a Ru catalyst was capable of catalysing the allylation of thiols29, 
a water soluble, cell permeating ‘half-sandwich’ type chelated Ru complex was reported to 
release amines from allylcarbamates under biocompatible conditions in cell culture30. Later, 
by modifying ligand design a new Ru catalyst emerged, capable of deprotecting 
allyloxycarbonyl bearing fluorescent probes and prodrugs with dramatically improved reactivity 
and reduced toxicity31. This proof of concept led to further investigation surrounding ligand 
design as a key factor for the performance and stability of bioorthogonal metal catalysts. 
 
Shortly after, a Pd0 catalyst was reported as being capable of deprotecting O-allyl carbamate 
protected fluorescein in vivo32. A separate heterogeneous Pd0 catalyst capable of metal 





Figure 1.6 Synthesis of Pd0 microspheres. Amino-functionalized polystyrene resin 
microspheres were treated with Pd(Oac)2. Coordinated Pd2+ was subsequently trapped by 
crosslinking with the bis acid chloride of racemic Fmoc-glutamic acid (generated in situ). 
Hydrazine was used to reduce Pd2+ to Pd0. Labelling of the Pd0 microspheres was carried out 
by deprotection of the Fmoc group and subsequent treatment with an activated dye under 
basic conditions. Reprinted with permission from reference33, copyright (2011), Nature 
Publishing Group. 
 
By internalizing Pd0 nanoparticles onto a solid support, the investigators reasoned that an 
‘artificial organelle’ type catalyst could permeate target cells and preferentially accumulate a 
product within the cellular cytoplasm. The solid support would prevent Pd0 nanoparticles from 
leaking into the surrounding environment by enhanced Pd0 ligand stability. Following this, 
extracellular Pd functionalized devices were developed as implantable devices to deprotect 
prodrugs and probes in cell culture and in vivo34.  
 
More recently still, ‘metal-free’ catalysts capable of bioorthogonal cleavage without the 
presence of a metal have been investigated. Initially utilized for bond ligation, the inverse 
electron demand – Diels Alder (IED-DA) reaction product between a trans-cyclooct-2-ene 
(TCO) and a tetrazine was observed to readily undergo cycloaddition and tautomerisation to 
form a 1-4,dihydropyridazine product19. Evidence suggests that the 1-4,dihydropyridazine 
intermediate can further undergo base-promoted deprotonation with subsequent elimination 
of the carbamate group via pyridazine formation35. This observation lead to the development 
of a modified TCO bearing a carbamate-linked drug at the 2 position of the cyclooctene ring36 





Figure 1.7 Tetrazine ligation to release drugs in living systems. Proposed IED-DA 
cycloaddition reaction between a strained trans-cyclooctene (TCO) and tetrazine releases N2, 
resulting in a 4,5-dihydropyridazine intermediate that re-arranges through double bond shift, 
releases a leaving group at the vinylic position (in this case a carbamate), liberates an NH2 
bearing drug, CO2 and 3-hydropyridazine which rearranges to the pyridazine byproduct. 
Reprinted and adapted with permission from reference36, copyright (2013), Wiley-VCH Verlag 
GmbH & Co. 
 
This modified IED-DA reaction, termed ‘click and release’, has been employed to release a 
TCO carbamate linked drug from an anti-tumour antibody drug conjugate (ADC) in vitro by 
simply adding tetrazine36. By replacing tetrazine with an aryl azide, the unstable cycloaddition 
product formed rapidly breaks down to an imine upon nitrogen release, which then hydrolyses 
to the aryl amine product. This strategy has selectively released an active compound in vitro37. 
As with bioorthogonal ligation partners, a range of cleavage reaction partners now exist. Bond 
breakage, including with metallic catalysts, non-metallic strained cyclic partners and traceless 





Figure 1.8 Bioorthogonal cleavage reactions to release amines. A representative 
collection of three widely used bioorthogonal cleavage strategies that have been developed 
over the last few decades to release amines, including (i) prototypical Photo-induced 
cleavage; Metal-triggered (ii) Copper(I)-induced removal of tertiary propargyl group, (iii) 
Ruthenium-induced deallylation, (iv) Palladium nanoparticle (PdNP)-induced depropargylation; 
and Non metal-triggered (v) IED-DA-induced ‘click and release’, (vi) strain-promoted trans-
cyclooctene (TCO)-azide cycloaddition, also capable of releasing an R-NH2 group at the TCO 
vinylic position (see fig 1.7), and (vii) the Staudinger reaction. 
 
Bioorthogonal cleavage reactions are increasingly relevant for new targeting methods in 
medicine. The development of drugs and their excipient formulations has historically focused 
on modulating absorption, distribution, metabolism and excretion (ADME) properties to 
improve efficacy. Bioorthogonal cleavage reactions offer the added potential to modulate the 
activity of a drug proximal to its intended target by spatio-temporal control of molecule release 
in living systems. Much research in this field focuses on developing technologies capable of 





1.3 Cancer Therapy 
Cancer is an amalgamation of diseases defined by specific neoplastic properties; namely self-
sufficient growth, insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis38. Prior to 1950, excision surgery was the only viable method of 
treatment routinely available to cancer patients. Radiation therapy alone or as an adjuvant 
became available in the 1960’s, however neither surgery nor radiation was capable of treating 
metastasis, the primary cause of relapse, progression and death.  
 
Since the discovery of nitrogen mustards and antifolate drugs in the 1940’s, traditional 
chemotherapeutic agents have also developed as a mainstay in cancer treatment. 
Chemotherapy describes the various small molecules, biologics and immune-mediated 
therapies developed over the last 75 years to systemically treat the disease, where an 
administered therapeutic is carried by the bloodstream to act on cancer tissue irrespective of 
its position in the body. Treatments seek to exploit empirical and molecular pathway 
differences between healthy and malignant tissue to hinder cell neoplasticity; alone or in 
combination; as the first line of defence or in an adjuvant setting. 
 
The first evidence that systemic drug administration could cause tumour regression was 
demonstrated by the use of nitrogen mustard on non-Hodgkin’s lymphoma in the 1940s39. By 
studying the molecular mechanism of action, the same investigators deduced that nitrogen 





Figure 1.9 Schematic of DNA alkylating agents. Nitrogen mustard agents adduct to DNA 
through nucleophilic attack of the strained iminium ring system by Guanine. Resulting mono 
and di-alkylation (crosslinked) adduct to DNA triggers apoptosis. Figure reprinted and adapted 
with permission from reference40, copyright (2002) Nature Publishing Group. 
 
For the first time small molecules were shown to preferentially induce apoptosis in cancer cells 
over healthy cells by leveraging fundamental differences in tumour cell biology. Nitrogen 
mustards such as cyclophosphamide and chlorambucil are still routinely used to treat various 
tumours in combination with other therapeutics. Despite widespread use, cyclophosphamide 
alkylates DNA in healthy tissue, inducing severe side-effect to patients at therapeutically 
relevant doses. Cyclophosphamide induced side effects significantly increases the risk of 
treatment attributed patient death, limiting the maximum efficacious dosage41,42. 
 
A separate study during the same period correlated folic acid administration with cancer cell 
stimulation in acute lymphoblastic leukaemia (ALL) patients. This led to the development of 
the ‘antifolate’ class of chemotherapeutics; folate analogues capable of blocking enzymes that 
drive ALL proliferation. One such antifolate, methotrexate was observed to induce short 
periods of remission in patients, a key step that linked cancer progression in patients with the 
ability to disrupt critical proliferative pathways in cancer cells. Methotrexate reduces the level 
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of folate available to proliferating cells by competing with dihydrofolate at the active site of 
Dihydrofolate Reductase (DHFR)43 (fig 1.10). Competitive inhibition of DHFR prevents the 
reduction of dihydrofolate to tetrahydrofolate44. Tetrahydrofolate is required as a co-factor for 
the enzyme Thymidine Synthase (TS) to methylate uracil to thymine, a key DNA building block 
in dividing cells45. By disrupting the conversion of uracil to thymine in rapidly dividing cell 
populations, growing DNA chains fragment after erroneous incorporation of uracil in the 
absence of thymine. DNA fragmentation then drives cellular apoptosis46. Currently, high dose 
methotrexate regimens in combination with toxicity limiting adjuncts treat a wide range of 




Figure 1.10 Dihydrofolate Reductase (DHFR) complexed with methotrexate. 
Methotrexate binds tightly to DHFR by mimicking the structure of folate. Key DHFR residues 
involved include pi-stacking between aromatic rings in methotrexate and Phe 31, Phe 34 as 
well as hydrogen bonding donation to Glu 30, Ile 60, Asn 64, Gln 35 and Arg 70. Figure 
reprinted from open source database Proteopedia (2011). 
 
All chemotherapeutic agents exhibit side-effect by virtue of non-tumour specific activity. An 
entire field of medicine has been developed for treating chemotherapeutic derived toxicity, with 
many adjuncts administered alongside conventional chemotherapeutics to mitigate toxicity 
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burden to the patient. Chemotherapeutic side-effect has driven investigation of new classes of 
molecules capable of specifically targeting tumour cells.  
 
Tumour cell biology understanding has advanced rapidly over the last 30 years. Key 
developments have elucidated cellular signalling networks underpinned by genetic and 
molecular differences between healthy and cancerous tissue. Some cancers have been 
stratified into specific disease subsets based on aberrant signalling pathways48–51, prompting 
concerted efforts to develop ‘targeted therapies’ capable of repairing or blocking specific 
molecular aberrations. Tractable (treatable) molecular targets now include cell growth and 
repair factors, proliferation drivers, cell-cycle modulators and cell surface receptors. Key 
chemotherapeutic targeting therapies approaches include small molecule kinase inhibitors 
and immunotherapy. Each will be briefly detailed. 
 
1.4 Small Molecule Kinase Inhibitors  
The search for small molecule kinase inhibitors began in the early 1990s. Large combinatorial 
chemistry libraries underwent in vitro screens against cancer cell lines with known point 
mutations. Small molecule kinase inhibitors promised to turn cancer into a treatable chronic 
condition; eliminating cancer cells by binding with high affinity to aberrant kinases present in 
cancer tissue only. This would drive cancer cell specific apoptosis whilst reducing the off target 
toxicity burden associated with chemotherapy. Imatinib and Gefitinb are two landmark 
examples notable for their success in the clinic. 
 
Imatinib is an inhibitor of BCR-ABL1 kinase. When the two independent genes Breakpoint 
Cluster Region (BCR) and Abelson murine leukaemia viral oncogene homolog 1 (ABL1) are 
erroneously fused during chromosomal translocation, the gene forms a protein product, BCR-
ABL1 that drives cancer proliferation. As well as inhibiting BCR-ABL1, Imatinib also inhibits 
platelet-derived growth factor receptors (PDGFRs) and tyrosine-protein kinase Kit (KIT) 
proteins. PDGFR and KIT are also responsible for driving tumour proliferation in chronic 
myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST) patients52. Potent, orally 
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available and metabolically stable, Imatinib has achieved high remission rates amongst 
subsets of the CML patient population53,54. Whereas BCR-ABL1 fusion proteins are expressed 
uniquely in cancer cells, BCR, ABL, KIT and PDGFR are also independently expressed in 
normal cells where they modulate vascularization, typical injury and stress response pathways 
in healthy cardiac tissue55,56. As a result, cardiotoxicity is commonly observed in Imatinib 
treated patients57. Furthermore, approximately one in three patients will develop hematologic 
and cytogenetic resistance, rendering Imatinib ineffective within those patient subsets after 
initial treatment58. 
 
Gefitinib is an ATP binding site competitive inhibitor to epidermal growth factor receptor 
(EGFR). EGFR is a kinase that mediates cancer cell growth, proliferation, apoptosis invasion 
and metastasis59. EGFR over-expression is routinely detected in non-small cell lung cancer 
(NSCLC) resected primary tumours by immuno-histochemistry60 and mRNA analysis61, and a 
clear correlation exists between overexpression of EGFR and NSCLC progression62. By 
inhibiting EGFR, Gefitinib provides partial remission to roughly 10 % of NSCLC patients, 




Figure 1.11 Effect of Gefitinib on the epidermal growth factor receptor (EGFR) signalling 
pathway. Ligand binding to EGFR extracellular domain triggers formation of homo- or 
heterodimeric complexes with HER family, causing autophosphorylation at the tyrosine (pY) 
residue. This leads to activation cascades across numerous cell signalling pathways. Two key 
pathways are shown. (Yellow boxes) GRB2 and SOS recruitment activates small G-proteins 
RAS and RAF, then MEK and MAPK. (Brown boxes) pY also activates PI3K and AKT which 
is the signal transducer and activator of STAT. Signal transduction to the nucleus in both 
pathways activates gene transcription factors MYC, JUN, FOS and Cyclin D1, inducing cancer 
proliferation pathways (blue boxes). Gefitinib inhibits the interaction between pY and the 
tyrosine kinase binding domain of EGFR, inhibiting EGFR and signal transduction. Figure 
reprinted with permission from reference63, copyright (2004) Nature Publishing Group.  
 
The unique clinical success of Imatinib, Gefitinib and others, coupled with improvements in 
genetic testing has markedly increased efforts to develop precision medicines over the last 20 
years. As a result, a number of targeted therapeutics have been developed over the last 
decade to match with validated biological targets deemed crucial to tumour growth and 
metastasis. Despite this, accumulated evidence is beginning to push back on the assumption 
that targeted medicines will drive remission rates for many other indications as is observed in 
CML64. The survival and growth of heterogeneous cancer cell populations in different tissues 
may not be wholly contingent on the activity of a single molecular pathway. Targeted 




Recent empirical evidence from clinical trials matching precision medicine with traditional 
therapies has provided data to affirm this. The SHIVA trial65 found that assigning treatment 
according to molecular profiling did not improve outcome, and conversely those administered 
targeting agents recorded more grade three-four adverse events. Another recent trial could 
only pair 6.4 % of 2,600 patients with a targeted therapy based on identifiable mutations66. A 
third could only pair 2.5 % of relapsed solid tumour and lymphoma patients with a targeted 
therapy67. Incidents of ‘super-responders’ continue to fuel enthusiasm about the potential of 
targeted therapeutics, and though individual cases are meaningful, these are rare events 
typically confined to very small patient subsets. Basic drug resistance pathways and toxicity 
induced side effects still drive the pursuit of enhanced treatment options.  
 
1.5 Immunotherapy 
Immunotherapy describes manipulation of the immune system to favour cell polarization states 
capable of eliciting a strong anticancer effect. The immune mediated anticancer effect is 
utilized by targeting specific surface antigens that trigger cancer cell death or killing. This effect 
was uncovered over a century ago in the 1890s68. By injecting patient tumours with dead 
bacterial cultures, Coley’s toxin was capable of triggering a remarkable immune response that 
drove remission in sarcoma patients. The immunological effect caused by Coley’s toxin is now 
mechanistically well understood. 
 
Tumour-infiltrating leukocytes (including neutrophils, macrophages, T and B cells and Natural 
Killer (NK) cells) are first recruited to the site of injection. Bacterial cell surface antigens engage 
with and prime CD4+ and CD8+ T cells within the tumour69 to drive inflammatory interleukin 
production70, induce clonal T cell expansion and activate B cells71. This ultimately stimulates 
leukocyte mediated tumour cell targeting and elimination. This cascade of immune cell 
recruitment and activation still underpins the function of immuno-oncology drugs that harness 
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the immune-system to recognise, infiltrate and eliminate tumours. Recent treatment strategies, 
including the development of Chimeric Antigen Receptor-T cell (CAR-T) therapies and immune 
checkpoint inhibitors have reported high remission rates in previously relapsed treatment 
resistant indications72.  
 
 
Figure 1.12 Treatment of patients with B-cell malignancies using anti-CD19 CAR-T cells. 
Patients with relapsed/refractory B-cell malignancies that express the CD19 cell-surface 
protein may be treated with anti-CD19 CAR-T therapy. Patient derived T cells are isolated to 
undergo adoptively transferred autologous genetic engineering by a retroviral anti-CD19 CAR 
vector. Engineered T cells are then infused back into the patient alongside chemotherapy to 
induce an immune mediated anti-CD19 cellular response. Figure reprinted with permission 
from reference73, copyright (2014) Nature Publishing Group. 
 
Now showing efficacy in some solid tumours, immunotherapy is positioned as the preeminent 
strategy for targeted cancer treatment. Despite new approvals for monoclonal antibodies in 
2016, immunotherapy still faces significant hurdles. Reduced efficacy in low-immunogenic 
cancers74 and tissues that cannot be targeted by immunotherapy (i.e. the brain), immune 
dependant side effects75 and induced autoimmunity76 restrict the relevance of immunotherapy 
to certain indications. Coupled with the high costs of manufacture and typically exorbitant 
prices of treatment, new ground breaking treatments in immunotherapy may only be applicable 





Whereby targeted therapeutics are limited to small patient subsets, prodrug therapies leverage 
the demonstrated efficacy of already established chemotherapeutics. Prodrugs are derivatives 
of active drugs designed for selective activation. Activation may be via irradiative, enzymatic, 
or chemical action after prodrug administration, allowing for accumulation of the active drug at 
the site of interest. By careful selection of the masking group; enhanced adsorption, 
distribution, metabolism and excretion (ADME) properties of the prodrug may simultaneously 
improve physiochemical and pharmacokinetic properties of the parent drug alongside 
improved activity at the site of interest77. Thus a clear rationale exists for the use of prodrug 
therapy in cancer treatment. 
 
Directed enzyme prodrug therapy (DEPT) first localizes an exogenous enzyme to the tumour 
site. Next a prodrug is administered where it is ‘un-masked’ in the presence of that exogenous 
enzyme or its products. Enzymatic prodrug activation requires that the exogenous enzyme is 
sufficiently accumulated only in tumour tissue to ensure high levels of selective drug activity. 
Genetic (GDEPT), viral-vector (VDEPT)78, and antibody (ADEPT)79 approaches (fig 1.13) have 





Figure 1.13 Overview of Directed Enzyme Prodrug Therapy (DEPT). ADEPT relies on the 
introduction and antibody directed localisation of exogenous enzymes to the target tissue to 
catalyse the activation of prodrugs to drugs in intra- or intercellular space. VDEPT and GDEPT 
introduces a synthetic gene into the target tissue which may directly encode a toxic protein, or 
an enzyme capable of activating a prodrug to a drug. 
 
DEPT technology is intrinsically restricted by the effectiveness of exogenous enzymes to 
activate the prodrug80. This is a common limitation encountered by activation strategies that 
rely on enzymes for efficacy. As therapeutic advances continue to drive the search for safer, 
more efficacious treatments, new methodologies emerge as promising ways to control the 
release of cytotoxins in cancerous tissues. 
 
1.7 BOOM Chemistry - Development and Current Advances  
In 2011, Yusop et al described the development of heterogenous Pd0 microspheres capable 
of deprotecting molecular probes in biocompatible conditions by allylcarbamate cleavage33. 
This catalytic system laid the groundwork for the use of Pd0 beads to conduct inter/extracellular 
chemical reactions in cell assays81. Described as bioorthogonal organometallic (BOOM) 
chemistry, this cleavage concept is under investigation as a new potential for 
chemotherapeutic treatment. By postulating that a heterogenous Pd0 source could affect 
localised bioorthogonal activation of Pd0 labile prodrugs, the selective high concentration 
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release of drugs could be directed into cancer tissue. This approach would confer advantage 
over DEPT by removing reliance on enzymatic action to drive drug activation. Instead the site 
of activation would be determined by accurate surgical implantation of the Pd0 device into a 
tumour (fig 1.14). 
 
 
Figure 1.14 BOOM Chemotherapeutic Concept. A heterogeneous catalytic palladium 
implant is surgically inserted into patient tumour during standard intraoperative tumour 
resection treatment or during initial biopsy. Implant is benign and does not convey toxicity 
during essential post-operative wound healing. Pd0 labile prodrugs would be systematically 
administered, where they are activated exclusively in the presence of the implant.  
 
Theoretically a Pd0 functionalised implant inserted into the tumour would activate drug at the 
site of interest on systemic administration of a Pd0 labile prodrug. Drug activation in a 
biocompatible environment is solely dependent on the interaction between a Pd0 source and 
the Pd0 labile functional group masking the prodrug, and does not require further biotic or 
environmental stimulus to induce cell death. Therefore the BOOM chemotherapeutic concept 
most closely approximates a focalised chemotherapy and radiotherapy approach. Although a 
novel strategy, BOOM chemotherapy could be employed using established focal radiotherapy 




Brachytherapy is a radiotherapy focalised technique used in head and neck, prostate and 
cervical cancers82. Sealed radioisotope ‘seeds’ (notably including palladium 103Pd) are 
surgically inserted by an implant gun into the tumour mass, which then induce cell death by 
emitting high energy short-range radiation to the surrounding tissue. Guided ultrasound allows 
for accurate positioning of the radioisotope seeds within the body to deliver optimal radiation 
doses across the entire tumour site whilst reducing damage to nearby healthy tissue and 
organs83.  
 
Implantable carmustine wafers (Gliadel®, BCNU) show efficacy as a focal therapy used in 
glioblastoma multiforme84. Wafers soaked in carmustine are placed on the tumour bed during 
intraoperative tumour resection, where they release carmustine to the surrounding tissue as a 
single dosed treatment over a five day period85. 
 
Both brachytherapy and wafer implantation suffer from wound healing complications post 
implantation. This is due to the uncontrolled ‘ON’ activation state of implants, inducing 
cytotoxicity to the surgical wound as well as cancer tissue immediately once inserted. Wound 
healing complications in both radioactive seed86 and BCNU implants87 cause more 
conservative dosing regiments, resulting in detrimental reduction in tumour ablation efficiency 
and also subsequent difficulties in reconstructing the excised area. 
 
BOOM chemotherapy may resolve this complication. The Pd0 implant can be inserted 
immediately into the tumour excision space after surgical resection. A brief uninterrupted 
period of essential wound healing takes place, and then the prodrug can be administered to 
drive a chemotherapeutic response. The catalytic nature of the activating device means that 
prodrugs can be repeatedly administered as many times as required. In addition, the 
therapeutic effect may be regulated by altering the type and dosage of BOOM activatable 
prodrug, a clinically desirable option during treatment. 
 
1.8 Design of Bioorthogonal Pd0 labile prodrugs 
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Several important design features are required for the development of palladium activatable 
cytotoxic prodrugs and the catalysts that activate them.  
 
First, prodrugs should be designed with sufficient information about key functional groups 
responsible for eliciting biological effect. This information will allow the rational development 
of chemical ‘masking groups’ capable of employing a pharmacophoric blockade on the activity 
of the drug. Second, the masking group must be designed to simultaneously impart resistance 
to biological cleavage and lability in the presence of the palladium device. Improving the 
masking group by rational design will fine tune the extent of both bioorthogonality and Pd0 
activation. Third, whereby the drug itself undergoes metabolic conversion in the body to its 
active form (such as an antimetabolite), the prodrug must not competitively inhibit the enzymes 
that manage this conversion process; as this would limit the efficacy of ongoing treatment by 
saturating enzymes with inactive prodrug, preventing the accumulation of antimetabolites and 
repressing the cytotoxic effect associated. Fourth, the masking strategy should ideally reduce 
the cytotoxicity of the drug by at least 100 fold. Fifth, the conversion process between the Pd0 
device and the prodrug should liberate the active drug alongside non-toxic by-products, and 
do so in a way that allows for the repeated turnover of prodrug to drug without reducing the 
catalytic effect of the Pd0 device. Sixth, the Pd0 catalyst must be biocompatible, capable of 
repeated prodrug conversion and amenable to incorporation into a medical device capable of 
being implanted into a tumour. This suggests the use of a heterogeneous catalytic system. 
 
Prior work in the Unciti-Broceta lab has made significant progress in each of these design 
considerations. Promoieties were developed to chemically mask key functional groups in four 
established chemotherapeutics (5-fluorouracil, Gemcitabine, FUdR and vorinostat), drastically 
reducing the cytotoxic effect of each drug in in vitro assays. Pd devices that were simple to 
synthesise, handle and modify were adapted from previous work to mediate deprotection in 
vitro33. Each of the chemotherapeutics was subsequently re-activated in the presence of the 
catalyst34,88–90. Preliminary in vivo work further validated the ability to selectively mask and 
-	37	-	
	
activate a chemotherapeutic drug in zebrafish34,89. Importantly this work proposed important 
considerations to guide the development of subsequent research in this field.  
 
1.9 Aims: to advance BOOM chemotherapeutic approaches 
Building on previous work, this thesis will advance the chemistry and biology of a prodrug 
chemotherapeutic strategy already validated in in vitro models for two chemotherapeutics. 
Exploratory research will improve the effect of the catalyst and develop novel protecting groups 
capable of improving both the bioorthogonality and Pd lability of the promoiety. These findings 
will be incorporated into a previously untested chemotherapeutic in order to further expand the 
applicability of the BOOM prodrug approach in cancer research. Specifically: 
 
1. The lactam/lactim tautomery properties of 5-fluoruracil will be utilised to synthesise 
and test a novel O-alkylated prodrug capable of fast deprotection and tautomerisation 
to the active antimetabolite in biocompatible conditions. 
2. Utilising self-immolative linker chemistry, a new promoiety will be developed and 
incorporated into gemcitabine as a series of N- and O- linked prodrugs capable of 
improved bioorthogonality and activation. 
3. Findings from 2. will guide the development of a BOOM prodrug strategy in 
doxorubicin. 
4. New Pd0 devices will be investigated to improve aspects of BOOM activation in vitro. 
5. A 3D cell culture assay will be designed and tested to validate the efficacy of 
doxorubicin prodrugs in a representative in vivo setting. 
6. A zebrafish cardiac toxicity assay will be developed to study the effect of masking 
doxorubicin on cardiac tissue. 
7. in vivo / ex vivo BOOM mouse models will be designed and tested using the best 





A Prodrug of 5-Fluorouracil 
 
The antimetabolite 5-fluoruracil will be investigated to develop optimised candidates of 
previously reported prodrugs sensitive to Pd-mediated activation. Prodrug design will focus 
on improving the physicochemical properties of the prodrug based on lactam/lactim 
tautomeric forms of the active drug. Analytical modalities will be investigated for their 
potential utility in future in vivo ADME studies. 
 
2.1 5-fluorouracil Overview 
5-fluorouracil (5FU) 1 is a fluorinated pyrimidine analogue of uracil, designed in the 1950’s as 
one of the earliest antimetabolite anticancer compounds (fig. 2.1). Early studies in rat 
hepatomas suggested that the endogenous pyrimidine uracil was metabolised at a higher rate 
in cancer cells than in healthy tissue91. By chemically replacing the C5 hydrogen atom of uracil 
with a fluorine atom, 5FU was capable of eliciting selective cancer cell cytotoxicity via 
disruption of the upregulated anabolic uracil pathway; by conversion of 5FU into active 
metabolites capable of inhibiting biosynthesis and incorporating into essential 
macromolecules92. 
 
Initial tests demonstrated that 5FU was cytotoxic against numerous cancer cell lines in vitro93, 
predicting broad efficacy in the treatment of cancer due to the increased demand for uracil in 
the macromolecule synthesis of all rapidly proliferating cells. 5FU is now routinely administered 
as a monotherapy or in combination across a range of cancers including pancreatic94, 
stomach95, breast96 and head and neck97. The indication for which 5FU has had the greatest 
impact however is colorectal cancer, where 5FU is used as a frontline treatment in patients 





Figure 2.1. Structure of 5-fluorouracil. 
 
5FU is administered by bolus injection, continuous infusion or oral administration during a 
dosing cycle with typical concentrations not exceeding 1000 mg/m2 99,100. In addition, 5FU is 
administered as a topical treatment for eye101 and skin102 cancers. 5FU rapidly enters into the 
cell using the same facilitated transport mechanism as uracil103. 5FU simultaneously 
undergoes anabolic activation to its cytotoxic products and catabolic deactivation to inactive 
by-products via the same pathways as uracil. Accordingly, much of the study pertaining to the 
understanding of 5FU has focused on metabolic pathways that activate, deactivate or clear 
the drug from the body upon administration. 
 
The availability of 5FU active metabolites to the tumour is dependent on the rate of drug 
catabolism. Early studies demonstrated that 5FU is catabolised, primarily in the liver, by 
dihydropyrimidine dehydrogenase (DPD) into 5,6-dihydrofluoruracil, and subsequently α-
fluoro-β-ureido-propionic acid (FUPA) and α-fluoro-β-alanine (FBAL)104. This pathway rapidly 
removes 5FU, with the majority (~80 %) of the administered drug excreted as FBAL in urine 
within 24 hr105. An additional ~10 % of 5FU is directly excreted in urine as non-metabolised 
drug106, leaving ~10 % of administered 5FU available to exert an antitumour effect.  
 
Studies with a halogen analogue of 5FU, 5-Iodouracil (5IU) suggest that 5FU binds to the 
active site of DPD via numerous hydrogen bonding interactions. Coordination likely occurs 
between 5FU’s C4-O atom and Asp 668/Asp 736, the N3 atom and Asp 736, the C2-O atom 
and Thr 737/Asp 609 and the N1 atom and Asp 609 within the active pocket of DPD107 (fig 
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2.2). This coordination complex then allows for the reduction of 5FU to 5,6-dihydrofluorouracil 
by a closely bound NADPH molecule in a catalytic fashion108,109.  
 
 
Figure 2.2 5-fluorouracil binds to Dihydropyrimidine Dehydrogenase via interaction 
with multiple amino acid residues. Proposed molecular interactions between 5FU and DPD 
amino acid residues within the active pocket of DPD based on 5-iodouracil crystal structure110. 
Predicted coordination occurs between active site amino acid residues Asp 668, Asp 736, Thr 
737, Asp 609 and 5FU. 
 
After catabolism and excretion, remaining bioavailable 5FU is preferentially accumulated into 
proliferating cells and converted through multiple intermediates into three active metabolites: 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and 
fluorouridine triphosphate (FUTP)92.  
 
The enzymes orotate phosphoribosyltransferase (OPRT), thymidine synthase (TS) and the 
sequential action of uridine phosphorylase (UP) and uridine kinase (UK) facilitate 
functionalisation of 5FU’s N1 atom to synthesise downstream active metabolites92,105,111. 
During anabolism, 5FU’s N3 atom is crucial for hydrogen bonding based enzyme recognition 
by Uridine Monophosphate (UMP) Synthase during nucleotidic synthesis112. FdUMP and 
FdUTP drive DNA damage by TS inhibition and direct incorporation respectively113,114, while 
FUTP damages RNA molecules by direct incorporation115,116. Both pathways disrupt essential 





Figure 2.3 Cellular metabolism of 5-fluorouracil. Up to 90 % of administered 5-fluorouracil 
is catabolised to FUPA/FBAL and excreted, or excreted as the unmodified drug. The remaining 
~10 % is available to accumulate in tumour cells where it is converted intracellularly into active 
metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate (FUTP), driving apoptosis via enzyme inhibition and 
DNA / RNA damage pathways. 
 
As 5FU simultaneously undergoes multiple de-activating and activating pathways upon 
administration, accurately dosing the drug is a significant challenge. It is estimated that up to 
80 % of patients receive non-optimal dosages of 5FU during routine treatment117. Dose limiting 
side effects such as myelosuppression and gastrointestinal toxicity events are commonly 
observed118. If prodrug design could mask 5FU from uncontrolled metabolic activation / 
deactivation on administration, a lower dosage of non-toxic prodrug would deliver significantly 
more 5FU directly to tumour tissue whilst reducing side-effects. 
 
2.2 Current Progress with N-alkylated 5FU Prodrugs 
Both endocyclic NH groups at the N1 and N3 positions have unusually low experimental pKa 
values due to charge delocalisation across the pyrimidine π system arising from lactam 
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(keto)/lactim (enol) tautomerization119 (scheme 2.4). Consequently, various N1 and / or N3 
protected prodrugs of 5FU have been investigated111,120, including from our laboratory34,88.  
 
 
Scheme 2.4 5-fluorouracil conjugate bases. Negative charge delocalisation around the π 
system pyrimidine ring of 5-fluorouracil reduces the N1 and N3 experimental pKa of 5FU 
 
By alkylating the N1 and/or N3 position of the pyrimidine ring, we have previously deactivated 
5FU using a protecting group that is both resistant to metabolic cleavage and exclusively labile 
to a Pd0 source. Conversion to active drug occurs by Pd-mediated N-dealkylation in the 
presence of a Pd0 catalyst in biocompatible conditions34,88. A semisynthetic strategy was 
previously used to synthesise allyl (All-), propargyl (Pro-) and benzyl (Bn-) N1 functionalised 
5FU prodrugs in a one-step reaction (scheme 2.5).  
 
 
Scheme 2.5 Synthesis of N1 alkylated 5-fluorouracil prodrugs. Reagents and conditions: 
(i) DBU (1.2 equiv.), DMF, alkylbromide (1 equiv.), 4 °C, then RT overnight (31-40%). 
 
N1 protected Pro-5FU was progressed as the only candidate that displayed excellent 
bioorthogonality ([EC50 (Pro-5FU) / EC50 (5FU)] > 500 – 700 fold reduction) and 100 % Pd-
















N1 position, it was predicted that an N3-alkylated 5FU would improve upon the reaction 
kinetics of Pd-mediated cleavage. N3 and N1,N3-bis-alkylated 5FU prodrugs were 
synthesised and tested in vitro for biocompatibility and Pd0 activation, however, the conversion 
of N3-monoalkylated 5FU prodrug was incomplete after 24 hr, with only 26 % of an N1,N3-bis-
alkylated 5FU prodrug converted to active 5FU in the same time period. Further investigation 
is required to develop an optimized Pd0 labile prodrug of 5FU with improved kinetic reactivity.  
 
An ideal prodrug of 5FU would retain rapid conversion to 5FU whilst removing NH bonding 
recognition at both N1 and N3 positions. By modifying the electronic configuration of 5FU’s 
pyrimidine ring, a new prodrug may improve the kinetic rate of Pd-mediated dealkylation with 
increased lipophilicity and retained metabolic stability. More lipophilic prodrugs could be more 
rapidly absorbed into the Pd0 bead, itself a hydrophobic resin, to affect faster catalytic cleavage 
and release of the polar 5FU product.  
 
Rapid uptake and deprotection of prodrug by an intratumoural Pd0 implant would be expected 
to increase the quantity of 5FU delivered locally to proliferating cancer cells. Therefore we 
expect a more lipophilic prodrug of 5FU to improve the dose efficiency and rate of catalytic 
conversion in a clinical model of activation. Accordingly, we set about to develop a new 
bioorthogonal 5FU prodrug that would:  
(1) retain excellent bioorthogonality characteristics across all cell lines investigated 
(2) improve lipophilicity by modification of the electronic structure of 5FU 
(3) increase stability against DPD catabolic activity 
(4) increase the rate of conversion to 5FU with respect to the N1,N3-bis-propargylated 
5FU prodrug 
 
2.3 Design and Synthesis of a Novel O-propargylated 5FU prodrug 
Inspired by the tautomeric resonance forms of 5FU at physiological pH, we considered a 
trapped lactim-type prodrug of 5FU that would reconvert to the parent 5FU lactam form upon 





Figure 2.6 Development of a trapped di-lactim analogue of 5FU. By bis-O-propargylating 
5FU, NH bonding interactions are removed. Pd-mediated conversion of the lactim product 
would rapidly undergo tautomerization to active 5FU, re-establishing the cytotoxic effect  
 
The trapped lactim form would impose aromatic restriction to the pyrimidine ring by converting 
the endocyclic –NH- groups into =N-. 2,4-bis-propargyloxy 5-fluoropyrimidine 2 would block 
enzymatic interaction at N1 and N3, preventing critical NH hydrogen bonding interactions that 
facilitate enzymatic recognition and metabolism of 5FU. When incubated in the presence of 
Pd0 it is expected that propargyl bond cleavage would produce the lactim form of 5FU, which 
then rapidly undergoes tautomerization to the parent drug in biocompatible conditions (i.e. at 
pH 7.4). Computational predictions show that O-alkylated prodrugs of 5FU display a higher 
clogP than N-alkylated prodrugs (fig 2.7).  
 
 
Figure 2.7. Experimental clogP of 5FU and 5FU prodrugs. Whereas N-alkylated prodrugs 
of 5FU have low clog P values, O-propargylated 5FU prodrugs are increased, increasing the 




2 has a clogP of 1.66, an order of magnitude higher than either N1 and/or N3 functionalised 
5FU prodrugs and indicating enhanced lipophilicity. It is important to note that drug candidates 
with logP values between 2 and 3 are generally considered to be orally available121,122, and 
are likely to achieve the right balance between permeability and first-pass elimination during 
systemic administration. 
 
2 was synthesised in a one-step synthetic strategy (scheme 2.8). 2,4-dichloro-5-
fluoropyrimidine 8 was reacted with two equivalents of propargyl alcohol and NaH in THF to 
afford the diprotected product in moderate yield.  
 
Scheme 2.8 Synthesis of 5FU prodrug 2. Reagents and conditions (i) propargyl alcohol (2 
equiv.), NaH (2 equiv.), THF, rt overnight (36 %) 
 
Attempts to synthesise mono-alkylated derivatives 6 and 7 were unsuccessful. Two strategies 
are described (scheme 2.9)(scheme 2.10). 2-Chloro-4-(2-propargyloxy)pyrimidine 9 was 
isolated as the major byproduct of the reaction affording 2. This product was synthesised in 
higher yield by repeating this reaction with one equivalent of propargyl alcohol and NaH. 
Mixing 9 together with various alkali hydroxides in a range of conditions failed to affect hydroxy 





Scheme 2.9 1st Attempted synthesis of O-monoalkylated propargyloxy-5-fluorouracil 
prodrug 7. Reagents and conditions (i) propargyl alcohol (1 equiv.), NaH (1 equiv.), THF, rt 
overnight (50 %) (ii) alkali hydroxides: (NaOH, KOH) (1 equiv. à excess), solvents: (H2O, 
MeCN, THF, MeOH or neat), variable time, heat, pressure, atmosphere. 
 
A separate methodology was next developed to attempt synthesis of monoalkylated prodrugs 
directly from 5FU (scheme 2.10). First 5FU was mono-benzoylated at the N1- or N3-position. 
N1- benzoylation product 10 retains lactim/lactam tautomerization at the N3- site, whilst N3-
benzoylation product 11 retains N1 tautomerization; each potentially allowing the distal oxygen 
atom to act as a nucleophile during subsequent alkylation reactions, as reported by 
Ludek123,124 and others125–127. 1-benzoyl-5-fluorouracil 10 was prepared by stirring one 
equivalent of aryl acid chloride into a pre-mixed solution of one equivalent of 5FU and one 
equivalent of potassium hydroxide128,129. 3-benzyl-5-fluorouracil 11 was prepared by adding 
three equivalents of the aryl chloride to one equivalent of 5FU, then treating with water and 
concentrated HCl129.  
 
Mitsunobu chemistry has synthesised carbocyclic pyrimidine nucleosides from N3 
benzoylated thymine starting material, with 2-alkyloxy by-products isolated during this 
reaction123,125–127. Whilst the mechanism for selective N vs O alkylation is unknown, N or O 
alkylation products could be selected for by altering reagents and conditions used during the 
Mitsunobu reaction; specifically by changing the coupling reagent126, N3-protecting group or 
solvent124. For example, N3-benzoylated thymine and cyclopentanol treated with DIAD and 
PPh3 in THF has been reported to afford the 2-alkyloxy product in a 34 % yield124. 
 
Accordingly we predicted that treating 10 or 11 with propargyl alcohol, DIAD, PPh3 and THF 
would produce a mixture of N1/O2 alkylated products 14 and 15 or N3/O4 alkylated products 
12 and 13 respectively. N- and O- alkylated products could be separated by standard 
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chromatography then treated with ammonia in methanol to cleave the benzoyl group and 
afford final products 6 or 7 (scheme 2.10). 
 
 
Scheme 2.10 2nd Attempted synthesis: O-monoalkylated propargyloxy-5-fluorouracil 
prodrugs: O vs N Alkylation of 5FU derivatives. Reagents and Conditions: (i) KOH (1 
equiv.), benzyl chloroformate (1 equiv.), MeOH, MeCN, 0 °C à rt, 3 hr (19.2 %) (ii) pyridine 
(2.25 equiv.), BnCl (2 equiv.), MeCN, N2, 0 °C à rt, 48 hr then in air at rt: K2CO3 (0.5 M), conc. 
acetic acid, NaHCO3, 0 °C à rt, 1 hr (25.8 %) (iii) Ph3P and DIAD (2.5 equiv.) added to 
propargyl alcohol (1 equiv.) and 10 or 11 in N2, -78 °C, 24 hr. (iv) 7N NH3 in MeOH  
 
Unfortunately only N-alkylated products 12 and 14 were isolated from separate Mitsunobu 
reactions, confirmed by 2D NMR. The unexpected difficulty associated with synthesising 
mono-O-alkylated 5FU prodrugs 6 and 7 meant that only compound 2 was progressed into in 
vitro studies. 
2.4 5FU Novel Prodrug Biocompatibility Assays 
 
5FU is a widely utilized chemotherapeutic agent deployed against multiple indications, 
including in pancreatic cancer as a combination therapy and colorectal cancer as a frontline 
therapy. Therefore pancreatic (BxPC-3) and colorectal (HCT116) cancer cells were chosen to 
test the bioorthogonality of the novel prodrug 2. Although 5FU was cytotoxic in both cell lines, 
2 completely unaffected cell viability, even at 100 μM (fig 2.11). As expected, a trapped lactim 




                           a 
 
                            b 
 
Figure 2.11 Study of 5-fluorouracil cytotoxic reduction produced by prodrug 2 in cell 
culture. Semilog dose − response curves and calculated EC50 values of 2 (dashed-purple) in 
comparison to unmodified 1 (solid-red) in (a) HCT116 cells and (b) BxPC-3 cells. Cell viability 
was measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from n = 3 
 
2.5 Pd-mediated 5FU Prodrug in vitro Conversion Study  
Our lab explores the reactivity between Pd0-functionalised devices and Pd-labile 
chemotherapeutic prodrugs. Previous reports have utilised a 130 μm sized Pd0 functionalised 
bead catalyst de-protect prodrugs in biology34,88,89,130,131. This device will be utilised for Pd-
mediated activation studied herein. The Pd0 device is described in more detail in Section 4.6.  
 
As 2 was completely non-toxic when incubated in cell culture, we investigated the sensitivity 
of the trapped lactam prodrug to Pd-mediated catalysis by UPLC. Initially the signal 
corresponding to reactants and expected prodrugs was obtained by incubating a 100 µM 
solution of prodrug or drug in PBS (1 mL) with a thermomixer at 1400 rpm, 37 °C. Aliquots 
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collected after 24 hr incubation were analysed by UPLC (fig 2.12) using a UV detector that 
removed the interference of salts to the signal.  
 
       a 
 
        b 
 
Figure 2.12 Non-biological stability assay of 5FU prodrug 2. UPLC chromatograms of (a) 
5FU (1) (red) and (b) Prodrug (2) (purple) as 100 μM solutions in PBS incubated at 1400 rpm, 
37 °C for 24 hr in a thermomixer. UPLC experiment was conducted with flow rate 0.4 mL / min. 
A = Water + 0.1 % TFA, B = Acetonitrile. Method 0 min = A:95 / B:5, 8 min = A:20 / B:80, 8.5 
min = A:95 / B:5 
 
Notably 5FU is a very polar small molecule that elutes early from the only UPLC column 
available for this experiment. This caused partial overlap between the peak corresponding to 
5FU and the signal corresponding to general sample injection, though separation of these 
peaks was evident from the zoomed in image in figure 2.12 during the first min of elution time. 
Altering the eluent polarity (MeCN 90 – 99 %) and modifier (+/- TFA) was unable to shift the 
5FU peak towards a later elution time. Furthermore, 2 gave a very weak signal despite 
incubating equimolar quantities of 5FU and 2 in each experiment, possibly indicating lower UV 
activity at 254 nm. Despite this challenge, repeated experimentation confirmed the elution of 
5FU and 2 (1 = 0.42 min), (2 = 3.59 min). This suggested that 2 would be stable in 
biocompatible conditions over 24 hr in the absence of Pd0 beads (fig 2.12).  
  
Next, 2 was incubated in a thermomixer at 1400 rpm, 37 °C for 3, 9, 24 and 48 hr with 1 mg / 
mL of Pd0 beads in 1 mL of PBS (fig 2.12). Significant generation of 5FU was observed after 
only 3 hr, with sustained production of the drug during a 48 hr period. Complete disappearance 
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of the peak corresponding to 2 at 3 hr suggests that the prodrug is rapidly “sequestered” by 




Figure 2.13 Non-biological Pd0 conversion assay with 5FU prodrug 2. UPLC 
chromatogram runs over 5 minutes producing 5FU (red) from 2 (purple) as 100 μM solutions 
in PBS incubated with 1 mg / mL of Pd0 beads at 1400 rpm, 37 °C for 3, 9, 24 and 48 hr in a 
thermomixer. UPLC experiment was conducted with flow rate 0.4 mL / min. A = Water + 0.1 % 
TFA, B = Acetonitrile. Method 0 min = A:95 / B:5, 8 min = A:20 / B:80, 8.5 min = A:95 / B:5. 
Impurities consistent with the signal produced from injection (at t = 0.25 min) and background 
are presented in light grey. 
 
2.6 5FU Prodrug Biological Conversion Assay in Combination with Pd0 
2 was next assessed for BOOM activation in cell culture. Pd0 beads, 2 or a combination of 
both were initially evaluated in BxPC3 cells and HCT116 cells at 1 μM and 3 μM concentrations 
respectively. The combination of 2 and Pd0 beads displayed a significant cytotoxic effect 
across both cell lines. Neither 2 nor Pd0 beads individually affected cell viability. This confirmed 
the ability of Pd0 beads to release 5FU from the trapped lactim analogue 2 and produce a 








Figure 2.14 Preliminary Pd-mediated activation assay to compare activity of 5FU 
prodrug 2 against drug. Experiments: 0.1 % (v/v) DMSO (untreated cell control, white); 1 mg 
/ mL of Pd0 beads (negative control, black); 5FU (positive control, red); 2 (negative control, 
solid purple); and 1 mg / mL of Pd0 beads + 2 (BOOM activation, striped purple). (a) BxPC3 
pancreatic cancer cells incubated at 1 μM drug / prodrug, (b) HCT116 colorectal cancer cells 
incubated at 3 μM drug / prodrug. Cell viability was measured at day 5 using PrestoBlue® 
reagent. Error bars: ± SD from n = 3. 
 
This initial BOOM activation study was expanded to test the prodrug across a concentration 
range (0.03 – 3 μM  for BxPC3 cells), (0.3 – 30 μM for HCT116 cells) in combination with Pd0 
beads. (fig 2.15). DMSO is used as standard control vehicle for drug or prodrug in all 
experiments throughout this thesis. 0.1 % (v/v) DMSO is accepted as a concentration that 
does not accept cell viability during in vitro testing.  




                                     b 
 
Figure 2.15 Pd-mediated activation of 5FU prodrug 2 in BxPC3 and HCT116 cell culture. 
Toxigenic effect of bioorthogonally activated 5FU prodrug across a concentration window in 
(a) BxPC3 and (b) HCT116 cells. Experiments: 0.1% (v/v) DMSO (untreated cell control, white); 
1 mg / mL of Pd0 beads (negative control, black); 5FU (positive control, red); 2 (purple); 2 + 
Pd0 beads (striped purple). Drug and Prodrug concentrations 0.03 – 3 μM (BxPC3 cells), 0.3 
– 30 μM HCT116 cells. Cell viability was measured at day 5 using PrestoBlue® reagent. Error 
bars: ± SD from n = 3.  
 
This study confirmed the ability of 2 to undergo Pd-mediated cleavage to form 5FU over a 
range of concentrations in vitro (fig 2.15).  
 
2.7 Investigating Analytical Modalities to Study 5FU Prodrug Deprotection: 
NMR 
Over the past thirty years a variety of methodologies have been developed in the clinic to study 
the active drug uptake and metabolism of fluorinated antimetabolites. Positron Emission 
Tomography (PET) is one such imaging technique capable of detecting gamma rays produced 
from the positron decay of short-lived isotopes. 18F is an isotope of fluorine with a 110 min half-
life, producing gamma rays with discrete energy upon positron decay132. 18F based radiotracer 
surrogates of 5FU have been used to study intra-tumoral uptake of 18F-5FU in patients with 
metastatic colorectal cancer133. 19F NMR spectroscopy is another technique used to detect the 
heterogeneous accumulation of 5FU in tumours. As 19F is a naturally occurring stable NMR 
active isotope of fluorine, 19F-NMR spectroscopy has been utilised to study the intratumoral 
half-life of 5FU in tumour tissue both in in vivo models134 and in the clinic134,135. Whereas PET 
imaging can only detect the single emission of short lived 18F drug surrogates, NMR is capable 
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of distinguishing between fluorinated compounds based on electronic structural differences 
that alter the polarization of an 19F atom in a molecule. In addition, as the 19F isotope of fluorine 
does not rapidly decay, longitudinal studies of drug and prodrug signals within a tumour would 
be possible. 
 
Propargylated 5FU prodrugs will significantly modify the electronic characteristics of the 
pyrimidine ring, resulting in shifted NMR 19F signals in prodrugs relative to 5FU. This would 
allow for the study of prodrug to drug turnover. An experiment was designed to visualise the 
19F signal of drug 1 and prodrugs 2, 4 and 5 by NMR in a test tube that approximated the 
conditions of a living system. 3 was not included due to the slower kinetic rate compared with 
4 as previously reported for N3-dealkylation88. 
 
5 mM of 1, 2, 4 or 5 in 0.1 % (v/v) DMSO was mixed with 10 % FBS solution in PBS (1 mL) in 
a thermomixer at 1400 rpm, 37 °C for 36 hr, then sonicated and transferred into a standard 
NMR tube. A heat sealed capillary tube of 10 % TFA solution in d-Benzene was added into 
the NMR tube to provide an internal reference signal and deuterated solvent for adequate 





Figure 2.16 Overlaid 19F NMR spectra of 5FU and prodrugs. Conditions: 1, 2, 4 and 5 (5 
mM in 0.1 % DMSO with PBS + 10 % FBS solution (1 mL) incubated for 36 hr at 1400 rpm, 
37 °C in thermomixer. Solution transferred into NMR tube with sealed capillary of 10 % TFA 
in d-benzene and submitted for paramagnetic non-spin 19F NMR experiment.  
 
Both N- and O-propargylation alters the electronic effect about the pyrimidine ring system, 
shifting the 19F signal upfield (less negative) for all 5FU prodrugs. Unfortunately 2 gave a very 
weak 19F signal at -162.90 ppm, likely due to poor solubility in H2O at 5 mM. 4 showed an 
intermediate signal at -165.51 ppm. 5 displayed an excellent single peak signal at -164.84 ppm 
and was chosen as the model prodrug to monitor catalytic cleavage to 5FU by 19F NMR 
spectroscopy as a proof of concept experiment. 
 
A BOOM activation assay was next developed to monitor the conversion of 5 to 5FU by 19F 
NMR. 5 was incubated together with Pd0 beads under biocompatible conditions. As 5 mM does 
not approximate a relevant therapeutic concentration, efforts were made to optimise the 
experiment to retain signal resolution with reduced concentration. By increasing the length of 
data acquisition (from 30 min to overnight) and the scan rate (from 16 – 2046 scans) it was 
determined that the 19F signal from a 500 μM solution of 5 in PBS would provide adequate 
signal to quantify conversion. As the concentration of prodrug was increased, a corresponding 
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increase in the amount of catalyst was required. The maximum volume of Pd0 beads that could 
be loaded into a 1 mL Eppendorf and mixed efficiently (determined as 4 mg/mL) was used. A 
500 μM, 0.1 % (v/v) DMSO solution of 5 in a 10 % FBS solution of PBS (1 mL) was incubated 
together with 4 mg of Pd0 beads in a thermomixer at 1400 rpm, 37 °C for 5 days, then submitted 
for 19F NMR paramagnetic non-spin analysis (fig 2.17). Initial concerns that the Pd0 beads 
would interfere with the NMR analysis were overcome by the use of a non-spinning 
paramagnetic experiment. This reduced the likelihood that rotational movement would move 





Figure 2.17 19F NMR reaction product of 5FU prodrug 5 with Pd0 beads. Conditions: 5 
(500 μM in 0.1% DMSO) incubated with 4 mg Pd0 beads in PBS + 10 % FBS solution (1 mL) 
for 5 days at 1400 rpm, 37 °C in thermomixer. Solution transferred into NMR tube with sealed 
capillary of 10 % TFA in d-benzene and submitted for paramagnetic non-spin 19F NMR 
experiment 
 
After 5 days of incubation 5 was still present in large excess. While this conflicts with evidence 
of deprotection from previous HPLC studies88, compound 5’s protection kinetics were the 
slowest of all N-alkylated prodrugs. The lower sensitivity of NMR relative to HPLC requires a 
higher concentration of 5 to monitor conversion; one likely cause of an excess of reactant after 
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long incubation with a high quantity of the catalyst. Despite this, an intermediate at -167.20 
ppm was resolved which may be the 19F signal corresponding to a mono-deprotected 
derivative of 5 (possibly 3), as well as presence of 5FU at -168.71 ppm. Both signals were 
observed in low quantity.  
 
Our objective was to develop a sensitive 19F NMR spectroscopic method to allow for the 
quantitative turnover of fluorinated prodrugs to drugs without perturbation. The accumulation 
and metabolism of 5FU and fluorinated metabolites by 19F NMR spectroscopy has been 
previously visualised in an in vivo tumour model134. We attempted to develop a system that 
could accurately monitor the Pd-mediated conversion of 5FU prodrugs to 5FU using the 19F 
signal to detect electronic changes incurred by functionalising a propargyl group to 5FU at the 
N1 and/or N3 and O2 and O4 positions. Whilst initial work has verified that 19F NMR would be 
in principle capable of facilitating the analysis of a BOOM activation assay; it is clear that the 
experimental procedure requires further optimisation before it is progressed into more complex 
ex vivo and in vivo models. 
 
2.8 Investigating Analytical Modalities to Study 5FU Prodrug Deprotection: 
Raman Spectroscopy 
Raman Spectroscopy detects the specific vibrational signals of molecules excited by a laser. 
A distinct molecular spectrum (known as a fingerprint) is produced for Raman active molecules 
under investigation. The low intensity laser beam required for Raman Spectroscopy has 
historically limited signal detection in living systems. Despite this, recent developments in 
beam sensitivity and new molecular probes have established Raman Spectroscopy as a non-
perturbing imaging technique to visualise the distribution of molecular probes in cells136. As 
biological molecules show limited Raman scattering in the ‘silent region’ of the spectrum (1800 
– 2800 cm-1), optimized bioorthogonal Raman active molecular probes have been developed 




The alkyne group is a well suited functional group for use in Raman imaging. The alkyne group 
does not exist within mammalian cells, and is uniquely Raman active within the silent region 
of a Raman spectrum This allows for the accurate signal detection of alkyne functionalised 
molecules in cellular environments. Early analysis of polyacetylene natural products in carrot 
roots137 and alkyne-substituted oleic acids138 visualised alkyne functionalised molecules in 
living systems. 5-ethynyl-2’deoxyuridine (EdU), a pyrimidine analogue similar to an alkylated 
5FU has been detected in real time during in vitro incubation139–141, and the conversion of 1-
ethyloxycarbonyl-5FU to 5FU has been monitored in the transdermal layer of skin142. We were 
encouraged to explore the use of Raman spectroscopy to visualise the conversion of 2 into 






Figure 2.18 Raman Spectroscopy of 5FU and 5FU prodrug 2 as powder samples. Raman 
spectroscopy of (a) 5FU and (b) 2. Raman spectra were acquired by localising beam onto an 
amorphous solid sample at λex = 532 n m for 10 s using a 20x objective. Raman spectra were 
scaled between 0 – 120 000 counts (a) and 0 – 60 000 counts (b) and offset for clarity. The 
peak at 2130 cm-1 has been annotated and the silent region appropriately framed.  
 
The Raman spectrum of 5FU (fig 2.18.a) is consistent with other reported spectra140,143. The 
Raman spectrum of 2 (fig 2.18.b) shows a strong alkyne signal within the silent region at 2130 
cm-1. An in vitro assay was next developed to visualise 2 in the presence of typical cellular 
contents at a therapeutically relevant concentration. Following analogous protocols for the 
imaging of Raman active molecules in cellular pellets141,144, adenocarcinoma human alveolar 
basal epithelial (A549) cells were grown to confluence in a T75 flask, detached and centrifuged 
into a cell pellet. The supernatant was removed and the cell pellet was bathed in 1 mL of a 
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500 μM solution of 2 in 0.1 % (v/v) DMSO for 15 min, then the cell pellet was snap frozen in 
liquid nitrogen for transport, re-thawed and pipetted gently onto a glass cover for imaging. The 
Raman spectrum (fig 2.18) was unable to resolve peaks corresponding to cellular content or 
2 across the range 0 – 3500 cm-1, with the exception of a small peak at 2094 cm-1. It is unclear 
whether this peak corresponds to the alkyne of 2, and if so why it is slightly downshifted from 
the signal seen in fig 2.19. Repeated attempts to optimise the experiment consisted of bathing 
the cell pellet in a higher concentration of 2 (1 mM), increasing the incubation time of 2 within 
the cellular pellet (1 hr) and increasing the length of laser scanning time on the cover slip 
sample, however altering these parameters was unable to resolve other peaks.  
 
 
Figure 2.19 in vitro Raman study of 2 in cell pellet. Spontaneous Raman spectrum recorded 
of A549 cells within a cellular pellet treated with 2 (1 mM, 30 min). Raman spectra were 
acquired by focusing beam on cellular membrane edge at λex = 532 nm for 60 s using a 20x 
objective. Raman spectra were scaled between 60 000 – 90 000 counts and offset for clarity. 
The peak at 2094 cm-1 has been annotated.  
 
One reason for this could be that 2 rapidly diffuses across the cell membrane as it is not 
retained by any biomolecule, an expected outcome for a bioorthogonal reagent candidate. As 
Raman imaging is emerging as an important tool for bioorthogonal alkyne visualisation in living 
systems, we attempted to leverage the unique imaging properties of the alkyne group to 
visualise 2 in a living system by modifying two successfully utilized protocols141,144. Although 
the alkyne signal corresponding to 2 was detected when submitted to Raman imaging as a 
dry powder, this did not translate into an analogous in vitro experiment, supporting the highly-





By N-alkylating endocyclic NH groups within the pyrimidine ring, our group has previously 
reported an N1 prodrug of 5FU, 3, capable of selective Pd-mediated deprotection in biological 
environments34. This strategy eliminated cytotoxicity associated with 5FU in cellular assays. 
In the presence of a Pd0 source, N-dealkylation produced 5FU, restoring cytotoxicity in cancer 
cell cultures. A clear rationale exists to alkylate 5FU at both the N1 and N3 positions92, 
removing key hydrogen bonding associations and disrupting the incorporation of 5FU into 
antimetabolites. As the pKa of N3 is lower than at the N1 position, N3-alkylated 5FU 4 and N-
bis-alkylated 5FU prodrug 5 were also synthesised and tested88. Despite excellent 
biocompatibility, 4 and 5 in combination with Pd0 released active drug more slowly than 3.  
 
3 and 4 display clogP values of -0.86; 5 has a clogP of - 0.4. These values are not typically 
associated with drug candidates amenable to administration. LogP values between 2 and 3 
are desired as an optimal balance for good drug absorption or elimination during first-pass on 
administration. Since mono-N-alkylated 5FU prodrugs 3 and 4 still possess endocyclic NH 
enzymatic recognition sites, metabolism is still possible. Although bis-N-alkylated 5FU 
candidate 5 has no endocyclic NH enzyme recognition sites, a slow stepwise release of 5FU 
in the presence of a Pd0 source may reduce the efficacy of treatment.  
 
These suboptimal intrinsic properties may prevent N-alkylated prodrugs of 5FU from 
progressing into a pre-clinical study. Bis-O-propargylated 5FU prodrug 2 was developed to 
overcome this. 2 possesses improved lipophilic properties, retained biocompatibility and 
rapidly releases 5FU via Pd-mediated depropargylation in cell culture. 
 
By locking into place the lactim tautomeric state of 5FU via bis-O-propargylation, 2 blocks NH 
bonding interactions required to metabolise the parent drug. 2 displayed no cytotoxicity across 
all tested cell lines. Non-biological UPLC studies showed that 2 was taken up by Pd0 beads 
when mixed in solution, rapidly producing 5FU without the observation of mono-propargylated 
intermediate byproducts. This is an attractive property as conceptually Pd0 beads inserted into 
a tumour would be capable of capturing free circulating 2 and catalysing the localized release 
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of 5FU. The lipophilicity of 2 (clogP = + 1.66) was calculated as one order of magnitude higher 
than 5 and two orders higher than 3 and 4, a possible explanation as to why 2 could sequester 
into the lipophilic matrix of Pd0 beads, whereas 1, 3, 4 and 5 do not. This clogP value is typical 
of drug candidates with ideal pharmacokinetic properties and amenable to oral availability, 
unlike the much lower clogP values of 3, 4 and 5. 
 
2 and Pd0 beads underwent BOOM activation in vitro across a range of concentrations. At high 
concentrations, 2 + Pd0 beads is capable of matching the cytotoxic profile of 5FU, however at 
low concentrations an appreciable gap remains between the cytotoxicity produced by 5FU 
alone and that of 2 and Pd0 beads in combination. This effect may be attributed to the time 
delay required for Pd0 bead catalysis of 2 and subsequent release of 5FU into solution.  
 
Initial attempts to utilise imaging and analytical modalities on prodrugs of 5FU were explored 
by NMR and Raman Spectroscopy. 19F NMR spectroscopic biocompatible conversion assay 
in an NMR tube was expected to allow for visualisation of the real time conversion of prodrugs 
into intermediates and 5FU through intermediates. Unfortunately, the weak 19F NMR signal 
observed for 2 precluded further investigation for this prodrug. Instead 5 was determined as 
the best candidate to test this assay. However this experiment did not produce 5FU at the rate 
observed by prior HPLC and suggested by cytotoxicity from in vitro studies. It is important to 
note that the concentration of 5 and Pd0 beads were optimised for NMR studies, and do not 
reflect those used in HPLC and in vitro studies. 
 
Raman Spectroscopy has been used to monitor the accumulation and compartmentalisation 
of Raman active molecules in living systems. The alkyne group has emerged as a useful tool 
to study functionalised alkyne bearing molecular probes in cellular biology. A modified 
procedure for the uptake of 2 into a cell pellet was unable to resolve a clear signal produced 
by alkyne in the silent region of the spectrum, suggesting that the compound is not retained 




2, an optimised lactim tautomerised O-alkylated prodrug of 5FU has been developed to 
overcome the non-drug like properties of previously reported N-alkylated BOOM 5FU prodrug 
candidates. With improved physicochemical properties, non-toxic and Pd0 labile, 2 potentially 
represents a viable candidate for pre-clinical in vivo testing. Next steps will be to test in vivo 
pharmacokinetics (PK) in a rodent model to verify if key PK properties such as oral availability 
and plasma half life are improved over 5FU and N-alkylated prodrugs. Based on the analytical 
investigations performed with 2, it is recommended to use standard HPLC studies to carry out 




CHAPTER 3  
 
Prodrugs of Gemcitabine 
 
Gemcitabine is the second antimetabolite to be investigated for use as a Pd-labile prodrug. 
Previously developed prodrugs of gemcitabine focused on functionalising at the C4NH2 and 
C5’OH position with Pd-labile groups. Moderate reduction in cytotoxicity with Pd-mediated 
activation was achieved. This chapter focuses on developing novel protecting groups to 
improve the cytotoxic fold change afforded from C4NH2 and C5’OH functionalisation with 
retained sensitivity to Pd0. 
 
3.1 Gemcitabine Overview 
2’, 2”-difluoro 2’-deoxycytidine, commonly known as Gemcitabine (16), is an antimetabolite 
chemotherapy first approved in 1997 for the front line treatment of pancreatic cancer145 (fig. 
3.1). Since its approval as a monotherapy, gemcitabine has been the standard of care for 
patients with metastatic pancreatic cancer, improving overall survival and median response 
rates in large patient population studies relative to 5-fluorouracil, the historical standard of 
care146. Recent studies have expanded the number of indications for which gemcitabine may 
be used as a monotherapy or as part of a combined chemotherapeutic regime to include 
cancers of the lung147, ovary148, liver149 and breast150. 
 
  

















Gemcitabine is a C2’ di-fluorinated pyrimidine antimetabolite analogue of the nucleoside 
deoxycytidine. Nucleosides are critical intracellular substrates required for nucleic acid 
synthesis, DNA elongation and replication. As cancer cells undergo sustained proliferation and 
uncontrollable DNA synthesis, the demand for nucleoside uptake and metabolism is 
accordingly upregulated151. This upregulated demand for DNA metabolites has been exploited 
by the development of nucleoside analogues designed to mimic endogenous metabolic 
processes; eliciting apoptosis by competition and inhibition of key enzymes involved in 
nucleoside anabolism or by direct incorporation into growing DNA chains152,153. Selective 
isosteric replacement of hydrogen atoms with fluorine or isopolar replacement of hydroxy 
groups with fluoro groups has successfully converted a number of well-studied nucleosides 
into approved antimetabolite cancer medicines. Although the fluorine atom mimics the size 
and geometry of the hydroxy group, increased stability and electronegativity properties of the 
C-F bond leads to a dramatic change in the pharmacological activity of an analogue with 
respect to its metabolic mimic154.  
 
Deoxycytidine, the molecular mimic of gemcitabine, undergoes mono phosphorylation at the 
C5’OH position by Deoxycytidine Kinase (dCK)155,156, thus trapping the metabolite in the cell. 
Following di and tri phosphorylation by other enzymes, the tri phosphorylated metabolite is 
then delivered into the nucleus where it is incorporated into growing DNA strands156. The 
increased rate of DNA synthesis in proliferating cancer cells corresponds to a higher demand 
for deoxycytidine. Gemcitabine is preferentially accumulated in cancer cells via the same dCK 
phosphorylation pathway. dCK recognizes gemcitabine via coordination with multiple amino 
acid residues conserved within the active pocket of dCK. Key enzymatic interactions take 
place between the C5’OH, C4-NH2 and N3 position of gemcitabine and Glu 53, Arg 128, Asp 
133 and Gln 97 residues within the active pocket of dCK157,158 (fig 3.2). Hydrogen bonding 
interactions in the active pocket then catalyze an Adenosine Diphosphate (ADP) assisted rate-






Figure 3.2 Deoxycytidine Kinase (dCK) in complex with gemcitabine. Molecular 
recognition sites between the C5’OH, C4NH2 and N3 position of gemcitabine and Glu 53, Arg 
128, Asp 133 and Gln 97 residues within the active pocket of dCK110. 
 
Subsequent di- and tri-phosphorylations by UMP/CMP kinase (CMPK1) and nucleoside-
disphosphate kinase (NDPK) occur in the cellular cytoplasm. Gemcitabine diphosphate 
induces cytotoxicity by inhibition of ribonucleotide reductase, which depletes intracellular 
deoxyribonucleotide pools and starves the cell of DNA building blocks. Gemcitabine 
triphosphate is synthesized into elongating DNA chains, which triggers ‘masked chain 
termination’ by incorporation of deoxyribonucleotide triphosphate into the growing DNA chain, 
halting chain elongation and inducing apoptosis159,160.  
 
Gemcitabine is routinely administered by intravenous infusion at a dosage of 1,000 mg/m2 on 
intermittent or recurrent days during a standard dosing cycle161. A family of membrane bound 
nucleoside transporters, including sodium dependent concentrative (CNT) and sodium-
independent equilibrative (ENT) nucleoside transporters162–164 deliver gemcitabine from blood 





Figure 3.3. Cellular metabolism of gemcitabine. Cytidine deaminase CDA is responsible 
for the removal of up to 90 % of administered gemcitabine. The remaining 10 % accumulates 
in tumour cells where it undergoes successive phosphorylation events to mono-, di- and tri-
phosphorylated gemcitabine by Deoxycytidine kinase (dCK), UMP/CMP kinase (CMPK1) and 
nucleoside-disphosphate kinase (NDPK). Gemcitabine diphosphate inhibits ribonucleotide 
reductase, depleting intracellular deoxyribonucleotide pools and starving the cell of DNA 
building blocks. Gemcitabine triphosphate is transported into the nucleus where it induces 
false nucleotide incorporation via masked chain termination. 
 
Despite initial reports of a well-tolerated safety profile165, increasing evidence from widespread 
use has shown that gemcitabine has significant off-target toxicity166,167. Myelosuppression is a 
common dose-limiting side effect, with an infrequent incidence of pulmonary toxicity166 and 
rare cases of treatment induced cardiomyopathy168. In addition, up to 90 % of the drug is 
rendered biologically inert via cytidine deaminase (CDA) mediated C4NH2 hydrolytic 
deamination to difluoro-deoxyuridine. This process takes place in most organs169 with the 
majority of deactivation occurring in the liver160 (fig 3.3). 
 
Preclinical and clinical studies have shown that CDA upregulation increases resistance to 
gemcitabine treatment, whereas CDA downregulation reduces the maximum tolerated dosage 
that may be administered, reducing efficacy170,171. Further evidence has shown that genetic 
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variations associated with CDA expression levels in biliary tract cancer patients correlate to 
the efficacy of gemcitabine treatment172.  
  
There is a clear need to improve the pharmacokinetics and safety characteristics of this 
essential medicine. An optimized selectively and focally activatable gemcitabine prodrug 
would have the dual advantages of masking the drug to dCK activation in off target tissues 
and variable CDA deactivation. This would reduce side effects and allow for a precise dosage 
regimen to be determined independent of CDA expression variability in patient populations. 
Selective activation at the tumour site would deliver a high dose of gemcitabine to undergo 
dCK mediated metabolism into active anti-metabolites, driving a highly localized cytotoxic 
effect. 
 
3.2 Current Progress with Gemcitabine Prodrugs 
By reviewing the metabolic pathways of gemcitabine, a rational basis emerges for developing 
C5’OH and C4NH2 masked gemcitabine prodrugs that would reduce metabolic deactivation of 
the drug and off-target activation and toxicity. Masking gemcitabine at the C4NH2 position 
would block recognition of the drug by CDA and dCK. Our group has previously invented 
gemcitabine prodrugs that block this C4NH2 group89 using a carbamate. Separately a 
cholesteryl hemisuccinate C4NH2 carbamate protected gemcitabine prodrug has been being 
progressed into in vivo studies173–175. This evidence suggests that C4NH2 carbamate protected 
derivatives of gemcitabine are resistant to cellular cleavage. 
 
Masking gemcitabine at the C5’OH position would block dCK mediated mono-phosphorylation 
at the hydroxy group. Downstream synthesis of di-, and tri-phosphorylated antimetabolites 
would be blocked, preventing cytotoxicity in off-target tissue. We previously concluded that 
C5’OH carbonate protected gemcitabine derivatives are susceptible to cleavage in cell 
culture89. A literature search does not find examples of C5’OH protected gemcitabine 
derivatives able to resist enzymatic cleavage during extended (> 12 hr) incubation in cell 
culture. One report functionalizes a targeting peptide to gemcitabine via a C5’OH carbonate 
group, and suggests stability from a 10 hr in vitro assay176, indicating that the use of bulky 
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protecting groups could increase the stability of the carbonate bond. Another study concludes 
that an analogue of gemcitabine, a peroxy-caged-fluorodeoxy thymidine-1 was stable to 
enzymatic processing incubating the compound with serum for only 2 hrs177. No selectively 
labile C5’OH carbonate protecting group of gemcitabine has been capable of achieving 
significant resistance to enzymatic cleavage during an extended drug incubation assay. 
 
We set out to develop a new protecting group that could (1) afford resistance to C5’OH 
carbonate cleavage and (2) enhance the BOOM activation profiles of previously reported 
C4NH2 masked prodrugs of gemcitabine.  
 
Prior work within our group developed prodrugs of 16 by incorporating allyloxycarbonyl (Alloc), 
propargyloxycarbonyl (Poc) and carboxybenzyl (Cbz) at both the C5’OH and C4NH2 positions. 
This semisynthetic strategy afforded Alloc 17 and 24, Poc 18 and 25 and Cbz 19 and 26 
protected carbamate or carbonate derived prodrugs of 1689 (scheme 3.4).  
 
 
Scheme 3.4 Synthesis of reported gemcitabine prodrugs. Reagents and conditions: (i) 
DBU (2.5 equiv.), DMF, alkyl chloroformate (1.5 equiv.) at 4 °C, rt, overnight (47 – 53 %); (ii) 
TBS-Cl (1.1 equiv.), imidazole (3.5 equiv.), DMF, rt, 2.5 hr (88 %); (iii) pyridine (3.2 equiv.), 
DMF or THF, alkylchloroformate (1.5 equiv.) at 4 °C, rt, overnight 12 – 48 hr (42 – 69 %); (iv) 


















































Whilst Poc, Alloc and Cbz carbamate prodrugs 24, 25 and 26 were capable of conferring 
increased bioorthogonality with respect to gemcitabine in pancreatic adenocarcinoma BxPC-
3 and MiaPaCa-2 cell lines (> 20 fold cytotoxic reduction)89, carbonate protected prodrugs 17, 
18 and 19 were sensitive to metabolic activation. This was likely due to the enhanced 
propensity of the carbonate bond to undergo hydrolysis178,179. 
 
3.3 Rational Design and Incorporation of a Novel Protecting Group for 
Gemcitabine Prodrugs 
Based on observations that; (1) Poc is superior to Alloc as a C4NH2 protecting group for 
bioorthogonality and activation, (2) Cbz and Poc groups at the C4NH2 position are resistant to 
metabolic cleavage in the absence of Pd0, and (3) Poc is readily cleaved in the presence of a 
Pd0 source, we designed the propargyloxybenzylcarbonyl protecting group (Pobc) (fig 3.6).  
This ‘self-immolative’ linker combines the bioorthogonality of Cbz and Poc groups. By 
imposing increased steric bulk around the carbamate/carbonate bond, we sought to reduce 
the rate by which endogenous enzymes could cleave the protecting group. By positioning the 
Propargyloxy group at the ortho position, we would expect improved bioorthogonality to the 
carbamate with respect to para position functionalization due to increased steric bulk.  
 
 
Figure 3.5. The propargyloxybenzyl carbonyl (Pobc) group. 
 
The Pobc group would also retain Pd lability via a self-immolative trigger mechanism180–183. 
Rapid O-depropargylation group triggered 1,4- or 1,6-self-immoliative benzyl elimination would 
take place in the presence of a Pd0 source. The initial reaction expected to take place between 
a Pobc group and Pd0 is oxidative cleavage of the propargyl group. This reaction was 









para-propargyloxybenzyl carbonyl (p-Pobc) ortho-propargyloxybenzyl carbonyl (o-Pobc)
X = -NH-Drug
            or
         -O-Drug
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innocuous biological substrate present in human cells for glycogenesis185. O-depropargylation 
would then trigger benzyl elimination (the self-immolation step) (scheme 3.6). 
 
When the leaving group of benzyl elimination is an o- or p- amino or hydroxy substituent and 
a good leaving group, a quinone methide and a carbamic- or carbonic- acid anion are 
respectively released25 . Under biological conditions the carbamic or carbonic acid anions 
break down further to release CO2. The amino or hydroxy group is subsequently protonated, 
and the unstable quinine methide byproduct undergoes rapid nucleophilic attack (i.e. by H2O) 
to produce p- or o- hydroxybenzyl alcohol.  
 
 
Scheme 3.6 Proposed mechanism for the Pd0 catalysed cleavage of Pobc groups in 
water. Pd-mediated oxidative cleavage of the propargyl group triggers benzyl elimination to 
release X (an -NH2 or –OH bearing drug), CO2, p- or o- hydroxybenzyl alcohol and acetol. 
 
The expected by-products resulting from Pd-mediated Pobc cleavage, 1,4- or 1,2- 
hydroxybenzyl alcohol, were each incubated at between 0.003 – 100 μM across a five different 
cancer cell lines. This confirmed that the by-product would be innocuous in cellular assays (fig 
3.8). Acetol has been previously verified as non-toxic in pancreatic BxPC3 and HCT116 cancer 
cell lines within our group (fig 3.9). C4NH2 carbamate gemcitabine derivatives were 
synthesized by incorporation of 4-nitrophenyl activated protecting groups at the NH2 position. 
27 and 28 were first alkylated using propargyl bromide and sodium carbonate. Treatment of 
29 or 30 with pyridine in the presence of 4-nitrophenyl chloroformate formed the corresponding 
activated carbonates 31 and 32 in good yield. Separately the C5’OH position of 16 was 
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silylated to 20 using TBS-Cl and imidazole then treated with 31 or 32. TBAF-mediated silyl 
deprotection yielded the final carbamate prodrugs 33 and 34 in low yield (scheme 3.7). C5’OH 
carbonate gemcitabine prodrugs were synthesized by treating gemcitabine directly with 31 or 
32 in the presence of pyridine to form 35 or 36 in low yield. 
 
 
Scheme 3.7. Synthesis of novel gemcitabine prodrugs. Reagents and Conditions: (i) 
propargyl alcohol, Na2CO3, MeCN; (ii) 4-nitrophenyl chloroformate, THF (iii) TBS-O-gem 20, 









Figure 3.8 Study of hydroxybenzyl alcohol by-product cytotoxicity. (a, b) Toxicity effect 
study of (a) 2-hydroxybenzyl alcohol and (b) 4-hydroxybenzyl alcohol across multiple cancer 
cell lines. Cells were incubated with increasing concentration of the alcohol (0.003 – 100 μM) 







Figure 3.9 Study of acetol by-product cytotoxicity. (a, b) Toxicity effect study of acetol in 
(a) HCT116 and (b) BxPC-3 cells Cells were incubated with increasing concentrations of the 
alcohol (0.003 – 100 μM) for 5 days and cell viability measured. Error bars represent ± 
standard deviation from n = 3. 
 
Therefore, incorporating p- or o-Pobc protecting group moieties at the C4NH2 or C5’ OH 
positions could further enhance the bioorthogonality characteristics previously reported by 
Poc, Alloc and Cbz prodrugs, whilst retaining sensitivity to Pd-mediated activation.  
 
Two semisynthetic strategies were developed to incorporate o-Pobc and p-Pobc groups into 
gemcitabine at both the C5’OH or C4NH2 positions via a 4-nitrophenyl carbonate precursor. 
27 and 28 were first propargylated using propargyl bromide and sodium carbonate. Treatment 
of 29 and 30 with pyridine in the presence of 4-nitrophenyl chloroformate formed the 




3.4 Gemcitabine Prodrug Biocompatibility Assays 
 
As gemcitabine is used as a frontline treatment for pancreatic cancer, we tested our prodrugs 
in pancreatic cancer MiaPaCa 2 cells. Previous work in our group reported bioorthogonality 
fold changes by dose response curves of both carbamate and carbonate protected prodrugs 
against gemcitabine in MiaPaCa2 cells. Whilst carbamate protected prodrugs were 
significantly deactivated, carbonate prodrugs were sensitive to metabolic activation. This 
followed the prediction that carbonate bonds would be more susceptible to cleavage than the 
carbamate bond179. As the Pobc protecting group combines the steric hindrance afforded by 
Cbz and sensitivity to Pd-mediated cleavage from Poc, Poc carbamate 25 and Cbz carbamate 
26 were chosen as controls for the biocompatibility study of novel prodrugs 33-36 in MiaPaCa2 
cells (fig 3.10).  
 
 
Figure 3.10. Study of gemcitabine cytotoxic reduction produced by prodrugs 25, 26 and 
33 – 36 in cell culture. Semilog dose−response curves and calculated EC50 values of 25 
(solid-yellow), 26 (solid-grey), 33 (solid-blue), 34 (dashed-green), 35 (dashed-blue) and 36 
(solid-green) in comparison to those of unmodified gemcitabine 16 (solid-red) in MiaPaCa-2 
cells. Cell viability was measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from 
n = 3 
 
As shown in fig 3.10, carbamate protected prodrug 33 displayed improved reduction of 
cytotoxicity relative to Gemcitabine [EC50 (33) / EC50 (16) ~ 27], slightly outperforming Poc 
[EC50 (33) / EC50 (25) ~ 3] and Cbz [EC50 (33) / EC50 (26) > 1] controls. On the contrary, 34 
displayed a cytotoxic effect equivalent to that of gemcitabine. The carbonate protected prodrug 
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36 displayed a reduction of cytotoxicity relative to gemcitabine [EC50 (36) / EC50 (16) ~ 6], while 
35 only displayed a limited reduction in cytotoxicity as compared against drug [EC50 (35) / EC50 
(16) ~ 3]. For the purpose of this study 33 shows the best safety profile, whilst the reduction 
of toxicity obtained with the carbonate prodrug 36 was noteworthy given the widely reported 
low stability of this group. 
 
 
3.5 Pd-mediated Gemcitabine Prodrug in vitro Conversion Study 
Having determined that 33 and 36 confer enhanced bioorthogonality to gemcitabine by 
masking the free amino and hydroxy group respectively, the next step was to determine 
sensitivity of the Pobc group to Pd-mediated catalysis. As in Chapter 2, a heterogeneous Pd 
source would be utilised as the catalyst. Pd0 functionalised beads (130 μm average diameter) 
were prepared according to a reported protocol34 to test the susceptibility of the best prodrug 
candidates to undergo Pd-mediated activation. 
 
Quantitative analysis of prodrug cleavage via UPLC analysis presented unexpected 
challenges. When any of 32 - 36 were directly injected into the UPLC machine at 
therapeutically relevant concentrations (10 – 1000 μM), broad bimodal peak distributions were 
consistently observed by UV-Vis detection. Fine-tuning by altering drug concentration, solvent 
mixture ratios and elution rate did not change this distinct peak distribution pattern, Thus the 
resolution of separate peaks corresponding to generation of drug from prodrug was not 
possible. 33 and 36 were therefore progressed directly into an in vitro BOOM assay. 33 and 
36 were incubated in combination with Pd0 beads in MiaPaCa-2 cells against 26 and 25 as a 
negative and positive control respectively. An initial assay was conducted at 30 nM to observe 





Figure 3.11 Preliminary Pd-mediated activation assay to compare activity of 
gemcitabine prodrugs 25, 26, 33 and 36 against drug in MiaPaCa-2 cells. Experiments: 
0.1% (v/v) DMSO (untreated cell control, white); 1 mg/mL of Pd0 beads (negative control, 
black); gemcitabine 16 (30 nM, positive control, red); 26, 25, 33 and 36 (30 nM, negative 
control, blue); and 1 mg/mL of Pd0 beads + 26, 25, 33 and 36 (30 nM, BOOM activation, green). 
Cell viability was measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from n = 3. 
 
As previously reported 25 was capable of releasing drug upon Pd0 bead incubation, whereas 
26 was resistant to cleavage89. A significant cytotoxic effect was observed when 33 and 36 
were incubated in combination with Pd0 beads, suggesting that Pd0 beads were able to cleave 
Pobc masked 33 and 36 to release cytotoxic 16. Encouraged by this preliminary study, 33 and 
36 were next tested for BOOM activation across a range of concentrations (0.003 – 0.3 μM) 
in combination with Pd0 beads in MiaPaCa-2 cells (fig 3.12). Pd0 beads were able to release 















Figure 3.12 Pd-mediated activation of gemcitabine prodrugs in MiaPaCa-2 cell culture. 
Toxigenic effect of Pd-activated gemcitabine prodrugs across a concentration window in 
MiaPaCa-2 cells. Experiments: 0.1 % (v/v) DMSO (untreated cell control, white); 1 mg/mL of 
Pd0 beads (negative control, black); 16 (positive control, red); Prodrug (26, grey) (25, yellow), 
(33, blue) and (36, green); Prodrug + Pd0 beads (26, striped grey) (25, striped yellow), (33, 
striped dark blue) and (36, striped green). Drug and Prodrug concentrations 0.003 – 0.3 μM. 




Prodrugs of gemcitabine have been designed based on mechanism of action studies to 
remove biological interaction with dCK and CDA, two key enzymes responsible for unwanted 
metabolism155–158,160. C4NH2 carbamate prodrugs of gemcitabine are considered to be 
resistant to enzymatic cleavage, whereas C5’OH hydroxy group carbonate derivatives of 




Gemcitabine 16 has been previously investigated as a drug candidate amenable to BOOM 
chemotherapy89. Poc, Alloc and Cbz protecting groups were functionalised to 16 at the C4NH2 
and C5’OH positions and tested in vitro. The N-Poc derivative 25 improved bioorthogonality 
with respect to 16, and was cleaved to release drug in the presence of Pd0 beads. The N-Cbz 
derivative 26 was also capable of reducing inherent cytotoxicity, however was resistant to Pd-
mediated cleavage. The best reported N-protecting group for 16 was capable of eliciting a 23 
fold decrease in cytotoxicity. No O-protecting group was bioorthogonal during a 5 day 
biocompatibility assay. 
 
In this work, the Pobc protecting group was designed and incorporated via a semisynthetic 
strategy at the C4NH2 and C5’OH positions of gemcitabine. The introduction of an N-Pobc 
(functionalised at the amino group of the pyrimidine ring) was sought to further enhance 
bioorthogonality observed in Poc and Cbz group masking. An O-Pobc (functionalised at the 
hydroxyl group) was also developed to improve the stability of the labile carbonate. Expected 
by-products of Pd-mediated Pobc cleavage were tested for bioorthogonality and found to be 
non-toxic across a broad range of cell types. 
 
The N-Pobc prodrug 33 was found to be slightly more biocompatible than N-Cbz and N-Poc 
groups [EC50 (33) / EC50 (25) ~ 3], [EC50 (33) / EC50 (26) > 1], reducing the cytotoxicity of the 
prodrug 27 fold relative to the unmodified drug 16. The o-Pobc prodrug 36 displayed a 6-fold 
reduction in cytotoxicity relative to gemcitabine. Both 33 and 36 were sensitive to Pd-mediated 
deprotection over a range of concentrations, validating the use of Pobc as a novel protecting 
group for BOOM prodrug protection strategies.  
 
Although this study validates the use of Pobc, a novel protecting group capable of generating 
prodrugs that exhibit low inherent cytotoxicity and high sensitivity to palladium mediate 
activation, the enhancement afforded relative to previous carbamate strategies is marginal 






Prodrugs of Doxorubicin 
 
Doxorubicin will be investigated as the next new drug candidate amenable to masking and 
Pd-mediated activation. Protecting groups designed and incorporated into gemcitabine will 
be functionalised to the C3’ amino group of the drug and tested for biocompatibility and 
sensitivity to Pd. The observation of prodrug and drug “sequestration” into established Pd0 
devices will lead to optimization – new Pd0 devices capable of preferentially accumulating 
prodrug and releasing drug will be reported. 
 
4.1  Doxorubicin Overview 
Doxorubicin (dox) 37 is an anthracycline antitumour antibiotic used alone or in combination for 
the treatment of a wide range of haematological malignancies, carcinomas and soft tissue 
sarcomas188 (fig. 4.1). A powerful cytotoxic drug with severe side effects, dox has been the 
subject of intense research since its discovery as an antitumour agent over 40 years ago189,190, 








In standard therapy dox is dosed as a single rapid intravenous infusion once every 21 days at 
or below 550 mg/m2 191. Once administered, dox diffuses passively into the cellular 
cytoplasm192,193 where it exerts cytotoxic effect via numerous distinct pathways (fig 4.2). At 
cellular and mitochondrial membranes, dox induces lipid peroxidation by way of complexing 
with Fe2+, inducing mitochondrial DNA damage and apoptosis through the production of 
Reactive Oxygen Species (ROS)194. Dox inhibits transcription directly by irreversibly binding 
to Topoisomerase II (TopoII)195 and adducting with DNA, which is classically considered its 
main cytotoxic mode of action196. Furthermore, dox impairs Ca2+ processing in the 
endoplasmic and sarcoplasmic reticulum, one of the key contributions to its off-target side 
effect in heart tissue197,198. Dox cytotoxicity produces multiple effects on cellular physiology, 
whereby a multitude of processes that each disrupt cellular function operate together to induce 
apoptosis in rapidly dividing tumour cells199,200. 
 
 
Figure 4.2 Doxorubicin mechanism of action. Doxorubicin chemotherapy has a range of 
effects on tumour cells. Dox complexes with Fe2+ causing lipid peroxidation across and within 
cellular membranes. Dox irreversibly binds to Topoisomerase II (TopoII) and adducts with 
DNA. By producing Reactive Oxygen Species (ROS), Doxorubicin-semiquinone induces 
mitochondrial DNA damage and energy depletion as well as impaired Ca2+ processing in the 
endoplasmic and sarcoplasmic reticulum. These processes work in concert to drive apoptosis 




Early studies of anthracycline antitumour activity investigated the ability of dox to intercalate 
into the DNA double helix and form DNA adducts201. Once taken up by the tumour cell, the 
planar ring structure of dox intercalates between adjacent DNA base pairs. The relationship 
between dox cytotoxicity and DNA adduct formation is a well-established property of this 
drug202, with the N3’ amino group forming key interactions between DNA strands within the 
dox-DNA adduct and along the minor groove of DNA during intercalation203,204.  
 
Dox irreversibly binds to DNA Topoisomerases (Topo)205,206, ubiquitous enzymes in biology 
that control access to DNA supercoiling and entanglement during transcription and replication 
of the cell cycle. A recent study implicated Topo II β, a key enzyme also conserved across all 
mammalian cells as the essential driver of dox-induced cardiotoxicity in mice207. The primary 
amino group at the C3’ position of the sugar moiety of dox plays an essential role in the 
formation of the TopoII-dox-DNA complex205.  
 
A multitude of moderate to severe side effects are observed in patients when dox is directly 
injected as the hydrochloride salt208–210. Dox is primarily dose limited due to the immediate risk 
of acute cardiac toxicity incidence at higher dosages200. As a result, much of the research 
pertaining to anthracycline development has focused on suppressing cardiotoxicity during 
administration of the drug211. Attempts to limit cardiac toxicity by altering aspects of the dosage 
rate or excipient formulations of dox have shown only limited clinical benefit212,213. Despite 
concerted efforts to improve the side-effect profile, ~ 10 % of patients will develop 
cardiomyopathy post administration, a chronic degeneration of cardiac tissue which may lead 
to fatal myocardial infarction214.  
 
4.2  The Rational Design Basis for Masking the C3’ Amino Group of 
Doxorubicin 
As much evidence supports the role of dox’s C3’ amino group in eliciting cytotoxicity, this 
functional group remains a focus for chemical modification. Prodrugs of dox that mask and 
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selectively de-protect this functional group have been developed. Below are three key 
examples that prompted the rational basis for our prodrug design. 
 
A peptidyl moiety was conjugated to the NH2 at C3’ of dox as a selective substrate of an 
upregulated intratumoural enzyme known as plasmin215 (Fig 4.3.a). When plasmin cleaves the 
peptidyl masking group, dox would be released and accumulate in tumour tissue expressing 
high levels of the enzyme. The (Boc-Val-Leu-Lys)-dox prodrug masked the amino group at 
C3’ by acylation to a short poly peptide via the C terminal of a Lysine. The peptidyl group 
incorporated a D configured Boc-protected terminal valine, which was expected to retain 
plasmin induced hydrolysis whilst preventing off target activation by other endogenous amino 
peptidases. Boc-Val-Leu-Lys-dox was six fold less toxic than the unmodified drug in a Rous 
sarcoma virus transformed chicken embryo fibroblast toxicity assay. This moderate 
improvement in toxicity came at the cost of significantly reduced dox potency from slow 
release, observed in a subsequent in vivo B16 Melanoma treatment assay. We noted the 
author’s suggestion that a cleavable spacer moiety between the drug and peptide may 
contribute to improved substrate metabolism by plasmin hydrolysis. 
Subsequently an antibody directed enzyme prodrug therapy (ADEPT) strategy reported a dox 
prodrug that incorporates a spacer moiety linked to the amino group at C3’ position, designed 
to be cleaved in the presence of glycosidases216. Conceptually this ADEPT strategy is as 
follows. A covalently bonded monoclonal antibody (MAb)-glycosidase complex would be 
administered and target tumour cells by MAb receptor-antigen recognition, resulting in 
elevated levels of glycosidase in tumour tissue. Next, dox prodrug would be administered, with 
the protected amino group masking drug activity during systemic circulation. Selective 
cleavage of the prodrug in the presence of the tumour-MAb bound glycosidase releases dox 
locally at the site of tumour. Accordingly, glucuronide, the sugar substrate of glycosidase was 
attached to dox through a self-immolative spacer group between the drug and sugar moiety. 
The linked spacer group, an ortho- or para-hydroxybenzylcarbamate derivative was expected 
to spontaneously eliminate after enzymatic cleavage (fig 4.3.b). Significant cytotoxic reduction 
of the dox prodrugs was observed in L1210 Leukemia cells in vitro in the absence of 
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glycosidase. The hydroxybenzylcarbamate spacer group was also reported as stable in human 
plasma. In the presence of 0.1 µg / mL E. Coli β-glucuronidase, the ortho-substituted prodrug 
underwent rapid enzymatic hydrolysis followed by spacer elimination to release dox. 
More recently, a bioorthogonal dox deprotection strategy utilized a similar reactivation 
strategy217. By masking the amino group with a benzyl azide functional group (fig 4.3.c), a dox 
prodrug decreased growth inhibition in A431 human vulvar skin squamous carcinoma cells. A 
cytotoxic effect was re-established by the repeated infusion of a phosphine derivative into cell 
culture, releasing dox via the Staudinger reaction. Further evidence that such prodrug was 
capable of bioorthogonal deprotection was reported in 2014 when a strain-promoted 1,3-
dipolar cycloaddition reaction between the same N-p-azidobenzyl dox (Fig 4.3.c) and a trans-






Figure 4.3 C3’ amino-protected prodrugs of doxorubicin. (a) A Boc-Val-Leu-Lys-dox 
prodrug was capable of releasing drug in the presence of plasmin, an upregulated enzyme in 
tumour tissue. (b) A dox prodrug masked with a spacer linked glucuronide promoiety released 
drug via glucoronidase hydrolysis followed by linker self-immolation; and (c) A dox prodrug 
masked with benzyl azide and unmasked by phosphine derivatives (Staudinger reduction) or 
trans-cyclooctene (a strained promoted 1,3-dipolar cycloaddition) followed by linker self-
immolation.  
 
These key publications focused our attention toward the development of bioorthogonal dox 
prodrugs by masking the amino group at C3’ with promoieties capable of selective 
deprotection by Pd0 bead catalysis. 
 
4.3 Synthesis of Novel Doxorubicin Prodrugs 
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Prodrugs were generated by using the novel propargyloxybenzylcarbonyl (Pobc) group 
described in Chapter 3. The Pobc group was incorporated to increase steric hindrance whilst 
providing sensitivity to Pd0 catalysis, as suggested by preliminary evidence from in vitro assays 
reported in Chapter 3 with gemcitabine prodrugs. 
 
The propargyloxycarbonyl (Poc) group was also chosen to mask the amino group of dox, as 
Poc deprotection has been utilized previously34,89,219 to conduct bioorthogonal Pd-mediated 
cleavage on fluorophores, proteins and chemotherapeutics. The carboxybenzyl (Cbz) group 
was chosen to mask dox with a metabolically stable group non-responsive to oxidative Pd 
catalysis. The Cbz group is labile to Pd catalysts in the presence of H2220. In the absence of a 
hydrogen source, i.e. in a biocompatible conditions, we have observed that the Cbz group is 
highly resistant to cleavage89. As a benzyl group imparts increased steric bulk relative to a 
propargyl group, it would be expected that an N-Cbz masked dox prodrug would increase 
steric hindrance about the carbamate bond, improving stability to metabolic cleavage.  
 
All dox prodrugs were synthesized in a semisynthetic strategy using 4-nitrophenyl activated 
protecting groups (scheme 4.4). 27 and 28 were first alkylated using three equivalents of 
propargyl bromide and sodium carbonate to yield 29 and 30 in 30 % and 99 % respectively.  
Treatment of 29, 30, 38 or 39 with excess pyridine in the presence of 4-nitrophenyl 
chloroformate formed the corresponding activated carbonates 31, 32, 40 and 41 in 72 – 75 % 
yield. Each reaction was undertaken in the dark at 0 °C, to reduce the possibility of 
polymerization. Each moiety was added to dox in the presence of pyridine in dry DMF under 






Scheme 4.4 Synthesis of doxorubicin prodrugs 42, 43, 44 and 45. Reagents and 
Conditions: (i) propargyl bromide (3 equiv.), Na2CO3, toluene; reflux overnight (30 – 99 %); (ii) 
4-nitrophenyl chloroformate (1.1 equiv.), pyridine (excess) THF, 0 °C, dark, overnight (72 – 
75 %); (iii) doxorubicin (1.5 equiv.), pyridine, DMF, N2, rt, overnight (45 – 64 %) 
 
4.4 Doxorubicin Prodrug Biocompatibility Assays 
Glioblastoma U87 and Prostate cancer DU145 cell lines were chosen as cancer cell models 
due to the use of dox in associated indications as a first-line or adjuvant drug alone or in 
combination therapy. Dose-response studies were conducted on dox and each of 42, 43, 44, 
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Figure 4.5 Study of doxorubicin cytotoxic reduction produced by 42 - 45 prodrugs in 
cell culture. Semilog dose−response curves and calculated EC50 values of prodrugs 42 
(dashed blue), 43 (dashed green) 44 (solid grey), and 45 (solid orange) in comparison to those 
of unmodified dox (solid red) in (a) DU145 and (b) U87 cells. Cell viability was measured at 
day 5 using PrestoBlue® reagent. Error bars: ± SD from n = 3 
 
 
All prodrugs showed a significant reduction in cytotoxicity relative to dox. As predicted, the Poc 
group conferred the least steric hindrance to the carbamate bond, resulting in a narrower 
therapeutic window [EC50 (45) / EC50 (dox) ~ 31(U87); 36(DU145)]. Notably, the two Pobc 
derived prodrugs displayed much higher reduction of cytotoxicity [EC50 (42) / EC50 (dox) ~ 
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64(U87); 242(DU145)], [EC50 (43) / EC50 (dox) ~ 134(U87); 310(DU145)], superior to that of 
the Cbz prodrug [EC50 (44) / EC50 (dox) ~ 40(U87); 117(DU145)].  
 
4.5 Design of the bis-o-Pobc Protecting Group 
As 43 was found to be the most efficient group for dox deactivation, we further envisioned 
functionalizing a bis-2,6-propargyloxybenzylcarbonyl (bis-o-Pobc) group to the amino group at 
the C3’ position. The introduction of a second propargyloxy group was intended to 
simultaneously enhance steric hindrance and increase the propensity of Pd-mediated moiety 






Scheme 4.6 The bis-2,6-propargyloxybenzylcarbonyl (bis-o-Pobc) group. (a,b) A 
proposed mechanism for the Pd0 catalysed cleavage of the bis-o-Pobc groups in water. Pd-
mediated oxidative cleavage of the propargyl groups trigger benzyl elimination to release X 




A semisynthetic strategy was developed to incorporate bis-o-Pobc (scheme 4.7). 46 was 
propargylated at each of the hydroxyl positions using propargyl bromide and sodium carbonate. 
The carboxylic group was then reduced to alcohol 48 by lithium aluminium hydride. Treatment 
with 4-nitrophenyl chloroformate in the presence of pyridine formed the corresponding 
carbonate 49. Adding 49 to dox in the presence of pyridine yielded carbamate prodrug 50 in 




Scheme 4.7 Synthesis of doxorubicin prodrug 50. Reagents and Conditions: (i) propargyl 
bromide (0.25 equiv.), Na2CO3, toluene, 4 °C, overnight (44 %); (ii) LiAlH4, THF, 10 % NaOH, 
0 °C, overnight (63 %); (iii) 4-nitrophenyl chloroformate (1.1 equiv.), pyridine, THF (86.5 %), rt, 
overnight; (iv) doxorubicin, pyridine, DMF, N2, 0 °C overnight (30 %) 
 
A dose-response study was conducted on 50 and dox in Glioblastoma U87 and Prostate 








Figure 4.8 Study of doxorubicin cytotoxic reduction produced by prodrug 50 in cell 
culture. Semilog dose−response curves and calculated EC50 values of prodrug 50 (light 
blue), in comparison to that of unmodified dox (solid red) in (a) DU145 and (b) U87 cells. Cell 
viability was measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from n = 3 
 
 
Although 50 reduced cytotoxicity with respect to dox, the effect was not as prominent as with 
either 42 or 43. It was noted that 50 was practically insoluble in standard solutions of cell media 
when added in a 0.1 % (v/v) DMSO solution at concentrations above 1 µM, which may account 
for the unusual semi-log dose response curves at concentrations above 1 µM. This precluded 
the ability to reliably assess the EC50 value of 50 at concentrations above 1 µM. Nevertheless, 
as 50 was considerably less cytotoxic to cells than dox it progressed together with prodrugs 




4.6 Reviewing the Pd Device 
Next, prodrugs of dox will be progressed into in vitro activation studies. As this section reports 
both on the Pd-mediated activation of dox prodrugs, as well as the subsequent development 
of novel Pd0 beads that enhance conversion and release kinetics of drug, a small update on 
the current state of Pd catalysis in our lab is provided herein.  
 
Palladium is a versatile transition metal that has revolutionized the last 50 years of 
organometallic chemistry221,222. Widespread application comes from the fact that Pd and Pd 
complexes are capable of adducting to many organic molecule classes; including alkenes, 
alkynes, dienes and CO, as well as alkyl, aryl and vinyl halides221. Adduct formation is capable 
of forming or cleaving carbon-carbon bonds, depending on the system in question. Pd has 
four oxidation states (PdII, Pd0, PdIV and PdI); allowing for the metal to function as an 
electrophile (PdII) or nucleophile (Pd0). Pd0 emerges as an attractive catalyst candidate to 
conduct bioorthogonal carbon cleavage reactions due to a low toxicity profile and broad scope 
of activity in standard carbon-heteroatom cleavage chemistry223. Pd0 catalysts have been 
investigated for their capability to deprotect prodyes and prodrugs in biological systems 224,225. 
 
We have utilized a previously reported methodology to routinely synthesise and encapsulate 
Pd0 nanoparticles into polyethylene glycol-polystyrene (PEG-PS) microspheres (beads) of 
regular size81. These Pd0 beads have formed the basis of the BOOM Pd0 labile prodrug and 
probe deprotection strategy for the past five years33,34,81,89,90,130. As the library of prodrugs 
amenable to Pd0 dependant deprotection continues to expand, a corresponding focus on 
advancing the Pd0 device is necessary. This will ensure that optimally functional forms of both 
the device and the therapeutic are at hand as BOOM chemotherapy progresses into the 
development of pre-clinical assays.  
 
4.7 Design, Synthesis and Characterization of Pd0 Functionalized Beads 
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Pd0 nanoparticles are highly reactive and efficient catalysts due principally to their high surface 
area to volume ratio226. Several drawbacks however preclude their direct use in complex living 
systems. The difficulty of positioning or administering a homogenous catalysts for site selective 
activation presents the most obvious challenge: undesired distribution of a soluble catalyst 
about the organism may lead to toxicity (i.e. via unwanted organ accumulation), low activation 
in the tissue of interest (as a result of off target accumulation and poor distribution) and/or 
rapid clearance (by immune system mediated phagocytosis and removal from the 
bloodstream). Encapsulating individual Pd0 nanoparticles within a solid support system as a 
heterogeneous catalyst would allow for the surgical insertion of a device directly into the tissue 
of interest. Ideally the device would function as a bio-inert medical insert loaded with 
immobilized Pd0 nanoparticles that would localise the effect of catalysis to the target tissue. 
 
An immobilization technique was initially reported227, then subsequently optimised228,229 for the 
encapsulation of Pd0 nanoparticles into 130 µm diameter PEG-PS microspheres. NovaSyn 
TG® amino resins (130 µm diameter) are treated with Pd(OAc)2 (3 equivalents.) causing the 
resin to change colour from translucent to dark orange. Resin bound Pd(OAc)2 is then reduced 
to Pd0 in a 10 % hydrazine monohydrate solution in MeOH, affecting a subsequent colour 
change to black. Addition of Fmoc-Glu(OH)-OH via a standard Oxyma/DIC amide coupling 
procedure physically entraps Pd0 to the resin. This protocol reliably synthesises comparable 
batches of Pd0 beads that may be stored at 4 °C for up to 12 months with no observed 
reduction in catalytic efficiency. Our group has previously undertaken extensive studies to 
characterise and image these beads. Once synthesised, each batch undergoes a ninhydrin 
test and Scanning Electron Microscopy (SEM) (fig 4.9) alongside a standard catalytic 
efficiency assay using an activatable molecular probe89. Suitable batches are directly utilized 








Figure 4.9 Assessment of 130 µm diameter Pd0 beads for coupling and size 
homogeneity. (a) Ninhydrin test to determine the efficacy of the final coupling reaction in 
accordance with a standard solid phase peptide synthesis protocol33. Left sample dyed blue 
due to incomplete Oxyma/DIC amide coupling reaction. Clear solution from right sample 
shows complete coupling81,230 (b) Scanning Electron Microscopy of successfully Oxyma/DIC 
amide coupled 130 µm diameter Pd0 beads to determine homogeneity in bead size and shape 
using a Hitachi S-4700 scanning electron microscope 
 
4.8 Non-biological Pd-mediated Doxorubicin Prodrug Conversion Study  
Having determined that Poc, Cbz, p-Pobc, o-Pobc and bis-o-Pobc groups confer reduced 
bioactivity by masking the C3’ amino group of dox, the next step was to determine the 
sensitivity of each of these groups to standard Pd0 bead mediated catalysis. This was achieved 
by first incubating 42, 43, 44, 45 and 50 at 100 µM in PBS solution in a thermomixer at 1400 
rpm, 37 °C for 48 hr then submitting 50 µL aliquots to UPLC analysis to determine the elution 
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Figure 4.10 Non-biological stability assay of doxorubicin prodrugs 42 – 45 and 50. UPLC 
chromatograms of (a) dox (red), (b) 44 (dark grey), (c) 45 (orange), (d) 42 (dark blue), (e) 43 
(green) and (f) 50 (light blue) as 100 µM solutions in PBS incubated at 1400 rpm, 37 °C for 48 





Each of 42 – 45 and 50 were stable in PBS after 48 hr. Retention times were assigned, dox 
(retention time 37 = 2.9 min) and prodrugs (retention time 44 = 4.8 min, 45 = 4.1 min, 42 = 4.9 
min, 43 = 5.0 min and 50 = 5.1 min). Next, 1 mg / mL of 130 µm Pd0 beads was added to each 
















Figure 4.11 Non-biological conversion assay of doxorubicin prodrugs 42 – 45 and 50 in 
combination with 130 µm Pd0 beads. UPLC chromatograms producing doxorubicin (red) 
from dox prodrugs of (a) 45 (orange), (b) 44 (grey), (c) 42 (dark blue), (d) 43 (green) and (f) 
50 (light blue) as 100 µM solutions in PBS incubated with 1 mg / mL of 130 µm Pd0 beads at 
1400 rpm, 37 °C for 3, 6, 24 and 48 hr (a-d) or 0, 0.5 and 24 hr (e). Impurities consistent with 
background are highlighted in light grey across all chromatograms. 
 
 
Figure 4.11 confirms the Pd0-mediated cleavage of 45, 42, 43 and 50, with each prodrug 
producing dox to varying degrees over 48 hr. 44 was unmodified by Pd0 catalysis, as predicted 
by previous studies and in accordance with the inability of Pd0 to cleave the Cbz group in the 
absence of a hydrogen source. By-products were not observed. 
 
One effect consistently observed was the reduction (or total disappearance) of either dox 
and/or prodrugs. This is seen in fig 4.11, whereby the signal for 44 (fig 4.11a), 42 (fig 4.11c) 
and 43 (fig 4.11d) diminishes over time without the equimolar generation or growth of other 
peaks (including dox). Further evidence is seen with 45 (fig 4.11b), whereby dox is rapidly 
produced then shrinks over time, and in the UPLC chromatogram of 50 (fig.4.11e) with peaks 
corresponding to both prodrug and drug absent after t = 48 hr. Despite this, significant 
quantities of dox was generated from prodrugs on incubation with a Pd0 source. The proposed 
reason for this inconsistency is addressed in detail in section 4.10.  
 
4.9 Pd-mediated Doxorubicin Prodrug in vitro Conversion Study  
An in vitro BOOM assay was next conducted to test the extent to which conversion to dox 
would take place in combination with Pd0 in a living system. Each of 42 – 45 and 50 was initially 






Figure 4.12 Preliminary Pd-mediated activation assay to compare activity of 
doxorubicin prodrugs 42-45 and 50 against drug in DU145 cells. Experiments: 0.1% (v/v) 
DMSO (untreated cell control, white); 1 mg/mL of 130 µm Pd0 beads (negative control, black); 
dox (1 µM, positive control, red); 45, 44, 42, 43 and 50 (1 µM, negative control, blue striped); 
and 1 mg / mL of Pd0 beads + 45, 44, 42, 43 and 50 (1 µM, BOOM activation, green checked). 
Cell viability was measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from n = 3. 
 
Whilst neither Pd0 beads nor prodrugs affected cell viability individually, a significant cytotoxic 
effect was observed in combination. This assay confirmed the ability of 130 µm Pd0 beads to 
cleave Poc, p-Pobc, o-Pobc and bis-o-Pobc protecting groups from a carbamate in situ to 
release dox. The Cbz group was resistant to cleavage as observed by UPLC studies and 
included as a negative control. 
 
Each prodrug was next tested for BOOM activation across a range of therapeutically relevant 
drug concentrations in combination with 130 µm Pd0 beads in prostate cancer DU145 cells (fig 















Figure 4.13 Pd-mediated activation of doxorubicin prodrugs in DU145 cell culture. 
Toxigenic effect of Pd-activated doxorubicin prodrugs across a concentration window in 
DU145 cells. Experiments: 0.1 % (v/v) DMSO (untreated cell control, white); 1 mg / mL of 130 
µm Pd0 beads (negative control, black); doxorubicin (positive control, red); Prodrug (a) 44, 
grey, (b) 45, orange, (c) 42, dark blue, (d) 43, green and (e) 50, light blue; Prodrug + 130 µm 
Pd0 beads (a) 44, striped grey, (b) 45, striped orange, (c) 42, striped dark blue, (d) 43, striped 
green and (e) 50, striped light blue. Drug and Prodrug concentrations 0.03 – 3 µM (42 - 45), 
0.1 – 3 µM (50). Cell viability was measured at day 5 using PrestoBlue® reagent. Error bars: 














Figure 4.14 Pd-mediated activation of doxorubicin prodrugs in U87 cell culture. 
Toxigenic effect of Pd-activating doxorubicin prodrugs across a concentration window in U87 
cells. Experiments: 0.1 % (v/v) DMSO (untreated cell control, white); 1 mg / mL of 130 µm Pd0 
beads (negative control, black); doxorubicin (positive control, red); Prodrug (a) 44, grey, (b) 
45, orange, (c) 42, dark blue, (d) 43, green and (e) 50, light blue; Prodrug + 130 µm Pd0 beads 
(a) 44, striped grey, (b) 45, striped orange, (c) 42, striped dark blue, (d) 43, striped green and 
(e) 50, striped light blue. Drug and Prodrug concentrations 0.03 – 3 µM (42 - 45), 0.1 – 3 µM 
(50). Cell viability was measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from n 
= 3.  
 
These studies (fig 4.13) (fig 4.14) confirm the ability of Pd0 beads to release dox from each of 
45, 42, 43 and 50 when incubated in combination across a broad therapeutic range. Although 
130 µm Pd0 beads incubated with 45, 42 and 43 released significant levels of dox, these 
combinations were unable to elicit a cytotoxic response equivalent to dox alone in either cell 
line. 50 in combination with the 130 µm Pd0 beads displayed a strong cytotoxic effect 
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comparable to dox, an indication consistent with the increased speed that 50 undergoes Pd0-
mediated cleavage (fig 4.11.e). 
 
4.10 The Sequestration Effect of Doxorubicin and Prodrugs on Activation 
The incomplete activation observed in BOOM in vitro assays and UPLC studies suggests that 
130 µm Pd0 beads do not activate prodrugs with optimal efficiency. In the routine process of 
UPLC sample preparation it was observed that after mixing for 30 min, the solution of all dox 
prodrugs and 130 µm Pd0 bead + dox prodrug combinations would change colour from bright 
red to clear, with Pd0 beads dyed dark red. This effect was not observed when dox and 130 
µm Pd0 beads where incubated together (fig 4.15).  
 
 
Figure 4.15 Sequestration of doxorubicin prodrugs by 130 µm Pd0 beads. Experiment: 
separate solutions of (a) 100 µM dox and 1 mg / mL of 130 µm Pd0 beads and (b) 100 µM 42 
and 1 mg/mL 130 µm Pd0 beads were stirred in 1 mL solutions of PBS at 37 °C for 30 min then 
flash frozen in liquid nitrogen and photographed.  
 
Whereas rapid sequestration of prodrug into the Pd0 bead from the surrounding environment 
is a highly attractive property for localised treatment (i.e. by absorbing administered prodrug 
from the bloodstream and accumulating it into the catalyst within the target tissue), this effect 
may be conversely limiting the catalytic effect during in vitro studies and thereby reducing the 
release (both physical and chemical) of the active drug.  
 




To overcome the catalytic inefficiency observed, we developed a library of Pd0 beads across 
a range of sizes. We expected beads of smaller diameter (i.e. below 130 µm) would have both 
a smaller total internal volume available to sequester prodrug, and a greater surface area to 
volume ratio to increase reactivity. Using Merck Millipore’s commercial catalogue of NovaSyn 
TG® amino beads, naked resins of varying size (10 µm – 110 µm diameter) were purchased 
and incorporated into the standard Pd0 bead synthetic methodology by simply replacing the 
130 µm diameter bead with a variable sized bead batch in the synthetic protocol. The author 
would like to acknowledge here that Dr Ana Pérez-López synthesised batches of Pd0 beads 
according to the below protocol to allow for analysis. 
 
Pd0-functionalized beads were prepared from NovaSyn TG NH2 HL resin (110 µm diameter 
(0.4 mmol NH2/g)), (75 µm diameter (0.4 - 0.6 mmol NH2/g)) and TentaGel® M NH₂ Monosized 
Amino TentaGel Microspheres (110 µm, 30 µm, 20 or 10 µm diameters) (0.2 - 0.3 mmol NH2/g)) 
as described in Section 4.7. To confirm that the structural integrity of the bead had not been 
compromised during the synthesis, SEM images confirmed the spherical shape and size 













Figure 4.16 Scanning Electron Microscopy images of variable sized Pd0 beads. (a) 10 
µm Pd0 beads (x 300 mag) (b) 20 µm Pd0 beads (x 450 mag) (c) 30 µm Pd0 beads (x 800 mag) 
and (d) 110 µm Pd0 beads (x 450 mag) (scale bar = 100 µm) 
 
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) was used to determine 
the loading of Pd0 functionalized into the respective beads. ICP-OES is a standard technique 
used for the detection of trace metals in a sample by measuring the characteristic 
electromagnetic radiation emission spectra of known metals (i.e. Pd) produced via inductively 
coupled plasma excitation. Using this process an unknown concentration of metal sample may 
be determined against a standard curve. Accordingly, Dr Ana Pérez-López prepared a sample 
for ICP-OES analysis. Each pre-prepared Pd0 bead batch was digested in a 10 % solution of 
nitric acid and heated overnight. The resultant mixture was diluted then submitted for ICP-OES 





Pd bead diameter Loading of Pd (mmol/g) Error ± 
110 µm 0.42 0.0022 
75 µm 0.52 0.0028 
30 µm 0.19 0.0012 
20 µm 0.06 0.0008 
10 µm 0.07 0.0007 
Table 4.17 Pd loading in variable sized beads. Pd loading (mmol / g) of Pd-beads calculated 
according to the amount of Pd-functionalized beads (mg) and the atomic weight of Pd (106.42 
amu) by ICP-OES. 
4.12 Testing the Catalytic Properties of 30 µm Pd0 Beads in a Biological 
System 
To determine the catalytic effect of each of the beads, a previously reported Pd0-mediated bis-
N,N’-propargyloxycarbonyl-rhodamine 110 (Poc-Rho) deprotection assay was tested against 
each batch of different sized beads34. This experiment was conducted by Dr Ana Pérez-López. 
Poc-Rho was prepared from Rhodamine 110 chloride as previously described89, then 10 μM 
was dissolved in individual solutions containing PBS (1 mL) and incubated together with 1 mg 
of each 10 – 110 µm sized Pd0-functionalized beads. The mixture was shaken at 1200 rpm 
and 37 °C in a thermomixer, then reaction crudes were scanned for Rhodamine 110 




Figure 4.18 Fluorescent analysis of Pd-mediated Poc-Rho activation assay in PBS. 
Experiment: bis-N,N’-propargyloxycarbonyl-rhodamine 110 (Poc-Rho) (10 µM) in 0.1 % 
DMSO was converted into Rhodamine 110 by Pd0-functionalized beads (1 mg/mL) of varying 
size after incubation in PBS (1 mL) for 6 hr at 1200 rpm and 37 °C in the Thermomixer. As a 
negative control, Poc-Rho in 0.1 % DMSO in the absence of Pd0 beads was incubated under 
the same conditions. Fluorescence signal was measured at λex/em 480/535 nm. Error bars: ± 
SD from n = 8. 
Observing an inverse relationship between catalytic effect and bead size, we were encouraged 
to repeat this experiment with addition of Fetal Bovine Serum (FBS). FBS is a complex milieu 
of enzymes that approximates the demands that biology would apply on the catalytic effect for 
each bead. Accordingly, Dr Ana Pérez-López conducted a Pd-mediated Poc-Rho deprotection 
assay was again tested by dissolving Poc-Rho (10 µM) in a 10 % FBS in PBS solution (1 mL), 
shaken at 1200 rpm and 37 °C in a thermomixer, then monitored for Rhodamine 110 
fluorescence signal at 6 hr by a standard multilabel plate reader (fig 4.19). 
 
Figure 4.19 Fluorescent analysis of Pd-mediated Poc-Rho activation in PBS with FBS 
serum added. Experiment: bis-N,N’-propargyloxycarbonyl-rhodamine 110 (Poc-Rho) (10 µM) 
in 0.1 % DMSO was converted into Rhodamine 110 by Pd0-functionalized beads (1 mg / mL) 
of varying size after incubation with 10 % Fetal Bovine Serum in PBS (1 mL) for 6 hr at 1200 
rpm and 37 °C in the Thermomixer. As a negative control, Poc-Rho in 0.1 % DMSO in the 
absence of Pd0 beads was incubated under the same conditions. Fluorescence signal was 
measured at λex/em 480/535 nm. Error bars: ± SD from n = 8. 
An overall trend towards increasing catalytic activity in smaller beads was observed, with 30 
µm beads outperforming other candidates. Although 10 and 20 µm beads also displayed good 
reactivity, studies have investigated the propensity of small particles231, including polystyrene 
microspheres232,233 of up to 10 µm in diameter to be engulfed by various phagocytes in vitro 
-	105	-	
	
and in vivo. As phagocytosis would have a detrimental effect on the function and positioning 
of Pd0 beads in a living system, 30 µm diameter beads were selected as an optimal candidate 
on the basis of excellent reactivity and size characteristics. 
4.13 Biocompatibility of 30 µm Pd0 Beads in vitro 
Once the catalytic effect of the new Pd0 beads had been established, the next step was to 
validate biocompatibility across a diverse range of cell types in vitro. Pd0 beads were incubated 
in DU145 and U87 cancer cell lines with increasing concentration and monitored for cell 
viability by adding PrestoBlue® reagent after 5 days and analysing with spectrofluorometry 
(fig 4.20). It was determined that 30 µm Pd0 beads were at least as biocompatible as 130 µm 
Pd0 beads in both cell lines, with cytotoxicity only observed across each cell line at 







Figure 4.20 Biocompatibility of 30 µm vs 130 µm Pd0 beads in cell culture. Study of the 
unspecific cytotoxic effect induced by incubating increasing concentrations (0.5 mg / mL – 2 
mg / mL) of 30 µm Pd0 beads (hatched) vs 130 µm Pd0 beads (checked) in (a) DU145 and (b) 
U87 cell culture. Cell viability was measured at day 5 using PrestoBlue® reagent. Error bars: 
± SD from n = 6. 
 
4.14 Non-biological Pd-mediated Doxorubicin Prodrug Conversion Study 
with 30 µm Pd0 Beads 
Having validated the safety and reactivity of the 30 µm Pd0 beads in biocompatible conditions, 
we progressed the beads into a non-biological Pd0 mediated in vitro dox prodrug conversion 
assay. 42, 43 and 50 were incubated at 100 µM in 0.1 % DMSO together with 1 mg/mL of the 
30 µm Pd0 beads in a thermomixer at 1400 rpm, with 50 µL aliquots taken and analysed by 









Figure 4.21 Non-biological conversion assay of doxorubicin prodrugs 42, 43 and 50 in 
combination with 30 µm Pd0 beads. UPLC chromatograms producing doxorubicin (red) from 
prodrugs of (a) 42, (b) 43, and (c) 50 (light blue) as 100 µM solutions in PBS incubated with 1 
mg / mL of 130 µm Pd0 beads at 1400 rpm, 37 °C for 3, 6 and 24 hr (a, b) and 0, 0.5 and 24 
hr (c). Impurities consistent with background are highlighted in light grey across all 
chromatograms. 
 
Prodrug peaks were determined as in Section 4.8 by submitting a 100 µM concentration of 
each sample mixed with 0.1 % DMSO to UPLC and determining retention time off the column. 
Peaks were then assigned accordingly to each aliquot run by UPLC analysis. 30 µm Pd0 beads 
are capable of rapidly generating high concentrations of dox in biocompatible conditions over 
short periods of time (fig 4.21). Whereas 130 µm Pd0 beads were observed to sequester 
prodrug and drug simultaneously, 30 µm Pd0 beads selectively sequesters prodrug alone, a 
significant advantage over the original Pd devices. 
 
4.15 Pd-mediated conversion of Doxorubicin prodrugs with 30 µm Pd0 
beads in cancer cell culture 
Next, 42 and 43 were separately incubated with 1 mg / mL of 30 µm Pd0 beads in a BOOM 
activation assay across three therapeutically relevant concentrations in DU145 (fig 4.19) and 
U87 (fig 4.20) cells, to determine whether 30 µm Pd0 beads were capable of producing a 









Figure 4.22 Comparative Pd-mediated activation of doxorubicin prodrugs 42 and 43 with 
30 µm vs 130 µm Pd0 beads in DU145 cell culture. Toxigenic effect of Pd-mediated 
activating dox prodrugs across a concentration window in DU145 cell culture. Experiments: 
0.1 % (v/v) DMSO (untreated cell control, white); 1 mg / mL of (a,c) 30 µm or (b,d) 130 µm 
Pd0 beads (negative control, black); Drug (doxorubicin positive control - red); Prodrug (42 - 
blue), (43 – green); Prodrug + (a,c) 30 µm or (b,d) 130 µm Pd0 beads (42 + Pd0 beads - striped 
blue), (43-Dox + Pd0 beads – striped green). Drug and Prodrug concentrations 0.1 – 1 µM. 








Figure 4.23 Comparative Pd-mediated activation of doxorubicin prodrugs 42 and 43 with 
30 µm vs 130 µm Pd0 beads in U87 cell culture. Toxigenic effect of Pd-mediated activating 
dox prodrugs across a concentration window in U87 cell culture. Experiments: 0.1 % (v/v) 
DMSO (untreated cell control, white); 1 mg / mL of (a,c) 30 µm or (b,d) 130 µm Pd0 beads 
(negative control, black); Drug (dox positive control - red); Prodrug (42 - blue), (43 – green); 
Prodrug + (a,c) 30 µm or (b,d) 130 µm Pd0 beads (42 + Pd0 beads - striped blue), (43 + Pd0 
beads – striped green). Drug and Prodrug concentrations 0.1 – 1 µM. Cell viability was 
measured at day 5 using PrestoBlue® reagent. Error bars: ± SD from n = 3. 
 
Remarkably the 30 µm Pd0 beads released dox from 42 and 43 sufficiently to produce a 
cytotoxic effect almost identical to the active drug when incubated in combination whilst 
remaining bioinert when incubated alone with cells. The extent to which 30 µm Pd0 beads 
improved the reactivity of the assay is shown as semi-log dose response curves with EC50 
values for dox, 42 and 43 in combination with 130 µm Pd0 beads or 30 µm Pd0 beads (fig 4.24 















30 µm Pd0 Beads 
42 
+ 
130 µm Pd0 Beads 
EC50 (DU145) 33.8 nM 31.3 nM 120.7 nM 
EC50 (U87) 112.5 nM 118.2 nM 168.1 nM 
 
 
Figure 4.24 Pd-mediated activation of 42 with 30 µm Pd0 beads. Semi-log dose response 
curves of dox (red), 42 + 130 µm Pd0 beads (dark blue) and 42 + 30 µm Pd0 beads (light blue) 
in (a) DU145 and (b) U87 cell culture. Error bars represent ± standard deviation from n = 3. 














30 µm Pd0 Beads 
43 
+ 
130 µm Pd0 Beads 
EC50 (DU145) 16.5 nM 21.1 nM 27.6 nM 
EC50 (U87) 76.7 nM 69.0 nM 88.7 nM 
 
 
Figure 4.25 Pd-mediated activation of 43 with 30 µm Pd0 beads. Semi-log dose response 
curves of dox (red), 43 + 130 µm Pd0 beads (dark green) and 43 + 30 µm Pd0 beads (light 
green) in (a) DU145 and (b) U87 cells. Error bars represent ± standard deviation from n = 3. 




Previously reported mechanistic insights have concluded that the C3’ amino group of dox plays 
a key role in eliciting cytotoxicity202–205. Numerous prodrug strategies have reported the 
successful masking and deprotection of amino bearing protecting groups in living systems215–
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218. Encouraged by the deactivation and activation profiles of Gemcitabine prodrugs 25, 26, 33 
and 34, Poc, Cbz and Pobc groups were incorporated at the C3’ amino position of dox to 
determine the influence of steric bulk on prodrug activity. A direct relationship between the 
reduction of bioactivity and increasing steric bulk around the carbamate group was observed 
in biocompatibility assays. EC50 values for prodrugs 42 - 45 were consistent with this 
hypothesis in two distinct cancer cell cultures [EC50 ~ Dox << 45 < 44 < 42 < 43)], concluding 
that the o-Pobc protecting group was capable of providing the greatest protection to the 
carbamate group at the C3’ position against biological cleavage.  
  
Having validated Pobc as an excellent protecting group in dox deactivation, we next designed 
and incorporated a bis-o-Pobc protecting group at the C3’ amino of dox, with the expectation 
of outperforming both 42 and 43 by virtue of increased steric bulk. Unexpectedly, prodrug 50 
was insoluble at concentrations higher than 1 µM, and for this reason it was not possible to 
determine an accurate EC50 for 50. 45, 44, 42, 43 and 50 were subjected to non-biological Pd-
mediated conversion assays in the presence of 130 µm Pd0 beads. As expected, 44 was 
resistant to Pd-mediated catalysis, whereas 44, 42, 43 and 50 released dox. Notably 45 rapidly 
released dox, whereas 42 and 43 were more slowly catalysed. 50 underwent extremely rapid 
conversion to dox, with significant quantities produced within 30 minutes of incubation in 
combination with a Pd0 source.  
 
Cell viability assays were performed to quantify the cytotoxicity elicited from dox release in a 
biological system. In these preliminary studies there remained a significant gap in cytotoxicity 
between the combined dox prodrug with Pd0 beads and unmodified dox. 130 µm Pd0 beads 
were observed to rapidly sequester both prodrug and drug when incubated in combination. 
This may be attributed to the cytotoxicity gap, as activated drug trapped within the internal 
matrix of the Pd0 bead is unable to induce cytotoxicity until it is released back into solution.  
 
We looked to overcome this problem by developing smaller Pd0 beads with a higher surface 
area to volume ratio. Pd0 functionalized amino beads of sizes between 10 – 110 µm were 
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synthesised and quantified according to standard practices. 30 µm Pd0 beads rapidly 
deprotected Poc-Rho when incubated together with a 10 % Fetal Bovine Serum solution. This 
signalled that the 30 µm Pd0 beads would be capable of catalysis in a biological system. 
Whereas 10 µm and 20 µm Pd0 beads were also capable of good catalysis in the presence of 
serum, their small size may cause elimination by phagocytosis in a living system. We expected 
an equimolar quantity of 30 µm Pd0 beads would provide an increased rate of catalysis with 
less sequestration of lipophilic prodrugs into a small internal matrix in comparison to the 130 
µm Pd0 beads. 
  
Dox prodrug candidates were incubated with 30 µm Pd0 beads and their reactivity analysed 
by UPLC. Remarkably, the new Pd0 beads were capable of rapidly sequestering and 
converting prodrugs 42, 43 and 50 into active dox, which was released into solution. This is 
an attractive feature for a new Pd0 device that would conceptually pull prodrug out of circulation 
at the site of activation, whereby it is converted and quickly released as active drug at the 
intended site of treatment. BOOM activation in cancer cell culture using 30 µm Pd0 beads 
provided comparable EC50 values between the combinations of Pd-beads and prodrugs 42 
and 43 and unmodified dox across two cell lines. This optimised BOOM activation capacity 
warranted further investigation. Dox prodrugs and the optimised Pd0 device were together 






Validation in Complex Models 
 
This chapter will detail efforts towards the development of more clinically relevant prodrug 
activation assays. A library of Pd-labile prodrugs previously reported in our lab and within this 
thesis constitute the list of potential candidates to employ. Although N- and O-alkylated 
prodrugs of 5FU are completely biocompatible in cell culture and capable of Pd-mediated 
deprotection, a relatively high concentration of the parent drug is required to elicit an 
anticancer effect. Poc, Alloc and Pobc functionalised Pd-labile prodrugs of the more potent 
antimetabolite gemcitabine did not exhibit cytotoxic fold changes sufficient to progress into 
animal model studies. A floxuridine prodrug previously reported embodied an ideal candidate 
for in vivo investigation, and will be utilised for a pilot study of Pd-mediated intratumoural 
activation. Subsequently, prodrugs of doxorubicin, a more widely used chemotherapeutic, will 
be used for an in vivo / ex vivo biocompatibility and activation assay using optimised Pd0 beads. 
 
First, a multicellular tumour spheroid (MCTS) model was developed to assess the 
biocompatibility and activation of prodrugs and Pd0 beads in a three dimensional in vitro cell 
culture. Second, an embryonic zebrafish assay will study dox and prodrugs in vivo for their 
ability to prevent cardiac oedema. Third, an ex vivo mouse prostate cancer assay will study 
the capacity of novel Pd0 beads to activate Pd-labile prodrugs and a fluorescent probe after 
short and extended Pd0 bead intratumoural in vivo incubation.  
 
5.1.1 Three-dimensional cell culture overview 
BOOM prodrugs, probes and their respective by-products have previously been validated for 
biocompatibility / activation via standard cell based studies34,88–90,130,131; a process that involves 
culturing and treating cellular monolayers on a two-dimensional (2D) plastic surface. Whilst 
undeniably efficient, scalable and reproducible234,235, this method does not accurately reflect 
the physiology of cancer tissue in a living organism. Morphological, metabolic and phenotypic 
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changes arise from growing cells as 2D monolayers, and as the absence of cell-cell and cell-
matrix interactions prevents the development of a tumour microenvironment (TME)236,237, in 
vitro assays do not fully represent native state cellular function. The TME (including an 
extracellular matrix, growth factors, cytokines and chemokines) is known to play a crucial role 
in both the proliferation of cancer238,239 and the efficacy of chemotherapeutic response240,241, 
including for 5FU242–244, gemcitabine245–247 and doxorubicin248. Furthermore, a 2D cellular 
monolayer assay does not provide insight into the physical interaction and cytotoxicity 
produced by introducing a Pd0 bead into a cellular environment. As BOOM chemotherapy 
requires the precise positioning of an extracellular catalyst proximal to tumour tissue to induce 
cytotoxicity, the effect of physically forcing Pd0 beads into a tumour via microsurgery followed 
by prolonged incubation within tissue is not yet known. 
 
Three-dimensional (3D) cell cultured assays allow for cell-cell and cell-matrix interactions that 
develop a TME and morphological features suggested to closely resemble that found in in vivo 
tumour biology237,249,250. A 3D cell cultured assay would allow for the study of biocompatibility 
and BOOM activation in a system closely approximating native tumour tissue. If patient tumour 
samples were readily available, a tumour tissue explant culture method would be one viable 
way of developing a 3D BOOM chemotherapeutic model. This method allows the study of 
preserved sections of in vivo tumour, where patient derived tumour biopsies are incubated on 
a collagen surface in media and treated with test compounds251. Unfortunately, natural 
intratumoural and intertumoural heterogeneity, rapid degradation of excised tissue and 
accessibility to fresh samples hinder the tumour tissue explant method as a simple means of 
studying BOOM chemotherapy in a representative 3D system. MCTS provide a viable 





Figure 5.1.1 Illustrative example of a two-dimensional (2D) vs three-dimensional (3D) in 
vitro BOOM assay. (a) A 2D model does not produce a tumour microenvironment (TME), and 
Pd0 beads are not embedded within the monolayer, preventing the study of bead-cell interface 
toxicity. (b) A 3D model, represented here by a multicellular tumour spheroid (MCTS), 
possesses a TME representative of an in vivo tumour, and allows for the study of toxicity at 
the bead-cellular interface by embedding Pd0 beads within the spheroid. 
 
 
MCTS are heterogeneous multicellular aggregates that cluster and grow together, typified by 
hypoxic regions, necrotic cores and physiochemical gradients when spheroid diameters 
exceed 500 μm252. MCTS recapitulate to reflect the TME of an in vivo tumour with equivalent 
cellular signalling, gene expression and growth kinetics profiles253. As 2D cell cultures can be 
stimulated to reorganise into MCTS via a variety of techniques237,249,250,254–256 an MCTS model 
was chosen to develop and optimise a 3D cell culture BOOM assay.  
 
5.1.2 MCTS Assay Optimization 
An ideal MCTS assay would reproduce comparably sized spheroids in a standard 96-well 
suspension culture that may be incubated with compounds and/or Pd0 beads. MCTS have 
been capable of taking up nm sized nanoparticle formulations257–259, 100 – 200 nm PEG 
micelles260,261 and 5 μm microspheres254, however a method for the uptake of 130 μm diameter 
objects into an MCTS is not reported in literature. Accordingly, MBA-231 MCTS were co-
cultured together with individual 130 μm Pd0 beads according to a modified MCTS formation 
methodology249 adapted by the Edinburgh Cancer Discovery Unit and imaged by widefield 





Figure 5.1.2. MCTS single Pd0 bead incubation model. Protocol: 10,000 human breast 
adenocarcinoma MB231 cells (without bead, top row) and with 130 μm Pd0 bead (bottom 
row) in fresh media with 2 % Matrigel® were dispensed into each well of a 96-well Corning 
ULA® U-bottom plate at 4 °C. The plate was centrifuged and incubated under standard 
conditions, and 2 µL of a 0.3 mM DRAQ7™ stock solution was added to each well after 3 days.  
Individual spheroids were imaged by widefield microscopy with transmitted light and a Cy5 far-
red filter at day 5 (a,c) and day 8 (b,d). 
 
By measuring the DRAQ7™ apoptosis signal it was determined that localised toxicity was not 
produced when a 130 μm Pd0 bead was incubated within an MBA-231 MCTS over 48 hr 
incubation time. Importantly the Pd0 bead-cellular interface did not show an increased rate of 
apoptosis with respect to typical background cell death in growing spheroids observed in an 
untreated MCTS. Adding 1 mg / mL of 130 μm Pd0 beads (~ fifteen beads per well) during 
formation of the MCTS did not appear to induce additional cytotoxicity, however the 





Figure 5.1.3. MCTS Pd0 bead incubation model with increased catalyst loading. Protocol: 
10,000 human breast adenocarcinoma MB231 cells and 1 mg / mL of 130 μm Pd0 beads in 
fresh media with 2 % Matrigel® were dispensed into each well of a 96-well Corning ULA® U-
bottom plate at 4 °C. The plate was centrifuged then incubated under standard conditions and 
2 μL of a 0.3 mM DRAQ7™ stock solution was added to each well after 3 days. Spheroids 
were imaged by widefield microscopy with transmitted light and a Cy5 far-red filter at day 8.   
 
5.1.3 MCTS BOOM Activation Assay 
A BOOM MCTS assay was next developed to test the biocompatibility and activation of 
prodrugs in a 3D cell culture system. Glioblastoma U87 were chosen as the preferred MCTS 
cell culture type based on the following attributes. U87 cells were found to form large spheroids 
with minimal cell death and the absence of a necrotic core after 10 days of incubation (fig 
5.1.4.a). This is important as a necrotic core produces a region of localised apoptosis that may 
overlap with the cytotoxic effect generated from Pd-mediated prodrug activation within the 
MCTS. Dox produces a strong cytotoxic effect to U87 cells in 2D in vitro studies (dox EC50 = 
78 nM) whilst 43 reduces the cytotoxicity of dox by 134 fold (fig 4.5.b) and undergoes Pd-
mediated activation with both 30 μm or 130 μm Pd0 beads (4.22.c,d). 
 
Accordingly 100 μM of 43 or dox was added with DRAQ7™ to pre-prepared U87 MCTS with 
or without 1 mg / mL of 75 μm or 130 μm Pd0 beads and incubated for 5 days (fig 5.1.4). 75 
μm Pd0 beads were used in this assay as they showed comparable catalytic reactivity with 
respect to the 130 μm Pd0 beads (figure 4.18). At this stage the optimal 30 μm beads had not 
















Figure 5.1.4. MCTS prodrug activation using 43 + Pd0 beads. Protocol: 10,000 
Glioblastoma U87 cells and DMEM media containing 2 % Matrigel® and no beads or 1 mg / 
mL of 75 μm or 130 μm Pd0 beads were dispensed into each well of a 96-well Corning ULA® 
U-bottom plate at 4 °C. The plate was then centrifuged and incubated under standard 
conditions. At day 3 wells were examined by microscope to exclude non-formed MCTS or 
those that had not taken up the Pd0 bead. Media was replaced with a solution containing 3 μM 
DRAQ7™, 0.1 % (v/v) DMSO, drug or prodrug. (a) 0.1 % DMSO, (b) 100 μM 43, (c) 100 μM 
dox, (d) 100 μM 43 + 1 mg / mL 130 μm Pd0 beads and (e) 43 + 1 mg / mL + 75 μm Pd0 beads. 
Wells were imaged by widefield microscopy with transmitted light and a Cy5 far-red filter at 
day 10, and images were modified using ImageJ. Scale bar = 250 μm 
 
 
MCTS incubated with 0.1 % DMSO produced a low cytotoxic effect scattered throughout the 
spheroid typically also observed with untreated growing spheroids (fig 5.1.4.a). 43 alone did 
not produce any cytotoxic effect at 100 μM (fig 5.1.4.b), whereas dox produced a strong 
cytotoxic effect, confirmed by DRAQ7™ apoptosis staining and the reduced size of the MTCS 
(Fig 5.1.4.c). However the combination of 43 + 130 μm Pd0 beads (fig 5.1.4.d) or 43 + 75 μm 
Pd0 beads (fig 5.1.4.e) was unable to produce a cytotoxic effect. To investigate whether this 
was due to the addition of Matrigel® during spheroid formation, 100 μM 43 in 0.1 % (v/v) 
DMSO + 1 mg / mL 75 μm Pd0 beads was pre-incubated in cell media for 72 hr then used to 
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replace the media of a preformed non-Pd incubated MCTS at day 3 and incubated for an 






Figure 5.1.5. MCTS prodrug activation using pre-incubated 43 + 75 μm Pd0 beads. 
Protocol: 10,000 Glioblastoma U87 cells and DMEM media containing 2 % Matrigel® were 
dispensed into each well of a 96-well Corning ULA® U-bottom plate at 4 °C. The plate was 
then centrifuged and incubated under standard conditions. At day 3 wells were examined by 
microscope to exclude non-formed MCTS. Media was replaced with a pre-incubated solution 
containing (a) 3 μM DRAQ7™, 0.1 % (v/v) DMSO or (b) 3 μM DRAQ7™, 0.1 % (v/v) DMSO, 
100 μM 43 and 1 mg / mL 75 μm Pd0 beads. Wells were imaged by widefield microscopy with 
transmitted light and a Cy5 far-red filter at day 10, and images were modified using ImageJ. 
Scale bar = 250 μm 
 
 
A strong cytotoxic effect was confirmed by DRAQ7™ staining, however the MCTS was of an 
equivalent size to the untreated control. This may be because less dox was generated from 
the pre-incubated sample over 72 hrs than wells treated with 100 μM dox. Whilst Pd0 beads 
were capable of catalysing 43 to dox in media to elicit a cytotoxic effect to MCTS, 43 was 
unable to undergo Pd-mediated catalysis when Pd0 beads were embedded for 3 days in a 
MCTS. One possibility for this is that the Matrigel® required for spheroid formation prevents 
the flow of 43 into Pd0 beads for conversion. Matrigel® is a highly viscous glue that may block 
the porous membrane framework of PEG resins from efficiently sequestering 43.  This study 
was developed as an initial step towards the development of a bridging in vitro to in vivo 
validation assay. Although prodrug activation was not observed, two key outcomes were 
achieved. The first was that 43 is non-toxic at 100 μM to a cell culture model recapitulating an 
in vivo tumour environment. The second is that Pd0 beads may be incubated together in direct 
contact with tumours for extended periods of time without producing cytotoxicity. These 




5.2.1  Zebrafish as a model animal for doxorubicin induced cardiomyopathy 
As described in Chapter 4.1, doxorubicin (dox) is intrinsically dosage limited by 
cardiotoxicity207. Dexrazoxane is an approved adjuvant co-administered with dox used to 
mitigate cardiotoxic effect262. However this adjuvant therapy reduces the efficacy of dox 
treatment263 and may cause secondary malignancies264. As a result it was restricted from the 
European market in 2011265. Dox treatment strategies capable of alleviating cardiotoxicity with 
retained efficacy are therefore essential to improve the safety profile of this essential medicine. 
An in vivo cardiac model is required to study the effect of prodrugs vs. dox on treatment-
induced cardiomyopathy. Zebrafish have undergone extensive cardiovascular developmental 
and disease based studies266–269 with the embryonic heart possessing key molecular, cellular 




Figure 5.2.1. Phases of heart formation in the zebrafish embryo. (A) Schematic lateral 
view, dorsal to the right, of the late blastula. Ventricular (purple) and atrial (yellow) myocardial 
progenitor cells are spatially organized within bilateral marginal zones at this stage. (B–D) 
Schematic dorsal views, anterior up, depicting the locations of ventricular (purple) and atrial 
(yellow) cardiomyocytes during cardiac morphogenesis. (B) Myocardial progenitors migrate to 
form bilateral heart fields. (C) The process of cardiac fusion recruits cardiomyocytes to the 
embryonic midline, where they form a cardiac cone. (D) Continued migration of 
cardiomyocytes elongates the cardiac cone to create the heart tube. (E-F) Schematic frontal 
view (E), and lateral view (F) anterior up, depicting the morphologically distinct ventricle (purple) 
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and atrium (yellow) that are separated by a constriction at the atrioventricular canal following 
chamber emergence. Adapted from reference272 Copyright (2011) Methods in Cell Biology. 
 
Zebrafish provide an attractive model for heart development. Cardiac contraction commences 
after 24 hours post fertilisation (hpf). Inducing cardiovascular specific defect or injury during 
the first week of zebrafish embryogenesis does not cause embryonic lethality266, as the embryo 
obtains sufficient oxygenation by diffusion alone through the skin at this time270. As embryos 
are transparent, cardiac damage can be monitored on live specimens through a conventional 
widefield microscope. A zebrafish cardiotoxicity assay was thus developed for the study of dox 
and 43 on zebrafish cardiac oedema. 
 
 
5.2.2 Zebrafish doxorubicin induced cardiac oedema assay 
Zebrafish embryos were initially treated with 20 μM or 40 μM dox between 12 - 72 hpf 
according to a reported protocol273, and pericardial area relative to whole body surface area 
was determined as a ratio to infer cardiac oedema from a population of viable fish of each 
condition (fig 5.2.2).  
 
 
Figure 5.2.2 Initial study of doxorubicin induced cardiac oedema on the zebrafish 
embryonic heart. Protocol: zebrafish embryos were incubated between 12 hpf and 72 hpf in 
E3 medium containing DMSO (0.1 %) or dox at 20 μM or 40 μM. Embryos were kept in 6-well 




This initial study showed that a positive trend was induced on the relative size of the cardiac 
region with increasing dox concentration during 3 days of treatment. During the course of this 
study, spectrofluorometric analysis of the zebrafish embryo at 72 hpf determined that 
significant quantities of dox was absorbed by the chorion, an acellular envelope surrounding 
the egg. By removal of the chorion (de-chorionation) and further modification of the assay by 
way of treating zebrafish embryos with 50 μM dox between 24 - 120 hpf, a pronounced cardiac 
oedema phenotype was produced.  
 
This modified protocol was used for a subsequent in vivo assay to monitor the effect of 43 vs. 
dox on zebrafish cardiac oedema. Dechorionated embryos were treated with 0.1 % DMSO in 
E3 media and 50 – 200 μM of dox or 43 between 24 hpf and 120 hpf and the pericardial 




Figure 5.2.3 Study on the potential cardioprotective properties of 43 on embryonic 
zebrafish cardiac tissue. Left panel - lateral view study on the effect of dox and 43 on 
embryonic zebrafish cardiac tissue between 24 - 120 hpf. Lateral view of 120 hpf larvae 
exposed to E3 medium, a 0.1 % DMSO solution, 50 μM dox and 50 μM, 100 μM, 150 μM and 
200 μM of 43. Pericardiac oedema indicated by black arrow for dox treated population. Right 
Panel - histogram displaying cardiac area / total body area ratio as an estimate of pericardial 
oedema formation for populations of fish in E3 media alone untreated (grey), 0.1 % DMSO 
(black), 50 μM dox (red) and 50 – 200 μM 43 (light to dark blue with increasing concentration). 
Zebrafish populations treated with > 50 μM dox died during incubation and were excluded from 
analysis. Results are expressed as mean SEM of three independent experiments (15 fish for 
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each experiment). Asterisks indicate significant differences between dox and DMSO, 
untreated, and prodrug exposed animals.  
 
A pronounced cardiac oedema was produced when zebrafish embryos were treated with dox 
at 50 μM. Notably, no cardiac oedema was observed in fish incubated with increasing 
concentrations of 43 (fig 5.2.3. and fig 5.2.4.a). Conditions of dox above 50 μM are not included 
as populations treated with 100 μM, 150 μM and 200 μM died within 3 days of treatment, 






Figure 5.2.4 Dose-dependent viability effects of exposure to dox or 43 between 24 - 120 
hpf. (a) Lateral view of 120 hpf larvae exposed to untreated E3 media, a 0.1 % DMSO (black), 
50 μM dox and 50 – 200 μM 43. Cardiac oedema indicated by red arrow absent in other images. 
Pericardial oedema is evident at both concentrations. Scale = 50 μm (b) Viability of embryonic 
zebrafish populations treated with untreated E3 media (grey), a 0.1 % DMSO (black), 50 μM 
dox or 50 – 200 μM 43 between 24 – 120 hpf, expressed as a percentage of viable fish 
remaining at 5 days post fertilisation after incubating 15 fish per condition. 
 
Fluorescence microscopy confirmed the presence of 43 in zebrafish at 120 hpf, however it is 
important to note that an equivalent dose of dox accumulates within the fish much more 
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abundantly (fig 5.2.5). The reduced uptake/retention of 43 at 50 μM with respect to dox is 
consistent with the reduced ability of 43 to engage with the expected targets of the active drug. 
Therefore, 43 is expected to diffuse between and within cells whilst dox is retained and 
accumulated. Significant quantities of 43 was observed in the yolk of zebrafish incubated at 
200 μM, which indicated that the higher lipophilicity of the yolk (which is rich in lipid content) 





Figure 5.2.5 Fluorescence study of prodrug and drug uptake into zebrafish. Lateral view 
fluorescence study on the absorption of dox and 43 on embryonic zebrafish cardiac tissue at 
120 hpf. Lateral view zoom of 120 hpf larvae exposed to untreated medium (E3), 50 μM dox, 
50 μM 43 and 200 μM 43. Representative images of n = 15 fish per condition 
 
 
This zebrafish cardiac oedema was developed to study the potential cardio protective effect 
produced by administering 43 vs. dox in an in vivo embryonic zebrafish model. Whereas dox 
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produced a large oedema at 50 μM and was lethal at all higher concentrations, 43 did not 
significantly affect embryonic viability, nor did it induce oedema during 5 days incubation even 
at 200 μM. A future in vivo BOOM activation study that systemically administers 43 in a rodent 
model should carefully analyse the extent to which cardiomyopathy is induced against an 
equivalent dosage of dox.  
 
 
5.3.1 in vivo / ex vivo prodrug activation assay overview 
 
The BOOM chemotherapeutic concept was next progressed into a pre-clinical animal model 
activation study. An N3 masked prodrug of floxuridine, 3-propargylfloxuridine (Pro-FUdR), 
developed previously within our lab90 (fig 5.3.1) was initially investigated in combination with 
130 μm Pd0 beads for an in vivo Pd0 bead injection / ex vivo drug treatment pilot study. As a 
result of significant assay optimisation, dox prodrugs 42, 43 and 30 μm Pd0 beads emerged 
as the preferred candidates based on cytotoxicity, fluorescence attributed activation and 
catalysis respectively. 
 
The efficacy of a BOOM chemotherapeutic treatment strategy is predicated on the sustained 
long term catalytic activity of the Pd0 bead implant. An in vivo catalytic performance study is 
important to assess the long term effect of intratumoural catalyst implantation. Therefore a 
longitudinal in vivo Pd0 injection / ex vivo activation assay was developed to study the effect 
of short vs. prolonged intratumoural Pd0 bead injection followed by Pd-mediated probe/prodrug 
activation. This investigation also lead to the development of a non-perturbing microsurgical 
technique; an ultrasound guided intratumoural injection protocol for the precise insertion of 
catalytic beads into the prostates of anaesthetized mice.  
 
5.3.2 Pilot study of intratumoural Pd-mediated floxuridine prodrug activation  
Floxuridine (FUdR) is an antimetabolite chemotherapy administered in advanced colorectal, 
stomach, kidney and metastatic liver cancer indications despite significant side-effect274,275. 
Monophosphorylated-FUdR inhibits thymidylate synthetase (TS), reducing the cellular 
reservoir of thymine nucleoside reserves and halting DNA synthesis49. Triphosphoylated-
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FUdR is incorporated predominantly into DNA where it prevents chain elongation and triggers 
cellular apoptosis50. N3 masked prodrugs of FUdR have been reported to reduce cytotoxicity 
and undergo selective activation by enzymatic action277 or via induced electromagnetic 
radiation in the presence of hypoxic conditions278–281. Pro-FUdR previously underwent 
biocompatibility and BOOM activation in vitro assays under normal and hypoxic conditions90. 
Pro-FUdR was capable of > 6,000 fold cytotoxic reduction across two cell lines (fig 5.3.1.b). In 
combination with 130 μm Pd0 beads, a strong cytotoxic effect was observed corresponding to 




Figure 5.3.1 Design and assessment of a biocompatible N3 alkylated Floxuridine 
prodrug in vitro. (a) Schematic overview of the Pd-mediated release of Floxuridine (FUdR) 
from 3-propargylfloxuridine (Pro-FUdR) by Pd0 beads. (b) Cytotoxic effect of Pro-FUdR (blue) 
in comparison to unmodified FUdR (red) on BxPC-3 cells measured by semi log dose 
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response curves of increasing drug concentrations (0.0003 - 1,000 μM) to calculate 
corresponding EC50 values. Cell viability was determined at day 5 using PrestoBlue® reagent 
and a fluorescent microplate reader. Error bars: ± SD from n = 3. (c) Study of BOOM activation 
in a dose response study of cell viability after 5 days of treatment with BxPC-3 cells. 
Experiments: 0.1 % (v/v) DMSO (untreated cell control; grey), 0.67 mg / mL of Pd0 beads 
(negative control; black); 0.0003 – 3 μM of Pro-FUdR (negative controls; blue); 0.0003 – 3 μM 
of FUdR (positive controls; red) and Pd0 beads + Pro-FUdR (BOOM generation assay; in 
green). 
 
Due to the remarkable bioorthogonality fold change and sensitivity to Pd-mediated catalysis in 
vitro, Pro-FUdR was chosen as the first candidate to undergo a proof of concept in vivo / ex 
vivo prodrug activation assay. 
 
Conducting metal catalyst implantation on a mouse prostate cancer model bears homology 
with brachytherapy, an established intratumoural metal implantation treatment protocol 
commonly used in the clinic282.  Brachytherapy is a type of radiotherapy in which a radioactive 
source (notably including Pd seeds283) is implanted directly into a tumour (fig 5.3.2). A localised 
radioactive emission causes cell death within a pre-determined zone dependant on the dose 
rate (related to the half-life of the radioactive source) and radioactive source positioning.  
 
 
Figure 5.3.2 High Dose Rate (HDR) Brachytherapy treatment protocol for prostate 
cancer.  Image reprinted from open source CRUK prostate cancer infographic. (Copyright 
2016 CRUK) 
 
Brachytherapy is commonly performed on prostate tumours due to ease of accessibility and 
the ability to precisely position the radioactive source via ultrasound guidance. As the BOOM 
chemotherapeutic concept approximates the clinical protocol of brachytherapy, a mouse 
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prostate cancer model was designed. The first step was to determine whether the FUdR / Pro-
FUdR cytotoxic fold change would be observed for BxPC3 pancreatic adenocarcinoma cells. 
A biocompatibility assay conducted by Dr Mark Salji confirmed that whilst FUdR produced a 
strong cytotoxic effect (EC50 = 8 nM), Pro-FUdR had no effect on cell viability at the maximum 
assay concentration of 1 µM (safety window >125-fold). FUdR and Pro-FUdr were progressed 
into an in vivo intratumoural Pd0 bead injection / ex vivo prodrug activation study. ~ 1 x 109 
CWR22 prostate cancer cells were injected into the prostate of male mice and grown to 
approximately 1 cm3 tumours in accordance with standard protocols. 1 mg / mL of 130 μm Pd0 
beads was suspended in 50 µL sterile PBS and injected by a 1 mL syringe fitted with 9 mm 
gauge needle into the centre of a freshly excised CWR22 prostate cancer tumour (fig 5.3.3).  
 
Figure 5.3.3 Observing the outcome of Pd0 bead injections on tumour tissue samples. 
(a) A freshly excised 1 cm3 CWR22 prostate tumour with injected Pd0 beads (b) Lateral view 
of a 1 mm thick CWR22 prostate tumour slice section imaged during tissue fixation process 
with an individual Pd0 bead. 
 
Whole tumours were immediately soaked in RPMI media containing 0.1 % DMSO as a vehicle 
control or 100 μM Pro-FUdR and incubated under standard conditions for 48 hrs. Tumours 
were then sliced into 1 mm sections and embedded in paraffin wax for immunohistochemistry 







Figure 5.3.4 Immunohistochemistry staining of an intratumoural Pro-FUdR Pd-mediated 
activation assay Caspase 3 (a,b), hematoxylin and eosin (H & E) (c,d) and γ-H2AX (e,f) 
staining of CWR22 prostate tumours injected with 1 mg 130 μm Pd0 beads in 50 µL PBS then 
excised and incubated for 48 hr in 0.1 % DMSO control or 100 μM Pro-FUdR and sliced into 
1 mm sections for tissue processing. Apoptosis is identified according to each staining 
technique; (Caspase 3 (a,b); H & E (c,d) and γ-H2AX (g,h) – dark brown circles). Note the 
circular fibroblast ring present in each slice corresponding to needle injection. Pd0 beads are 
absent due to the use of xylene during the tissue processing protocol.  
 
Each panel of figure 5.3.4 shows a 1 mm tumour section sliced perpendicular to the axial plane 
of needle injection. The circular fibroblast ring in each image measures 9 mm in diameter, 
corresponding to the needle injection. Pd0 beads present in tumour slices prior to fixation (fig 
5.3.4) are unexpectedly absent from each image. This was due to the use of xylene, a 
conventional tissue fixation solvent used to clear unwanted tissue debris, dissolving Pd0 beads 
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due to their polystyrene composition. Only the spaces left by implanted Pd0 beads are visible 
(fig 5.3.5).  
 
 
Figure 5.3.5 Proposed site of Pd0 beads within a caspase 3 stained CWR22 prostate 
tumour tissue slice Red arrows indicate the space left by dissolved Pd0 beads injected within 
the needle tract of a CWR22 prostate tumour in (a) 100 μM Pro-FUdR and (b) 0.1 % DMSO 
control treated tissue slices.  
 
IHC indicates dark brown stains within the needle injection region and surrounding blank areas, 
proposed as the sites of individual Pd0 beads, which were subsequently dissolved by xylene. 
Cellular activation of the caspase 3 pathway is a hallmark of apoptosis, and is indicated by a 
dark brown stain in cells undergoing apoptotic cell signalling. Hematoxylin and eosin (H & E) 
stain is another major determinant of single-cell necrosis/ apoptosis death, and is observed 
here by cellular morphology and dark stained colour associated with cell death. γ-H2AX 
staining also resolves localised regions of apoptotic activity by a dark brown stain in individual 
cells undergoing double stranded DNA breaks, an expected outcome of incorporating 
phosphorylated derivatives of FUdR into the cell. 
Localised apoptotic regions present in Pro-FUdR treated samples (fig 5.3.4. left panels) were 
absent in DMSO treated samples (fig 5.3.4. right panels). This effect was therefore attributed 
to the activation of Pro-FUdR in combination with Pd0 beads, and not due to needle injury or 
Pd0 bead induced cytotoxicity within the tumour. The concerted cytotoxic effect between Pro-
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FUdR and Pd0 beads is further evidenced by the confined distribution of apoptotic cells within 
the fibroblast ring, the only region that Pd0 beads were present in each sample, and the 
absence of cytotoxicity at the outer surface of tissue slices, which would be exposed to high 
concentration of the prodrug alone. Subsequently a new xylene free tissue fixation method 
was developed that would allow for the visualisation of the Pd0 beads within tumour tissue (fig 
5.3.6). 
 
Figure 5.3.6 Xylene free histology for Pd0 bead visualisation. Histology of a 1 mm2 CWR22 
tumour tissue slice mixed with a solution of Pd0 beads and fixed using a xylene free freezing 
protocol. 
 
This pilot study highlighted key areas for assay optimisation. First, FUdR and Pro-FUdR are 
not fluorescent molecules, the study of BOOM activation was ultimately confined to IHC. An 
ideal prodrug/drug candidate would possess fluorescent properties that could open the 
possibility for real time imaging of prodrug/drug biodistribution, interaction with the catalyst and 
cellular uptake by confocal microscopy. Although IHC identified localised regions of cell death, 
an accompanying fluorescing non-toxic live imaging apoptotic stain solution would also allow 
for the real-time observation of apoptosis within tissue samples.  
Second, injecting a solution of 130 μm Pd0 beads through a standard 1 mL syringe fitted with 
a 9 mm needle gauge was procedurally complex, as beads would fall out of suspension and 
settle within the syringe during the injection procedure. Smaller Pd0 beads were anticipated to 
remain in suspension longer, allowing for a more controlled infusion of Pd0 beads into the 
tumour. Pd0 bead implantation was carried out by simply injecting a solution containing the 
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catalyst into a freshly excised tumour. Access to injection guiding equipment would allow for 
the precise intratumoural placement of Pd0 beads into an anaesthetised mouse with minimal 
perturbation. This experimental setup would more closely approximate a clinical Pd0 bead 
injection protocol.  
 
5.3.3 Optimising an intratumoural in vivo Pd0 bead implantation / ex vivo 
activation assay 
Dox prodrugs 42 and 43 were selected for use in this assay. Dox is an anticancer therapy 
approved across several prostate cancer indications284–286, and is a potent cytotoxin in human 
prostate DU145 cells in vitro studies (dox EC50 = 23 nM) (fig 4.5.a). 42 and 43 reduce the 
cytotoxic profile of dox in vitro by 240 and 310 fold respectively, with both prodrugs sensitive 
to Pd0 bead mediated activation consistent with conversion of prodrug to drug after 5 days 
incubation (fig 4.25).  
30 μm Pd0 beads were selected on the basis of good biocompatibility (fig 4.20), selective 
prodrug 42 and 43 sequestration (fig 4.21 a,b) and rapid drug release (fig 4.25). In addition it 
is expected that smaller Pd0 beads will remain suspended in solution for a longer period, 
simplifying the injection protocol. Dox and prodrugs are highly fluorescent, allowing for 
fluorescence microscopy of incubated tissue samples in combination with dox and prodrugs. 
4',6-diamidino-2-phenylindole (DAPI) is a non-permanent nuclear stain that emits fluorescence 
in the blue range. DAPI cell penetration is significantly enhanced in cells that have lost 
membrane integrity. By binding to DNA and emitting a strong fluorescent signal, cellular 
populations that are undergoing cell death fluoresce with much stronger intensity than healthy 
cells. Accordingly, DAPI staining solution will be used as an accompanying non overlapping 
live imaging fluorescent apoptotic stain for the real-time observation of apoptosis within treated 
samples.  
As sustained catalytic efficiency is a key consideration for in vivo prodrug activation, the 
catalytic effect of Pd0 beads will also be investigated in parallel by use of a fluorescent probe 
- Bis-N,N’-Poc-Rhodamine 110 (Poc-Rho) and its Pd0 activated product Rhodamine 110 (Rho), 
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in a probe activation study. First a longitudinal in vivo intratumoural Pd0 bead injection / ex vivo 
probe activation assay was designed. This study investigated the effect of short vs. prolonged 
intratumoural Pd0 bead incubation followed by treating the resulting explant tissue with a Pd-
labile probe. Subsequently an ex vivo prodrug activation study was conducted. A schematic 
of this workflow is presented in figure 5.3.7 
 
 
Figure 5.3.7 Schematic representation of in vivo Pd0 implantation / ex vivo activation 
assay. (a) 1 x 109 DU145 prostate cancer cells were injected into nude mice prostates and 
grown to ~ 1 cm3. (b) Mice were anaesthetised and 1 mg of 30 μm Pd0 beads in 25 μL of sterile 
PBS was injected in vivo by ultrasound guidance into the DU145 tumour and incubated in the 
live mouse for 3 weeks then excised; or (c) tumours were resected and injected immediately 
ex vivo with 1 mg of 30 μm Pd0 beads in 25 μL of PBS. (d) Excised tumours were sliced into 
1 mm sections using a sectioned slicer matrix then fixed into 24 well plates using tissue glue 
and soaked in media containing prodrugs, probes or control. (e) Time-lapse live imaging of 
tissue slices by confocal microscopy monitored fluorescence increase attributed to Pd-
mediated activation.  
 
5.3.4 Development of an ultrasound guided in-vivo Pd0 bead injection protocol  
1 mg of 30 μm Pd0 beads was suspended in 25 µL of sterile PBS solution and injected via 
ultrasound guided subcutaneous injection into prostate tumours. 30 μm Pd0 beads remained 
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suspended in solution during the injection procedure. A shadowed region within the tumour 
was identified for Pd0 bead placement, as this region was expected as a lower density, spongy 
material that would more efficiently absorb the injection volume. Pd0 beads displayed strong 
echogenicity under ultrasound and were easily observed as intensely bright spots in the plane 
of detection (fig 5.3.8).  Controlled administration of the Pd0 beads directly into tumour was 
performed over a 30 s period. The injected region was monitored for an additional 10 min to 
ensure that Pd0 beads were not leaking from the tumour into the extratumoural space, then 
the mouse was transferred for recovery. 
 
 
Figure 5.3.8 Subcutaneous ultrasound guided intratumoural prostate injection of 30 μm 
Pd0 beads into anaesthetized mouse Top Left Panel: a schematic of the injection protocol 
to insert 1 mg of Pd0 beads suspended in 25 µL into a tumour. Images captures during injection 
at (a) t = 0 s, (b) t = + 10 s and (c) t = + 30 s from the beginning of the injection. After t = + 30 
s the 25 µL solution had been completely injected into the tumour mass. 
 
After 3 weeks, a Pd0 incubated tumour was removed and sliced in half to study the extent of 
Pd0 distribution (fig 5.3.9). Pd0 beads injected via this protocol were well retained within the 
injection site and highly concentrated along the needle injection tract. Examination of tissues 
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surrounding the injection site concluded that no Pd0 beads had been ejected from the tumour 
during incubation (fig 5.3.9).  
	
Figure 5.3.9 Resected tumor halved to visualise intratumoral Pd-implant distribution. 1 
cm3 mouse tumour implanted with Pd0 beads via ultrasound guided syringe, incubated for 3 
weeks then resected and sliced in half. 
 
 
5.3.5 ex vivo Pd-mediated probe activation 
The catalytic activity of Pd0 beads implanted via this procedure were next assessed by an in 
vivo implantation / ex vivo probe activation assay using the non-fluorescent probe bis-N,N'-
propargyloxycarbonylrhodamine 110 (Poc-Rho). Poc-Rho was selected as an off-on 
fluorescence probe capable of undergoing selective Pd-mediated activation in vivo89 (fig 
5.3.10).  
 
Fig 5.3.10 Conversion schematic of non-fluorscent bis-N,N'-
propargyloxycarbonylrhodamine 110 (Poc-Rho) into fluorescent rhodamine 110 (Rho) 




Tissue samples containing no Pd0 beads, short or +3 week incubated Pd0 beads were soaked 
in media containing 100 μM Poc-Rho and monitored for fluorescence by live cell-imaging 
confocal microscopy over 63 hr (fig 5.3.11).  
 
 
Figure 5.3.11 ex vivo Pd-mediated carbamate cleavage of bis-N,N’-Poc-Rhodamine 110 
incubated with in vivo Pd0 bead injected prostate tumour samples. Pd0 beads were 
injected and tissue samples prepared according to the procedure described in Section 5.3.1 
(short) or Section 5.3.4 (+ 3 weeks). Time-lapse images of fixed tissue samples incubated 
under standard conditions and treated with 100 μM Poc-Rho alone (a - d), 100 μM Poc-Rho + 
acutely administered Pd0 beads (e – h) or 100 μM Poc-Rho + 3 week incubated Pd0 beads (i 
- l) every 3 hrs for 21 hr.  
 
In the absence of Pd0 beads, Poc-Rho undergoes slow conversion to Rho over a 21 hr period 
(fig. 5.3.12. a - d), showing the relative stability of this carbamate bond to be cleaved over time 
within the tumour environment. Individual Pd0 beads can be observed within injected tissue 
slices as highlighted by the white arrows in (fig. 5.3.11. e,f) and (fig. 5.3.11. i,j). Pd0 beads that 
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underwent intratumoural incubation for 3 weeks prior to treatment did not appear to have a 
reduced catalytic effect. Both short and 3 week incubated Pd0 beads samples rapidly 
converted Poc-Rho to Rho after 9 hrs, and signal saturation in both tissue slices within 21 hrs 
(fig. 5.3.11. e - h, i - l). 
This study coupled with Pd0 bead distribution observations provide key insight into the non-
perturbing effect of the catalyst. Pd0 beads may be injected into a tumour mass using the 
conventional microsurgical technique of ultrasound guided injection. As Pd0 beads are highly 
echogenic, this procedure allows for the visualisation of Pd0 beads within a tumour. Once 
injected, Pd0 beads are retained within the tumour where they remain highly concentrated 
along the needle injection tract. No leakage is observed from the injection site into surrounding 
tissue, with mice bearing Pd-incubated tumours progressing with no additional effect attributed 
to the injection protocol or intratumoural presence of the catalyst during an 8 week study. 
Intratumoural incubated Pd0 beads are capable of rapidly converting Poc-Rho at a rate 
comparable to freshly injected Pd0 beads. This further validates the bioorthogonality of the 
catalyst, as extended exposure to biology does not interfere with the catalytic conversion 
properties of the non-toxic Pd0 beads. This is a key finding for the validation of a BOOM 
chemotherapeutic concept, whereby the catalyst is capable of retained Pd-mediated prodrug 
activation during repeated prodrug administration, lasting perhaps months or until remission 
is achieved.   
 
5.3.6 ex vivo tumour explant drug/prodrug biocompatibility study  
The next step was to investigate the fluorescence spectra of dox prodrugs for in vivo imaging. 





Figure 5.3.12 Fluorescence spectra of dox and prodrugs Protocol: dox and prodrugs were 
incubated at 10 μM in PBS and the fluorescence spectra were collected using a Nanodrop™ 
3300 Fluorospectrometer with an excitation wavelength of 365 nm. 
 
As shown in figure 5.3.12, fluorescence signals prevent the resolution of prodrug to dox 
conversion due to significant overlap. Red channel fluorescence imaging will be limited to 
providing information regarding the biodistribution and potential Pd0 bead sequestration of 
drug/prodrug. 4',6-diamidino-2-phenylindole (DAPI) was chosen as a non-overlapping cell 
death marker that fluoresces when bound to DNA (absorption maxima 358 nm, emission 
maxima 461 nm). A 0.1 % (v/v) DMSO control and 100 μM solutions of Dox, 42 or 43 in RPMI 
media were incubated under standard conditions together with prepared tumour tissue 
samples according to the protocol described in figure 5.3.8 and monitored for DAPI and 






Figure 5.3.13 ex vivo biocompatibility study of dox in prostate tumour samples. Time-
lapse images of a fixed tissue sample incubated under standard conditions and treated with 
100 μM Dox. Images taken every 3 hr from t = 0 – 63 hr under blue fluorescent channel (for 
DAPI) (a - d) and red fluorescent channel (for dox) (e - h) fluorescence, modified by ImageJ. 
Scale bar = 30 μm. n = 2 tissue slices. 
 
 
Figure 5.3.14 ex vivo biocompatibility study of 42 in prostate tumour samples. Time-
lapse images of a fixed tissue sample incubated under standard conditions and treated with 
100 μM 42. Images taken every 3 hr from t = 0 – 63 hr under blue fluorescent channel (for 
DAPI) (a - d) and red fluorescent channel (for 42) (e - h) fluorescence, modified by ImageJ. 





Figure 5.3.15 ex vivo biocompatibility study of 43 in prostate tumour samples. Time-
lapse images of a fixed tissue sample incubated under standard conditions and treated with 
100 μM 43. Images taken every 3 hr from t = 0 – 63 hr under blue fluorescent channel (for 
DAPI) (a - d) and red fluorescent channel (for 43) (e - h) fluorescence, modified by ImageJ. 
Scale bar = 30 μm. n = 2 tissue slices.  
 
Control tumour samples treated with 0.1 % (v/v) DMSO vehicle displayed no fluorescence 
signal during 63 hr (fig 5.3.13, top left panels). This suggested that the protocol developed for 
tumour tissue resection and preparation did not induce cytotoxicity. Dox distributed evenly 
throughout tissue samples and appeared to accumulate within individual cellular nuclei, 
producing bright fluorescence spots overlapping with the DAPI stain. Cell death was first 
observed after 48 hr. This suggests an initial step whereby dox concentrates within the cell 
over time, with accumulated cellular damage then triggering rapid cell death. 
 
The fluorescence signal corresponding to 42 in the red channel produced a distribution pattern 
discernibly different from that associated with dox (fig 5.3.14). Whereas the signal 
accumulated over time, intense spots representing the nuclear accumulation of dox were not 
observed, however cell death was patently observed after 48 hr. This may indicate that, whilst 
resistant to metabolic cleavage, the cell death produced after 48 hr is due to 42 alone inducing 
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cytotoxicity in its inactive form. This indicates that a 100 μM solution of 42 is not biocompatible 
in tumour tissue at 100 μM during a 3 day study.  
 
As with 42, the fluorescence signal associated to 43 was discernibly different to that of dox (fig 
5.3.15). 43 may be taken up more slowly into tumour tissue, observed by a relatively weaker 
fluorescence signal. A weak DAPI signal was observed after soaking the tissue sample in 100 
μM of 43 after 63 hr. This is consistent with the increased safety profile attributed to enhanced 
steric bulk for the o-Pobc protection strategy (see Chapter 4). The EC50 of 43 in in vitro 
biocompatibility assays are 1.3 fold and 2.3 fold higher than 42 in DU145 and U87 cells, with 
over 300 fold reduction in cytotoxicity with respect to dox. 43 was non-toxic to zebrafish during 
5 days incubation at 200 μM, and did not induce cytotoxicity to a MCTS during 7 days at 100 
μM. As a result, 43 was progressed into an intratumoural in vivo Pd0 bead implantation / ex 
vivo prodrug activation assay. 
 
5.3.7 Intratumoural in vivo Pd0 bead implantation / ex vivo prodrug activation 
assay 
Tissue samples containing shortly incubated or 3 week incubated 30 μm Pd0 beads were 
soaked in media containing 100 μM of 43 and monitored for fluorescence attributed to 
drug/prodrug distribution (red channel) or DAPI staining (blue channel) by live-imaging 




Figure 5.3.16 ex vivo Pd0-mediated carbamate cleavage of 43 with shortly administered 
in vivo Pd0 bead injection into prostate tumour samples. 30 μm Pd0 beads were injected 
and tissue excised according to procedure described in Section 5.3.1. Representative time-
lapse images of fixed tissue samples incubated under standard conditions and treated with 
100 μM 43 + shortly administered Pd0 beads in red (a – d), and blue (e – h) fluorescence 
channels. Images captured every 3 hrs for 63 hr and modified by ImageJ. Scale bar = 30 μm. 
n = 2 tissue slices. 
 
 
Figure 5.3.17 ex vivo Pd0-mediated carbamate cleavage of 43 with 3 week incubated in 
vivo Pd0 bead injections into prostate tumour samples. Pd0 beads were injected and tissue 
excised according to procedure described in Section 5.3.4. Representative time-lapse images 
of fixed tissue samples incubated under standard conditions and treated with 100 μM 43 + 3 
week Pd0 beads in red (a – d), and blue (e – h) fluorescence channels. Images were captured 




Remarkably, the prodrug sequestration effect observed in section 4.15 is clearly evident for all 
combinations of 43 and Pd0 beads, indicated by white arrows in figure 5.3.16, figure 5.3.17 
and below (fig 5.3.18).  
 
 
Figure 5.3.18 Sequestration effect of Prodrug 43 within + 3 week incubated Pd0 bead 
injections into prostate tumour samples. (a,b) 43 is rapidly sequestered into 30 μm Pd0 
beads, shown by fluorescing bead. Images of two samples (a,b) captured at + 36 hr during a 
100 μM 43 treatment study. 
 
The in vivo injection of Pd0 beads followed by immediate ex vivo BOOM activation of 43 
resulted in a strong cytotoxic effect. DAPI staining showed a clear cytotoxic response after 48 
hr incubation. The DAPI cytotoxic signal produced is not localised around individual beads, 
but rather increases across the frame from 48 – 63 hr (fig 5.3.16 & 5.3.17 panels c & d). This 
is likely due to the variable density of tissue within each explant. Active dox expelled from 
beads is absorbed by solution and evenly distributes about the well. Thinner peripheral 
sections of tissue are more exposed to solution and uptake a relatively higher proportion of 
drug compared with denser regions. The red fluorescence signal attributed to 43 or dox in both 
short and prolonged Pd0 bead incubation shows a biodistribution pattern more closely 
approximating that of the active drug, overlapping with DAPI (fig 5.3.18), which suggests that 






Figure 5.3.19 Fluorescence signal merge (blue and red channels) corresponding to dox 
induced cellular cytotoxicity. 
 
42 + Pd0 beads produced an effect similar to that seen with 43, however the underlying 
cytotoxicity induced by 42 alone precluded an independent analysis of BOOM induced 
cytotoxicity. The in vivo / ex vivo combination of 42 + Pd0 beads was not reported for this 
reason. Prodrug 43 preferentially and rapidly sequesters into Pd0 beads administered into a 
prostate tumour. 43 then undergoes Pd-mediated conversion to dox, which is released into 
the interstitial space and accumulates in tumour cells inducing cytotoxicity. A comparable 
effect is observed between short and prolonged intratumoural incubation of Pd0 beads within 
a live mouse for 3 weeks. This study provides in vivo evidence that BOOM chemotherapy 




Various biological assays have been developed to explore and validate BOOM chemotherapy 
in complex biological systems. A 3D cell culture MCTS assay provided evidence that 43 alone 
would not induce cytotoxicity to an in vivo tumour at 100 μM. This was higher than the cytotoxic 
effect observed in a 2D in vitro experiment (EC50 = 7.13 μM). By embedding Pd0 beads into 
pre-formed spheroids and monitoring for cytotoxicity using DRAQ7™ it was confirmed that Pd0 
-	146	-	
	
beads in direct contact with cellular surfaces were non-toxic. Ultimately prodrug activation in 
this assay was not achieved, attributed to the use of Matrigel®, a highly viscous glue required 
for the structural architecture of the growing spheroid. Matrigel® may have prevented 43 from 
accessing the Pd0 bead, or from the effective release of dox into solution post conversion. By 
separately incubating a 100 μM solution of 43 in combination with 1 mg / mL of Pd0 beads for 
72 hrs then replacing the media of a pre-formed spheroid with this mixture a strong cytotoxic 
effect was observed, further supporting the likelihood that Matrigel® was preventing effective 
prodrug uptake into individual Pd0 beads. 
 
An in vivo zebrafish cardiotoxicity assay was designed to study the effect of 43 on cardiac 
oedema. 50 μM dox induced large cardiac oedema’s in embryonic zebrafish, with 100 % 
lethality in all populations incubated at > 50 μM dox. 43 did not induce lethality or observed 
cardiac oedema even up to 200 μM – well above the theoretical maximum therapeutic dosage 
prescribed in a clinical dox dosing regimen. Fluorescence microscopy determined that 43 was 
less readily absorbed and retained by zebrafish with respect to dox.  
 
An in vivo microsurgery injection protocol was developed to insert a BOOM catalyst into the 
prostate tumour of an anaesthetized mouse. Ultrasound guided injection enhanced control 
over the injection process. Pd0 beads were revealed to be highly echogenic. Ultrasound would 
be an ideal modality for the non-invasive visualisation of Pd0 bead biodistribution within a 
tumour. Pd0 beads were retained within the tumour, where they remained highly concentrated 
within the intratumoural needle tract during 3 weeks of incubation. An off-on fluorescence 
probe, Poc-Rho, was utilized in an initial in vivo / ex vivo probe activation assay to study the 
effect of short vs extended Pd0 bead incubation within live tumour tissue samples. Extended 
intratumoural incubation did not reduce the underlying catalytic turnover rate achieved by Pd0 
beads. Rapid activation of Poc-Rho was achieved in combination with both acutely 




An ex vivo tumour biocompatibility study showed that 43 was relatively non-toxic at 100 μM. 
This was consistent with spheroid and zebrafish studies, and may be attributed to the 
enhanced steric hindrance afforded by an ortho positioned propargyl group on the Pobc 
protecting group. This lead to the in vivo injection / ex vivo prodrug activation study of prodrug 
43. Intratumourally injected Pd0 beads in short or extended incubation settings were both 
capable of rapidly sequestering 43 to rapidly release active drug at sufficient concentration to 
induce cytotoxicity in tumour tissue within 48 hr.  
 
The next step will be to conduct an in vivo Pd0 implantation and prodrug administration BOOM 
activation assay to evaluate the performance of this optimised system. This would allow for 
the study of 43 biodistribution and pharmacokinetics, as well as the ability for systemically 
circulated prodrug to be sequestered and converted by intratumourally inserted Pd0 beads. 
Furthermore, an embryonic zebrafish cardiac oedema study has laid the foundation for a 
parallel study on the in vivo effect of 43 on cardiomyopathy during localised BOOM activation. 
The methodology for precise intratumoural Pd0 bead implantation, tissue preparation and 
analysis in a rodent model has been optimised. 43 was validated as an ideal candidate for the 





Conclusions and Future Work 
 
Bioorthogonal chemistry unlocks new and transformative ways to undertake the non-
perturbing chemoselective making and breaking of chemical bonds in biology. Conducting 
chemistry within a biological system imposes extraordinary demands on chemical reactivity, 
and as such the scope of early bioorthogonal chemistry was initially confined to a limited 
number of reactions. Early investigations primarily focused on developing novel reaction 
partners to probe biology, allowing for the chemoselective study of recombinant proteins10, 
cellular surfaces11 and metabolic processes23. Since these and other landmark advances, a 
wide range of bespoke reaction partners have emerged. The field of bioorthogonal chemistry 
is now furnished with a rich catalogue of reaction partners for chemistry in the living cell. 
Despite the advent of non-metallic strain promoted reactions, bioorthogonal metal catalysts 
have already emerged as a novel subtype of bioorthogonal chemistry due in most part to 
dramatic improvements in ligand design and encapsulation methods that reduce the 
underlying toxicity of the metal whilst improving the rate of catalysis. 
 
To this extent, our group has focused on the use of Palladium (Pd) chemistry to conduct 
biocompatible covalent bond breaking. By immobilizing Pd0 nanoparticles onto matrix resin 
beads through a solid support chemical interaction with PEG-PS polymers, various drugs and 
probes have been unlocked in cellular culture, including within the embryonic yolk sac89 and 
even in the intracranial space of live zebrafish131. This catalytic system provides the basis for 
a new prodrug approach to chemotherapy, whereby the chemospecific transformation of a 
small molecule, such as a chemotherapeutic, may be focused by a device implanted within a 
target tissue. Both the method of delivering cancer therapeutics as well as the therapeutic 
window of many small molecule cancer drugs is sub-optimal. Conventional chemotherapy 
administers ‘free’ drug into the body via an oral or intravenous administration route. 
Intravenous administration ensures that the patient receives rapid systemic administration of 
the drug, whereas oral drugs must overcome absorption barriers resulting in increased 
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pharmacokinetic variability287. The activity of some non-targeting chemotherapies may be 
regulated to an extent by modification of the excipient formula and method of delivery, however 
off-target effects are an inevitable outcome when potent molecules circulate systemically 
throughout the body. Whereas targeting chemotherapies were envisaged to prevent side-
effects by virtue of molecular design, a new era of targeted therapies has done little to remove 
this underlying problem. Several clinical trials have reported increased incidence of severe 
treatment induced side effect caused by targeted medicines with no corresponding 
improvement in treatment efficacy.  
 
Treatment induced side-effects cause detrimental harm to the body and force dose-limitations 
which in turn reduce the efficacy of treatment. Many drugs are administered with adjuvants 
designed to reduce off-target effects, however some adjuvants are themselves toxic and 
known to reduce the underlying efficacy of treatment. Thus a non-ideal balancing act is 
required to maximize the tolerated dosage of a drug whilst managing acute side-effects that 
may themselves be life threatening.  
 
A strategy that masks the cytotoxicity of a drug until it reaches the site of tumour could alleviate 
this intractable drawback. Furthermore, if suitable modification of the molecule results in a 
prodrug that preferentially accumulates into the metal catalyst where it is converted and 
released, the effective dosage delivered to the target tissue may be dramatically higher than 
the systemically circulating dose. To that extent BOOM chemotherapy emerges as an 
attractive potential treatment strategy. Considerable effort has developed new methods of 
delivering molecules to tumours with improved pharmacokinetic and biodistributive 
properties288–292. Typical drug delivery systems applied to the chemotherapeutic space include 
lipid-based carriers (miscelles, lipid-drug emulsions and complexes), polymer-drug conjugates 
and polymer microsphere products288. Polymeric microspheres have undergone extensive 
investigation as drug carriers capable of synthetic modification293, high loading capability294 
and controllable drug release and/or activation in living systems291. Polyethylene glycol (PEG) 
constitutes the majority of polymeric microsphere drug delivery systems288. Drug eluting 
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polymeric microspheres have altered the PK, biodistribution and efficacy of multiple 
chemotherapeutics295–297 including microsphere formulations of 5FU298, gemcitabine299 and 
doxorubicin300–302. The non-toxic Pd catalyst employed in this thesis is constituted of resin 
formulations employed in many promising drug delivery PEGylated microsphere systems that 
would be highly relevant in the clinical setting.  
 
The work of this thesis progresses the BOOM chemotherapeutic concept into pre-clinical 
evaluation, by improving various aspects concerning bioorthogonal reactivity of the catalyst 
against a library of novel anticancer prodrugs. Three anticancer drugs were investigated.  
 
The first of these was 5-fluorouracil (5FU). Each of the endocyclic NH groups of 5FU plays a 
key role in enzymatic recognition for the biosynthesis of active metabolites that induce an 
antiproliferative effect92,105,108,111. By mono-alkylating 5FU at the N1 or N3 position (prodrugs 3 
and 4), and bis-alkylating at both (prodrug 5), the cytotoxic profile of the parent molecule was 
completely removed and subsequently restored by N-dealkylation in the presence of Pd 
beads34,88. Of these 5 is capable of simultaneously blocking both N1 enzyme mediated 
glycosylation and N3 mediated catabolism. 5 however displays a slow stepwise release of 5FU 
in the presence of a Pd source, which may result in the release of inactive mono-alkylated 
5FU derivatives into tumour tissue, reducing the effectiveness of treatment. Furthermore, the 
clogP of 5 is – 0.4, not ideal for bioavailability or the development of an oral chemotherapeutic. 
2 was developed as an optimised lactim trapped bis-O-propargylated analogue of 5. Like 5, 2 
displayed no cytotoxicity. Unlike 5 however, 2 was sequestered within Pd beads when mixed 
in solution, which then rapidly released 5FU without the appearance of mono-propargylated 
intermediates. This sequestration effect was due to increased lipophilicity, as 2 has a clogP of 
+ 1.66. The synergistic cytotoxicity produced when 2 was incubated together with Pd beads 
together in cell culture was comparable to that of 5FU.  
 
The preferential sequestration of lipophilic prodrugs into the polymeric matrix of the catalyst 
resin is in fact a highly attractive feature for BOOM prodrug activation. Conceptually, the 
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intratumoural implanted catalyst may be capable of pulling a lipophilic prodrug out of systemic 
circulation by sequestration, then converting and locally expelling the hydrophilic drug product. 
This would serve as a means of concentrating treatment to the site of the catalytic implant. 2 
represents an optimised physicochemical, biocompatible prodrug of 5FU capable of prodrug 
activation in the presence of a Pd source. 2 should next be progressed into an in vivo 
pharmacokinetic study. 
 
Gemcitabine was the second antimetabolite investigated for use as a BOOM reaction partner. 
Gemcitabine is expected to undergo strong binding affinity within the active pocket of 
deoxycytidine kinase (dCK), with key recognition between amino acid residues and 
gemcitabine’s C5’OH and C4NH2 groups during initial phosphorylation and subsequent 
activation160. In addition, gemcitabine is rapidly deactivated by cytidine deaminase (CDA) 
hydrolytic deamination via C4NH2 mediated enzymatic recognition169. These mechanisms 
have lead to the investigation of various alkyl carbamate and carbonate protected prodrugs 
that were expected to produce a pharmacophoric blockade to C5’OH and C4NH2 groups. No 
carbonate protected gemcitabine prodrug has been previously found to be resistant to 
metabolic cleavage, whereas Alloc, and Poc carbamate protected prodrugs produced a 
moderate reduction in cytotoxicity with lability to a Pd source89.  
 
By incorporating together aspects of the Poc and Cbz protecting groups, we designed a novel 
Propargyloxybenzylcarbonyl (Pobc) protecting group. Pobc would be capable of enhanced 
bioorthogonality afforded by steric bulk to restrict enzymatic cleavage. Pobc would also retain 
Pd lability by propargyloxy trigger initiated benzyl elimination. A palladium-triggered ‘self-
immolation’ event liberates the active drug along with the non-toxic by-products180–183 
acetol89,184 and hydroxybenzyl alcohol, both of which were confirmed as non-toxic in cell 
culture, as well as the benign gas CO2. A semisynthetic strategy was capable of masking the 
C5’OH and C4NH2 functional groups of gemcitabine. 33, the p-Pobc functionalised C4NH2 
promoiety was capable of 27 fold reduction in cytotoxicity against gemcitabine, a meaningful 
improvement over Poc functionalisation at the same site (EC50 (33) / EC50 (25) ~ 3. o-Pobc 
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was expected to outperform p-Pobc in terms of reduced cytotoxic fold change by virtue of 
increased steric bulk about the carbamate, however curiously 34 exhibited cytotoxicity similar 
to gemcitabine. The C5’OH o-Pobc masked prodrug 36 however produced a slight 
improvement over previously reported alkyloxycarbonyl functionalised prodrugs, although the 
cytotoxic fold change provided a narrow therapeutic window to observe the effect produced 
by Pd-mediated conversion to the active drug. Carbonate protected prodrugs of gemcitabine 
are not likely capable of withstanding extended incubation in cell culture.  
 
A synergistic effect was produced when 33 or 36 were incubated in combination with Pd beads, 
suggesting that Pobc functinalised prodrugs were capable of Pd-mediated ‘self-immolation’. 
Although the bioorthogonal fold change achieved with Pobc functionalised gemcitabine 
prodrugs was not sufficient to progress candidates into animal studies, this study provided a 
proof of concept for the design, synthesis and activation of the Pobc group for use in the next 
drug candidate. As the activity of gemcitabine is determined by multiple amino acid residue 
interactions within an active pocket, functionalising at one of C5’OH or C4NH2 may not provide 
a pharmacophoric blockade strong enough to completely restrict enzymatic recognition, 
metabolic cleavage and subsequent activation of the drug. A bi-functionalised prodrug of 
gemcitabine may further enhance the bioorthogonality fold change by simultaneously blocking 
both active sites. 
 
Poc, Cbz and Pobc promoieties were next functionalised to the C3’ amino of doxorubicin via 
a semisynthetic strategy. Dox is a widely used chemotherapeutic that induces severe off target 
side effects due to the broad range of pathways involved in eliciting 
cytotoxicity197,198,195,196,199,200. The C3’ amino group is established as a key functional group 
involved in the cytotoxic response203–205. Various C3’ acyl and carbamate functionalised 
prodrugs have been developed that were capable of effectively reducing cytotoxicity215–217. By 
N-functionalising doxorubicin with Poc, Cbz and Pobc promoieties, a direct correlation 




Both Pobc-functionalised dox prodrugs displayed > 100 fold reduction in cytotoxicity, achieving 
our self-imposed goal in terms of therapeutic window, with o-Pobc prodrug 43 approximately 
twice as bioorthogonal as p-Pobc prodrug 42. This suggests that masking the C3’ amino group 
of dox with a more sterically hindered carbamate protecting group provides an effective 
pharmacophoric blockade against DNA intercalation and TopoII binding. This lead to the 
development of bis-o-Pobc protected prodrug 50, which was expected to further enhance the 
bioorthogonality of this candidate with respect to o-Pobc (due to steric bulk) and Pd-lability (by 
adding an additional trigger group to the aryl ring). 50 was only capable of producing a 
moderate reduction in cytotoxicity fold change, whilst increased lipophilicity hindered 
subsequent in vitro study.  
 
42, 43, 45 and 50 underwent Pd-mediated carbamate cleavage by HPLC analysis, 
demonstrating dox release in combination with Pd beads. During this study, dox and prodrugs 
were also observed to undergo sequestration into the Pd0 bead. Whereas prodrug 
sequestration remains a desired outcome, sequestration and retention of the active drug 
product within the bead as well may ultimately limit the dosage of dox exposed to the tumour 
tissue. In vitro prodrug activation assays showed a cytotoxicity gap remained when prodrugs 
and Pd0 beads were incubated together, an effect likely attributed to the combined effect of 
dox sequestration and the time-delay resulting from slower catalytic turnover rate. This lead to 
the development of novel 30 μm Pd0 beads. When incubated in combination with 42 and 43 in 
HPLC studies and cell culture, 30 μm Pd0 beads were capable of increased catalytic effect, 
selective sequestration of prodrug alone and rapid release of dox into solution.  
 
Three variations of the the novel Pobc moiety have been revealed as versatile functional 
groups capable of effectively masking drugs and then reactivating them in the presence of Pd0 
catalysts. Future work should elucidate the general catalytic mechanism of activation that 
occurs between alkene, alkyne and Pobc groups together with Pd catalysts. The 
characterisation and assignment of all products generated from this catalytic system needs 
identification prior to advancing confidently into preclinical assays. Further investigation is 
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required specifically of the bis-o-Pobc functional group. The expected enhancement to the 
biocompatibility of Doxorubicin via steric bulk was not observed in 50, although it is clear that 
the incorporation of a second propargyl group dramatically enhances Pd lability. As ortho and 
para Pobc groups were unable to enhance the biocompatibility of Gemcitabine beyond that of 
Poc incorporation, biocompatibility induced by adding bis-o-Pobc at amine and/or hydroxyl 
positions of Gemcitabine should be considered.  
 
A multicellular tumour spheroid (MCTS) model was next developed to allow for the direct study 
of Pd bead cytotoxicity on a cellular interface that recapitulated an in vivo tumour. This model 
would also provide information on a representative cytotoxicity fold gap for dosing a 
subsequent ex vivo tumour implant. 43 and Pd0 beads alone did not induce any cytotoxicity. 
In combination, the expected toxigenic effect was not observed, perhaps due to the necessary 
addition of Matrigel®, a viscous gel required for spheroid formation that would coat the Pd0 
beads, possibly preventing prodrug entry into the spheroid. 
  
As dox is often dose limited by virtue of cardiomyopathy, an in vivo embryonic zebrafish 
cardiac oedema assay was developed to investigate the potential cardio protective effect of 
43 on heart tissue. A pronounced cardiac oedema was observed after 120 hpf when zebrafish 
embryos were incubated with 50 μM dox, with 100 % lethality occurring at higher 
concentrations. 43 did not cause significant lethality or observed cardiac oedema at any 
concentration tested (up to 200 μM). It is important to note that treatment with 43 showed 
reduced retention of the prodrug into the zebrafish embryo with respect to dox, corresponding 
to the reduced ability of 43 to engage with the molecular targets of dox. At 200 μM significant 
quantities of prodrug is observed without producing oedema, which is consistent with the 
inability of prodrug to interact with the molecular targets of the active drug. 
 
A pre-clinical animal model was next investigated to observe, for the first time, the BOOM 
activation of chemotherapeutic prodrugs by intratumoural inoculated Pd0 beads within a living 
tumour explant. A pilot study injected freshly excised mouse prostate tumours with 130 μm Pd 
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beads then incubated whole tumours with a previously reported prodrug of floxuridine, 
3’propargylfloxuridine (Pro-FUdR). Crucially, the apoptotic effect observed by 
immunohistochemistry resolved a cytotoxic effect localised to the Pd0 bead injection region.  
 
Significant optimisation of this study was then undertaken to develop a non-invasive 
microsurgery protocol capable of accurately injecting the more effective 30 μm Pd0 beads into 
prostate tumours of live mice. Ultrasound guided injection of Pd0 beads into prostate tumours 
in vivo allowed for the precise implantation of catalyst into tumour without any observed effect 
on the overall viability of the mouse. Pd0 beads were retained within the tumour at high 
concentration within the needle injection tract.  
 
The catalytic activity of Pd0 beads was assessed by incubating Pd-containing tumour slices 
with an off-on fluorescence probe, bis-N,N'-propargyloxycarbonylrhodamine 110 (Poc-Rho), 
and equating the fluorescence signal produced as a determinant of catalytic effect. Poc-Rho 
was activated with comparable rate in all Pd-containing tissue slices, even in samples that 
contained Pd0 bead in the tumor in vivo for over 20 days, suggesting that the catalytic effect 
produced by Pd0 beads could be sustained over extended incubation within a tumour. This 
finding presents an important step forwards for the development of catalysts amenable to long 
term chemotherapeutic activation within a patient. 
 
42 and 43 were chosen as drug precursors to undergo a prodrug activation assay in 
combination with 30 um Pd0 beads using the optimised microsurgery protocol. At 100 μM, dox 
produced significant cytotoxicity during a 63 hr window with a distinctive biosdistribution 
pattern corresponding to cellular uptake of the drug. Although the biodistrubution pattern for 
42 was discernibly different, significant cytotoxicity was also observed at 100 uM. This 
suggests that cytotoxicity was induced by 42 alone and not the activated drug. 43 alone 
produced almost no cytotoxicity after 63 hr at 100 μM, with a biodistribution pattern showing 
low retention of the prodrug into tumour cells. In combination with 30 μm Pd0 beads, 43 
produced a strong cytotoxic effect comparable to dox. The sequestration effect observed in 
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Chapter 4 was clearly visualised during this study, with 43 rapidly accumulating into individual 
Pd0 beads, causing them to ‘light up’ in a fluorescence study in preference to the surrounding 
tissue. The subsequent release of dox into the local environment was consistent with the 
marked cytotoxic effect and intense localised cellular fluorescence signal observed from 
treatment of dox alone.  
 
This body of work has contributed to the development of potentially clinically viable prodrug 
and metal catalyst reaction partners. By masking established chemotherapeutics with novel 
protecting groups (Pobc functionalisation) and masking strategies (lactim trap), new and 
improved prodrug candidates are available. Parallel optimisation of the Pd0 device, including 
a minimally invasive microsurgical protocol for the prolonged non-invasive in vivo incubation 
of the catalyst in a tumour, has generated a preliminary procedure for an in vivo BOOM 
chemotherapeutic activation study.  
The incision and incubation of Pd beads into mouse prostate tumor has apparently had no 
short term observable affect on the viability of the mouse or the activity of the catalyst. The 
evident next step towards validating this assay would be to develop excipient formulae of the 
bis-protected 5FU prodrug 2 and the oPOBC-amine protected Doxorubicin prodrug 43 to 
conduct pharmacokinetic dosing studies to determine the maximum tolerated dosage of each 
drug before toxicity and side effect are observed. 
Once this dosage window is determined, in vivo activation of the prodrug could be studied by 
first conducting intratumoral in vivo Pd0 bead implantation, followed by intravenous dosing (i.e. 
via intraperitoneal injection) of the prodrug into the mouse. The efficacy of treatment would be 
determined by control populations that are treated with either prodrug alone or Pd0 beads 
alone. Efficacy on dissection should assess the impact of treatment on tumor volume as well 
as key organs associated with drug related toxicity (i.e. the myocardium of heart tissue for 
Doxorubicin, the gastrointestinal tract for 5FU). 
Depending on the resources at hand, parallel studies should be conducted by repeated 
injecting mouse populations with prodrugs during staggered time points to determine the 
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efficacy of treatment after extended incubation of Pd0 beads. Future work must validate the in 
vivo generation of BOOM activated drugs over longer time periods and in more relevant animal 
models. 
The surgical procedure for incision of a Pd device into the prostate tumors of mice should next 
be progressed into larger animal models. As porcine and canine anatomy is more 
representative of human structure, function and scale, success in the mouse assays should 










All chemicals were purchased from Sigma Aldrich, VWR International Ltd or Fisher Scientific 
UK Ltd unless otherwise stated. Doxorubicin HCl was purchased from Cambridge Biosciences 
Ltd, Gemcitabine HCl was purchased from Fluorochem Ltd. 
 
7.1.2 Chromatography 
Compounds were purified by manual flash column chromatography with commercially 
available silica gel (220 – 440 mesh, Sigma-Aldrich). Columns and solvents used to elute and 
purify the products varied depending on the amount of starting material used and polarity of 
compounds. Rf values were determined on Merck aluminium backed TLC Silica gel 60 F254 
sheets. Compounds were visualized using a UV6L-58 Mineralight UV emitter at 254 nm. Semi-
preparative high-performance liquid chromatography (Semi-prep HPLC) was performed using 
a Waters 600E pump and a Waters 486 tuneable absorbance detector equipped with a 
Phenomenex Luna C18(2), 5 µm, 250 x 21.2 mm column, with compounds detected using an 
evaporative light scattering detector (ELSD) and UV detector. All solvents used were HPLC 
grade. Method: eluent A, H2O and formic acid (0.1 %); eluent B, acetonitrile and formic acid 
(0.1 %); A/B = 95 : 5 to 5 : 95 in 30 min. Ultra-performance liquid chromatography (UPLC) was 
performed using a Waters Acquity UPLC PDA with a 50 x 2.4 mm Waters BEH C18 1.7 µm 
column, with compounds detected using an evaporative light scattering detector (ELSD) and 
UV detector. All solvents used were HPLC grade. Method: eluent A, H2O and formic acid 
(0.1 %); eluent B, acetonitrile; A/B = 95 : 5 to 20 : 80 in 8 min, 95 : 5 in 8.5 minutes. 
 
7.1.3 Nuclear Magnetic Resonance 
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1H and 13C NMR were recorded at ambient temperature on Bruker Avance III 400 Mhz, 500 
Mhz or 600 Mhz spectrometers from the Edinburgh University School of Chemistry. All 
chemical shifts are reported relative to the solvent peak in parts per million (δ). 
 
7.1.4 Mass Spectrometry 
High Resolution Mass Spectra (HRMA) were obtained using a Bruker 3.0 T Apex II 
Spectrometer under electron spray ionisation (ESI) conditions. Low Resolution Mass Spectra 
(LRMS) was obtained using an Agilent 1100 HPLC Modular System coupled to an Agilent 
Technologies 6130 Quadrupole LC/MS Mass Spectrometer under electron spray ionisation 
(ESI) conditions. 
 
7.1.5 Scanning Electron Microscopy Imaging 
Samples were fixed in a solution of 3 % glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 
7.3) for 2 hr, then washed in 3 x 10 min changes of 0.1 M sodium cacodylate buffer. Samples 
were then fixed in 1 % osmium tetroxide in 0.1 M sodium cacodylate buffer for 45 min. A further 
three 10 min washes were performed in 0.1 M sodium cacodylate buffer. Dehydration in 
graded concentrations of acetone (50 %, 70 %, 90 %, and 3 x 100 %) for 10 min each was 
followed by critical point drying using liquid CO2. After mounting on aluminium stubs with 
carbon tabs attached, the specimens were sputter coated with 20 nm gold palladium and 
viewed using a Hitachi S-4700 scanning electron microscope. Preparation was performed with 
help from Stephen Mitchell from the School of Biological Sciences. 
 
7.1.6 Synthesis & Characterization of Pd0 beads 
NovaSyn TG amino resins HL of variable diameter (10 μm, 20 μm, 30 μm, 75 μm, 110 μm and 
130 μm) (1,000 mg, 0.39 mmol NH2 per gram) and palladium acetate (263 mg, 1.17 mol) were 
added into a 25 mL Biotage microwave vial (Biotage). Next, toluene (10 mL) was added to the 
vial and heated to 80 °C under stirring for 10 min. The mixture was then stirred at room 
temperature (rt) for an additional 2 hr. The resins were filtered and washed with 
dichloromethane (DCM) (5 x 20 mL) and methanol (MeOH) (5 x 20 mL). Resins were dispersed 
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in 10 % hydrazine monohydrate in MeOH (10 mL) and stirred at room temperature for 25 min. 
The resins were again filtered and washed with MeOH (5 x 20 mL) and DCM (5x 20 mL). 
Resins were added to a solution of Fmoc-Glu(OH)-OH (216 mg, 0.59 mmol), Oxyma (166 mg, 
1.17 mmol), N,N’-diisopropylcarbodiimide (DIC) (148 mg, 1.17 mmol) with 
DCM/dimethylformamide (DMF) (2 : 1, 9 mL) and stirred for 2 hr at rt. The resins were filtered 
and washed with DCM (5 x 20 mL), MeOH (5 x 20 mL) and H2O (5 x 20 mL) and dried in an 
oven at 40 °C for 3 days. Completed coupling was verified by ninhydrin test after the last MeOH 
wash. Pd0 beads were prepared together with Dr Ana Pérez-Lopéz and Dr Belén Rubio Ruiz. 
SEM images were performed at the School of Biological Sciences and Pd0 quantification (by 
inductively coupled plasma-optical emission spectrometry) was performed by Dr Lorna Eades 
from the School of Chemistry. Resins were previously characterized using X-ray diffractometry 
(Bruker D2 PHASER with LYNXEYE detector (Bruker), Cu radiation source at 30 kV, 10 mA 
and a Ni filter) by Dr Carmen Torrez-Sanchez from the Additive Manufacturing Research 




7.1.7 Synthesis and characterization of 5-fluorouracil prodrugs 
 
 
Synthesis of 5-fluoro-2,4-bis-propargylpyrimidine (2). Sodium hydride (60 % dispersion in 
mineral oil) (120 mg, 3 mmol) was added to dry THF (10 mL) at 4 °C and stirred rapidly for 30 
min. Propargyl alcohol (97 μL, 1.8 mmol) was added to dry THF (5 mL), and then added 
dropwise to the stirring mixture. An evolution of gas was observed with a slight exotherm, then 
the flask was sealed and flushed with nitrogen. A gas tight syringe containing 5-fluoro-2,4-
dichloropyrimidine (100 mg, 0.6 mmol) mixed with dry THF (5 mL) was added dropwise at 4 °C, 
then warmed to rt whilst stirring for 12 hr. The resulting mixture was partitioned between DCM 
(50 mL) and H2O (50 mL), acidified with acetic acid and separated. The organic layer was 
reduced by rotary evaporation then purified via flash chromatography (12.5 % ethyl acetate in 
hexane) The synthetic method described gave white crystals (0.45 mg, 0.22 mmol, 36 % yield); 
1H NMR (500 MHz, CDCl3) δ 8.13 (s, 1H), 5.06 (d, J = 2.5 Hz, 2H), 4.94 (d, J = 2.4 Hz, 2H). 
2.53 (t, J = 2.4 Hz, 1H), 2.4 (d, J = 2.4 Hz, 1H).  13C NMR (126 MHz, CDCl3) 158.5 (C), 158.4 
(C), 143.2 – 142.2 (d, JC-F = 255.4 Hz C), 144.2 – 143.9 (d, JC-F = 20.6 Hz CH), 78.3 (C), 77.4 
(C) 76.2 (CH), 75.0 (CH), 55.7 (CH2), 55.1 (CH2) HRMS (m/z): [M+H]+ calcd for C10H7FN2O2 





Synthesis of 2-chloro-5-fluoro-4-propargylpyrimidine (9) Sodium hydride (60 % dispersion in 
mineral oil) (120 mg, 3 mmol) was added to dry THF (10 mL) at 4 °C and stirred rapidly for 30 
min. Propargyl alcohol (32 μL, 0.6 mmol) was added to dry THF (5 mL), and then added 
dropwise to the stirring mixture. An evolution of gas was observed with a slight exotherm, then 
the flask was sealed and flushed with nitrogen. A gas tight syringe containing 5-fluoro-2,4-
dichloropyrimidine (100 mg, 0.6 mmol) mixed prior with dry THF (5 mL) was added dropwise 
at 4 °C, then left to warm whilst stirring for 12 hr. The resulting mixture was partitioned between 
DCM (50 mL) and H2O (50 mL), acidified with acetic acid and separated. The organic layer 
was reduced by rotary evaporation then purified via flash chromatography (12.5 % ethyl 
acetate in hexane). The synthetic method described gave white crystals (55.9 mg, 0.3 mmol, 
50 % yield) 1H NMR (500 MHz, CDCl3) δ 8.22 (d, J = 2.1 Hz, 1H), 5.08 (d, J = 2.5 Hz, 2H), 
2.57 (t, J = 2.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 158.2 (d, JC-Cl = 11.5 Hz CCl), 153.2 (d, 
JC-Cl = 4.8 Hz C), 145.9 (d, JC-F = 265.3 Hz C), 144.8 (d, JC-F = 20.1 Hz CH), 76.6 (CH), 76.5 
(C), 55.7 (CH2) HRMS (m/z): [M+H]+ calcd for C7H4ClFN2O [M+H]+: 187.0069, found: 187.0086 
 
 
Synthesis of 1-benzoyl-5-fluoropyrimidine-2,4(1H,3H)-dione (10) 5-fluorouracil (1.37g, 10 
mmol) was added to a solution of potassium hydroxide (0.69 g, 10 mmol) in MeOH (50 mL). 
The suspension was stirred at rt for 20 min, then concentrated and resuspended in acetonitrile 
(50 mL), stirred for 30 min then added portion wise to a solution of benzoyl chloride (1.4 g, 10 
mmol) in acetonitrile (50 mL) at 0 °C. The reaction mixture was allowed to warm to rt and 
stirred for 3 hr, then filtered via vacuum filtration. The resulting crude product was washed with 
cold DCM (3 x 20 mL) then purified via flash chromatography (25 % ethyl acetate in hexane). 
The synthetic method described gave white crystals in agreement with cited reference128. (450 
mg, 1.92 mmol, 19.2 % yield) 1H NMR (500 MHz, DMSO) δ 12.05 (s, 1H), 8.26 (d, J = 6.7 Hz, 
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1H), 7.85 (dd, J = 8.3, 1.2 Hz, 2H), 7.70 – 7.62 (m, 1H), 7.56 – 7.47 (m, 2H).13C NMR (126 
MHz, DMSO) δ 169.1 (C), 157.7 (d, JC-F = 26.8 Hz C), 148.3 (C), 141.2 (d, JC-F = 235.2 Hz C), 
133.6 (C), 132.9 (CH), 129.5 (CH), 124.6 (d, JC-F = 36.4 Hz CH), 76.5 (CH), 76.5 (C), 55.7 
(CH2). HRMS (m/z): [M+H]+ calcd for C11H7FN2O3 [M+23Na1]+: 257.0333, found: 257.0327 
 
 
Synthesis of 3-benzoyl-5-fluoropyrimidine-2,4(1H,3H)-dione (11) Benzoyl chloride (2.13 mL, 
18.9 mmol) was added to a stirring mixture of 5-fluorouracil (1.00 g, 9.1 mmol) and pyridine 
(3.06 mL, 38 mmol) in anhydrous acetronitrile (20 mL) at 0 °C under nitrogen. The mixture was 
allowed to warm to rt and stirred for 48 hr, then concentrated by rotary evaporation, re-
dissolved in DCM (200 mL), washed with cold H2O (3 x 50 mL) and re-concentrated. The 
resulting residue was dissolved in 1,4-dioxane (25 mL) and treated with aqueous potassium 
carbonate (0.5 M, 20 mL in H2O) at 0 °C. After stirring at rt for 30 min the pH was slowly 
lowered to 5 by dropwise addition of concentrated acetic acid. The solution was concentrated 
by rotary evaporation, then treated with saturated sodium bicarbonate (100 mL) and stirred for 
1 hr. The solution was then cooled to 0 °C, filtered by vacuum and washed with cold H2O (5 x 
20 mL) and the crude product was purified via flash chromatography (50 % ethyl acetate in 
hexane). The synthetic method described gave white crystals in agreement with cited 
reference129 (550 mg, 2.34 mmol, 25.8 % yield) 1H NMR (601 MHz, DMSO) δ 11.53 (s, 1H), 
8.08 (d, J = 6.1 Hz, 1H), 8.04 (dd, J = 8.4, 1.1 Hz, 2H), 7.80 (tt, J = 7.6, 1.2 Hz, 1H), 7.65 – 
7.58 (m, 2H).13C NMR (151 MHz, DMSO) δ 168.6 (C), 156.8 (C), 156.6 (C), 148.6 (C), 140.3 
(C), 138.7 (C), 135.7 (C), 130.9 (CH), 130.5 (CH), 129.5 (CH), 127.5 (CH). HRMS (m/z): 





Attempted synthesis of 3-benzoyl-5-fluoro-2-(prop-2-yn-1-yloxy)-2,3-dihydropyrimidin-4(1H)-
one (15); Synthesis of 3-benzoyl-5-fluoro-1-(prop-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione (14) 
DIAD (333 uL,1.6 mmol) was added to a solution of PPh3 (420 mg, 1.6 mmol) in THF (20 mL) 
at 0 °C under nitrogen. After 30 min the mixture was cooled to -78 °C and a solution of 
propargyl alcohol (35 uL, 0.64 mmol) and 3-benzoyl-5-fluoropyrimidine-2,4(1H,3H)-dione (150 
mg, 0.64 mmol) in THF (20 mL) was added by gas tight syringe. The mixture was allowed to 
warm to rt then concentrated under reduced pressure and purified via flash chromatography 
(25 à 100 % ethyl acetate in hexane). The synthetic method described gave white crystals 
(25.6 mg, 0.09 mmol, 14.7 % yield) 1H NMR (500 MHz, CDCl3) δ 7.93 (dd, J = 8.3, 1.1 Hz, 2H), 
7.73 – 7.63 (m, 2H), 7.52 (t, J = 7.9 Hz, 2H), 4.58 (d, J = 2.5 Hz, 2H), 2.60 (t, J = 2.5 Hz, 
1H).13C NMR (126 MHz, CDCl3) δ 167.1 (C), 156.2 (d, JC-F = 27.1 Hz C), 148.0 (C), 140.4 (d, 
JC-F = 241.1 Hz C), 135.7 (C), 131.0 (C), 130.8 (C), 129.4 (C), 126.7 (d, JC-F = 33.8 Hz CH), 
77.1 (C), 75.2 (C), 37.7 (CH2). 
 
7.1.8 Synthesis and characterization of Pd0 labile moieties 
Synthesis of propargyloxy-benzyl alcohol derivatives. Potassium carbonate (4.70 g 34 mmol) 
was added to a solution of o-hydroxybenzyl alcohol or p-hydroxybenzyl alcohol (2.50 g, 20 
mmol) or 2,6-dihydroxybenzyl alcohol (2.80 g, 20 mmol) dissolved in acetonitrile (50 mL). After 
stirring for one hr at rt, the mixture was treated dropwise with propargyl bromide (2.93 mL as 
80 % (v/v) in toluene, 35 mmol) and heated to reflux for 48 hr. The solution was then filtered, 
concentrated in vacuo, and the crude was purified via flash chromatography (30 % ethyl 






p-propargyloxybenzyl alcohol (29) The synthetic method described using p-hydroxybenzyl 
alcohol gave a viscous bright yellow liquid (3.7 g, 99 % yield); Rf = 0.36 (30 % ethyl acetate in 
hexane) 1H NMR (500 MHz, CDCl3) δ 7.19 (d, J = 8.8 Hz, 2H), 6.93 – 6.85 (m, 2H), 4.60 (d, J 
= 2.6 Hz, 2H), 4.44 (s, 2H), 3.73 (s, 1H), 2.55 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 156.6 (C), 133.9 (C), 128.3 (2 x CH), 114.6 (2 x CH), 78.5 (C), 75.7 (CH), 63.9 (CH2), 55.6 




o-propargyloxybenzyl alcohol (30). The synthetic method described using o-hydroxybenzyl 
alcohol gave a viscous dark yellow liquid (1.0 g, 30 % yield); Rf = 0.37 (30 % ethyl acetate in 
hexane) 1H NMR (500 MHz, CDCl3) δ 7.34 (dd, J = 7.5, 1.7 Hz, 1H), 7.28 – 7.22 (m, 1H), 6.99 
(td, J = 7.4, 0.9 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 4.68 – 4.61 (m, 4H), 3.42 (s, 1H), 2.57 (t, J 
= 2.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 154.8 (C), 129.7 (CH), 128.4 (C), 128.2 (CH), 
121.3 (CH), 111.6 (CH), 78.5 (C), 75.7 (CH), 60.3 (CH2), 55.7 (CH2). HRMS (m/z): [M+Na]+ 
calcd for C10H10O2 [M+Na]+: 185.0573, found: 185.0573 
 
Synthesis of p-nitrophenyl-carbonate moieties. A solution of 4-nitrophenylchloroformate (0.48 
g, 2.4 mmol) in dry DCM (8 mL) was added dropwise to a solution of the alcohol (2.2 mmol) 
and pyridine (0.19 mL, 2.4 mmol) in DCM (8 mL) at 0 °C under nitrogen in the dark. The mixture 
was stirred from 0 °C to rt overnight with TLC monitoring at t = 0 hr, 0.5 hr, 2 hr and 20 hr to 
indicate full consumption of the alcohol. After concentrating in vacuo, the crude residue was 
re-dissolved in ethyl acetate (70 mL), washed with H2O (2 x 50 mL) and brine (2 x 50 mL), 
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dried over MgSO4 and re-concentrated in vacuo, and the crude was purified via flash 
chromatography (50 % DCM in hexane). 
 
 
p-nitrophenyl-p-propargyloxybenzyl carbonate (31). The synthetic method described using p-
propargyloxybenzyl alcohol gave an off white oil that solidified to a white solid when below 
20 °C (0.54 g, 1.65 mmol, 75 % yield); Rf = 0.20 (50 % DCM in hexane) 1H NMR (500 MHz, 
CDCl3) δ 8.28 – 8.24 (m, 2H), 7.42 – 7.38 (m, 2H), 7.38 – 7.35 (m, 2H), 7.03 – 6.98 (m, 2H), 
5.24 (s, 2H), 4.71 (d, J = 2.4 Hz, 2H), 2.53 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
158.3 (C), 155.7 (C), 152.6 (C), 145.5 (C), 130.7 (2 x CH), 127.4 (2 x CH), 125.4 (CH2), 121.9 
(2 x CH), 115.3 (2 x CH), 78.4 (C), 75.9 (CH), 70.9 (CH2), 56.0 (CH2). HRMS (m/z): [M+Na]+ 




p-nitrophenyl-o-propargyloxybenzyl carbonate (32). The synthetic method described using o-
propargyloxybenzyl alcohol gave an off white oil that solidified to a white solid when kept below 
20 °C (0.52 g, 1.59 mmol, 72 % yield); Rf = 0.19 (50 % DCM in hexane) 1H NMR (500 MHz, 
CDCl3) δ 8.28 – 8.23 (m, 2H), 7.44 – 7.36 (m, 4H), 7.08 – 7.01 (m, 2H), 5.39 (s, 2H), 4.78 (d, 
J = 2.4 Hz, 2H), 2.53 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 155.9 (C), 155.8 (C), 
152.5 (C), 145.4 (C), 130.6 (CH), 130.5 (C), 125.4 (2 x CH), 123.4 (CH), 121.9 (2 x CH), 121.7 
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(CH), 112.4 (CH), 78.4 (C), 76.0 (CH), 66.6 (CH2), 56.3 (CH2). HRMS (m/z): [M+Na]+ calcd for 
C17H12O6N1 [M+Na]+: 350.0635, found: 350.0590 
 
 
p-nitrophenylpropargyloxy carbonate (40). The synthetic method described using propargyl 
alcohol gave white crystals in agreement with cited reference217 (0.31 g, 1.40 mmol, 64 % 
yield); Rf = 0.29 (50 % DCM in hexane) 1H NMR (500 MHz, CDCl3) δ 8.32 – 8.25 (m, 2H), 7.44 
– 7.38 (m, 2H), 4.88 (d, J = 2.5, 2H), 2.62 (t, J = 2.5, 1H). 13C NMR (126 MHz, CDCl3) δ 155.5 
(C), 152.1 (C), 145.7 (C), 125.5 (2 x CH), 121.9 (2 x CH), 77.4 (C), 76.9 (CH), 56.6 (CH2). 




 p-nitrophenyl benzyl carbonate (41). The synthetic method described using benzyl alcohol 
gave white crystals in agreement with cited reference217 (0.41 g, 1.5 mmol, 68 % yield); Rf = 
0.34 (50 % DCM in hexane) 1H NMR (500 MHz, CDCl3) δ 8.30 – 8.26 (m, 2H), 7.48 – 7.36 (m, 
7H), 5.30 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 155.6 (C), 152.6 (C), 145.5 (C), 134.3 (C), 
129.2 (2 x CH), 129.0 (CH), 128.9 (2 x CH), 125.5 (2 x CH), 121.9 (2 x CH), 71.2 (CH2). HRMS 





o-bis-propargyloxybenzoate (47) o-dihydroxybenzoic acid (6.96 g, 45.0 mmol) and potassium 
carbonate (30.5 g, 220 mmol) was suspended in dry DMF (40 mL) and stirred for 30 mins at 
0 °C. Propargyl bromide (21 mL, 80 % (v/v) in toluene, 16.8 mmol) was added dropwise and 
the reaction was warmed to ambient temperature and stirred for three days. The reaction was 
diluted with H2O (300 mL) and extracted with diethyl ether (6 x 200 mL). The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated in vacuo to yield a brown 
oil (5.37 g 20.1 mmol, 44%), used without further purification. 1H NMR (400 MHz, CDCl3) δ 
7.32 (t, J = 8.4 Hz, 1H), 6.76 (d, J = 8.4 Hz, 2H), 4.91 (d, J = 2.5 Hz, 2H), 4.71 (d, J = 2.5 Hz, 
4H), 2.51 (t, J = 2.4 Hz, 2H), 2.50 (t, J = 2.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 165.1 (C), 
156.0 (C), 131.3 (CH), 114.0 (CH), 106.8 (C), 78.2 (C), 77.7 (C), 76.2 (CH), 75.2 (CH), 57.0 
(CH2), 52.9 (CH2). 
 
o-bis-propargyloxyphenyl methanol (48) o-bis-propargylbenzoate (5.37 g, 20.1 mmol) was 
dissolved in THF and cooled to 0 °C for the addition of LiAlH4 (24 mL, 1 M in THF, 24 mmol) 
before warming to ambient temperature and stirring overnight. The reaction was quenched at 
0 °C with 10 % NaOH (40 mL), then stirred for 30 mins. The aqueous phase was extracted 
with DCM (3 x 70 mL) and the combined organic phases were washed with brine (40 mL), 
dried over MgSO4 and concentrated in vacuo. The crude residue was purified via flash column 
chromatography (30 % ethyl acetate in hexane) to yield a white solid (2.74 g, 12.6 mmol, 63%). 
1H NMR (500 MHz, CDCl3-d) δ 7.24 (t, J = 8.4 Hz, 1H), 6.72 (d, J = 8.4 Hz, 2H), 4.81 (d, J = 
6.7 Hz, 2H), 4.74 (d, J = 2.4 Hz, 4H), 2.51 (t, J = 2.4 Hz, 2H), 2.37 (t, J = 6.7 Hz, 1H). 13C NMR 
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(126 MHz, CDCl3) δ 162.5 (CH), 155.7 (CH), 129.1 (C), 106.6 (2 x CH), 78.5 (2 x C), 75.82 ( 2 
x CH) 56.6 (2 x CH2), 54.4 (2 x CH2); HRMS (ES+) calcd for C13H12O3 [M+H]+ : 217.0865, found: 
217.0859 
 
Synthesis of p-nitrophenyl-carbonate moiety. A solution of 4-nitrophenylchloroformate (0.48 g, 
2.4 mmol) in dry DCM (8 mL) was added dropwise to a solution of o-bis-propargyloxybenzyl 
alcohol (2.2 mmol) and pyridine (0.19 mL, 2.4 mmol) in DCM (8 mL) at 0 °C under nitrogen in 
the dark. The mixture was stirred from 0 °C to rt overnight with TLC monitoring at t = 0 hr, 0.5 
hr, 2 hr and 20 hr to indicate full consumption of the alcohol. After concentrating in vacuo, the 
crude residue was re-dissolved in ethyl acetate (70 mL), washed with H2O (2 x 50 mL) and 
brine (2 x 50 mL), dried over MgSO4 and re-concentrated in vacuo, and the crude was purified 
via flash chromatography (50 % DCM in hexane). 
p-nitrophenyl-o-bis-propargyloxybenzyl carbonate (49) The synthetic method described gave 
a white solid when below 20 °C (0.80g, 2.1 mmol, 86.5 %); Rf = 0.3 (25 % ethyl acetate in 
hexane) 1H NMR (500 MHz, CDCl3) δ 8.29 – 8.23 (m, 2H), 7.44 – 7.40 (m, 2H), 7.35 (t, J = 8.4 
Hz, 1H), 6.75 (d, J = 8.4 Hz, 2H), 5.49 (s, 2H), 4.76 (d, J = 2.4 Hz, 4H), 2.52 (t, J = 2.4 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 157.6 (C), 156.0 (C), 152.6 (C), 145.4 (C), 131.2 (CH), 
125.4 (2 x CH), 122.0 (2 x CH), 112.1 (2 x CH), 106.2 (2 x CH), 78.4 (2 x C), 76.0 (2 x CH), 
60.7 (2 x CH2), 56.7 (CH2). HRMS (m/z): [M+Na]+ calcd for C20H15O7N [M+Na]+: 404.0741, 
found: 404.0763. 
 





Synthesis of carbamate protected gemcitabine prodrugs. Gemcitabine HCl (500 mg, 1.67 
mmol) was dissolved in a stirred solution of dry DMF (5 mL) with imidazole (397 mg, 5.84 
mmol) and tert-butyldimethylsilyl chloride (302 mg, 2.00 mol) and stirred at rt overnight. The 
mixture was concentrated in vacuo, dissolved in ethyl acetate (50 mL) and washed with H2O 
(50 mL). The aqueous layer was then washed two more times with ethyl acetate and the 
organic layers were collected, washed with brine (150 mL), dried over MgSO4, concentrated 
in vacuo then purified via flash chromatography (8 % methanol in DCM) and directly used in 
the next step. Dry pyridine (35.5 μL, 440.7 μmol) was added drop wise to a solution of TBS-
gemcitabine (60 mg, 162 μmol) and the p-nitrophenyl carbonate moiety (106 mg, 324 μmol), 
propargyl chloroformate (37.8 μL, 390 μmol) or benzyl chloroformate (33.6 μL, 390 μmol) in 
dry THF (2 mL) with rapid stirring, and the reaction monitored by TLC (5 % methanol in DCM) 
at t = 1 hr, 6 hr and 24 hr, monitoring for formation of product at Rf = 0.13 (10 % methanol in 
DCM). After 24 hr the mixture was concentrated in vacuo, and the crude was purified via flash 
chromatography (0 à 5 % methanol in DCM). The carbamate protected TBS-gemcitabine (15 
μmol) was dissolved in dry THF (2 mL) and TBAF (30 μL, 101.8 μmol) was added. The solution 
was stirred rapidly for 24 hr, then concentrated in vacuo and the crude was purified via flash 




yl)pyrimidin-2(1H)-one (20) The synthetic method described above gave a white powder in 
agreement with cited reference34  (552 mg, 1.34 mmol, 88 % yield); Rf = 0.35 (2.5 % methanol 
in DCM). 1H NMR (500 MHz, DMSO) δ 7.63 (d, J = 7.5 Hz, 1H), 7.38 (s, 2H), 6.31 (d, J = 5.1, 
1H), 6.14 (t, J = 7.7 Hz, 1H), 5.76 (d, J = 7.5 Hz, 1H), 4.19 – 4.06 (m, 1H), 3.95 (d, J = 11.8 
Hz, 1H), 3.90 – 3.77 (m, 2H), 0.90 (s, 9H), 0.09 (d, J = 2.1 Hz, 6H). 13C NMR (126 MHz, DMSO) 
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δ 165.6 (C), 154.6 (C), 139.9 (CH), 123.0 (t, JC-F = 258.3 Hz, C), 94.5 (CH), 83.5 (t, JC-F = 31.5 
Hz, CH), 79.8 (CH), 68.2 (t, JC-F = 22.7 Hz, CH), 60.7 (CH2), 25.7 (CH3), 18.0 (C), -5.5(CH3), -




hydroxytetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate (22). The synthetic 
method described above gave a white powder in agreement with cited reference34 (335.5 mg, 
0.73 mmol 44 % yield); (Rf = 0.6, 10 % methanol in DCM). 1H NMR (500 MHz, MeOD) δ 8.30 
(d, J = 7.6 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 6.25 (t, J = 6.7 Hz, 1H), 4.84 (d, J = 2.5 Hz, 2H,), 
4.33 – 4.24 (m, 1H), 4.10 (d, J = 12.0 Hz, 1H,), 4.03 – 3.90 (m, 2H), 2.99 (t, J = 2.3 Hz, 1H), 
0.98 (s, 9H,), 0.17 (s, 6H,). 13C NMR (126 MHz, MeOD) δ 165.3 (C), 157.3 (C), 154.6 (C), 
145.0 (CH), 123.9 (t, JC-F = 259.6 Hz, C), 96.9 (CH), 86.2 (t, JC-F = 32.8 Hz, CH), 82.5 CH), 
77.7 (C), 76.9 (CH), 69.6 (t, JC-F = 22.7 Hz, CH), 61.7 (CH2), 54.3 (CH2), 26.4 (CH3), 19.3 (C), 






yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate (23). The synthetic method described above 
gave a white powder in agreement with cited reference34 (358.8 mg, 0.70 mmol, 42 % yield) 
(Rf = 0.53, 10 % methanol in DCM). 
1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 7.5 Hz, 1H), 
7.40 – 7.32 (m, 5H), 6.40 – 6.32 (m, 1H), 5.22 (s, 2H), 4.41 – 4.31 (m, 1H), 4.07 – 4.00 (m, 
2H), 3.90 (dd, J = 11.9 Hz, 2.2 Hz, 1H), 0.93 (s, 9H), 0.12 (s, 6H). 13C NMR (126 MHz, DMSO) 
δ 162.9 (C), 154.9 (C), 152.4 (C), 144.4 (CH), 135.0 (C),128.9 (CH), 128.4 (CH), 122.3 (t, JC-
F = 258.3 Hz, C), 95.5 (CH), 84.6 (t, JC-F = 32.8 Hz, CH), 81.6 (CH), 69.3 (t, JC-F = 26.5 Hz, 





dihydropyrimidin-4-yl)carbamate (25). The synthetic method described above gave a white 
powder in agreement with cited reference34 (4.5 mg, 15 μmol, 99 % yield); Rf = 0.41 (10 % 
methanol in DCM). 1H NMR (500 MHz, DMSO) δ 11.06 (s, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.08 
(d, J = 7.55 Hz, 1H), 6.30 (d, J = 6.5 Hz, 1H), 6.16 (t, J = 7.4 Hz, 1H), 5.29 (t, J = 5.5 Hz, 1H), 
4.80 (d, J = 2.4 Hz, 2H), 4.26 – 4.13 (m, 1H), 3.89 (dt, J = 8.5 Hz, 3.1 Hz, 1H), 3.84 – 3.63 (m, 
2H), 3.62 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 163.3 (C), 153.9 (C), 152.4 (C), 
144.6 (CH), 122.9 (C), 94.8 (CH), 84.1 (CH), 81.0 (CH), 78.2 (CH), 78.2 (C) 68.4 (CH), 58.8 
(CH), 53.01 (CH2). MS (ESI) m/z 344.0 [M-H]-. HRMS (m/z): [M - H]- calcd for C13H12O6N3F2, 






dihydropyrimidin-4-yl)carbamate (26). The synthetic method described above gave a white 
powder in agreement with cited reference34 (5.9 mg, 15 μmol, 99 % yield); Rf = 0.33 (10 % 
methanol in DCM). 1H NMR (500 MHz, DMSO) δ 10.98 (s, 1H), 8.23 (d, J = 7.6 Hz, 1H), 7.45 
– 7.32 (m, 5H), 7.11 (d, J = 7.6 Hz, 1H), 6.31 (d, J = 6.5 Hz, 1H), 6.16 (t, J = 7.4 Hz, 1H), 5.29 
(t, J = 5.5 Hz, 1H), 5.20 (s, 2H), 4.25 – 4.13 (m, 1H), 3.88 (dt, J = 8.5 Hz, 3.1 Hz, 1H), 3.84 – 
3.62 (m, 2H).13C NMR (126 MHz, DMSO) δ 163.4 (C), 154.0 (C), 153.0 (C), 144.5 (CH), 135.8 
(C), ), 128.5 (CH), 128.2 (CH), 128.0 (CH), 122.9 (t, JC-F = 259.6 Hz, C), 94.9 (CH), 84.1 (t, JC-
F = 30.2 Hz, CH), 81.0 (CH), 68.4 (t, JC-F = 22.7 Hz, CH), 66.7 (CH2), 58.8 (CH2). HRMS (m/z): 
[M – H]-
 




hydroxytetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate. The synthetic 
method described above gave a white powder (8.5 mg, 15 μmol, 9 % yield); Rf = 0.30 (2.5 % 
methanol in DCM). 1H NMR (500 MHz, MeOD) δ 8.26 (d, J = 7.7 Hz, 1H), 7.38 – 7.35 (m, 2H), 
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7.31 (d, J = 7.7 Hz, 1H), 7.00 – 6.97 (m, 2H), 6.24 (t, J = 6.7 Hz, 1H), 5.16 (d, J = 1.4 Hz, 2H), 
4.72 (d, J = 2.4 Hz, 2H), 4.28 (td, J = 12.5, 8.7 Hz, 1H), 4.09 (d, J = 12.0 Hz, 1H), 4.00 (dt, J 
= 8.7, 2.2 Hz, 1H), 3.92 (dd, J = 12.1, 2.3 Hz, 1H), 2.92 (t, J = 2.4 Hz, 1H), 0.97 (s, 9H), 0.16 
(s, 6H). 13C NMR (126 MHz, MeOD) δ 165.34 (C), 159.34 (C), 157.3 (C), 154.5 (CH), 144.8 
(C), 131.12 (CH), 129.8 (C), 123.89 (t, JC-F = 258.8 Hz C), 116.0 (CH), 97.90 (CH), 86.2 (t, JC-
F = 32.5 Hz CH), 82.5 (CH), 79.67 (C), 76.8 (CH), 69.67 (d, JC-F = 22.9 Hz CH), 68.55 (CH2), 
61.67 (CH2), 56.6 (CH3), 26.4 (CH3), 18.5 (C), -5.4 (CH3). HRMS (m/z): [M+Si]+ calcd for 




hydroxytetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate. The synthetic 
method described above gave a white powder (6.4 mg, 11.3 μmol, 6.9 % yield); Rf = 0.28 (2.5 % 
methanol in DCM). 1H NMR (500 MHz, MeOD) δ 8.26 (d, J = 7.7 Hz, 1H), 7.43 (dd, J = 7.5, 
1.6 Hz, 1H), 7.39-7.32 (m, 2H), 7.16 –7.12 (m, 1H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 6.27 (t, J = 
6.8 Hz, 1H) 5.35 - 5.25 (m, 2H), 4.82 (d, J = 2.4 Hz, 2H), 4.31 (td, J = 12.5, 8.7 Hz, 1H), 4.12 
(d, J = 12.0 Hz), 4.03 (dt,J = 8.7, 2.3 Hz, 1H), 3.95 (dd, J = 12.1, 2.4 Hz, 1H), 2.96 (t, J = 2.4 
Hz, 1H), 1.00 (s, 9H), 0.19 (s, 6H). HRMS (m/z): [M+Si]+ calcd for C26H34O7N3F2+Si28 566.2129 






oxo-1,2-dihydropyrimidin-4-yl)carbamate (33). The synthetic method described above gave a 
white powder (6.7 mg, 15 μmol, 99 % yield); Rf = 0.42 (5 % methanol in DCM). 1H NMR (601 
MHz, MeOH) δ 8.30 (d, J = 7.7, 1H), 7.39 – 7.36 (m, 2H), 7.35 (d, J = 7.6, 1H), 7.01 – 6.97 (m, 
2H), 6.29 – 6.19 (m, 1H), 5.17 (s, 2H), 4.73 (d, J = 2.4, 2H), 4.30 (td, J = 12.1, 8.7, 1H), 4.02 
– 3.91 (m, 2H), 3.81 (dd, J = 12.7, 3.0, 1H), 2.93 (t, J = 2.4, 1H). 13C NMR (151 MHz, MeOH) 
δ 165.6 (C), 159.5 (C), 157.6 (C), 154.7 (C), 145.8 (CH), 131.3 (CH), 130.0 (C), 125.8 – 124.1 
(C), 116.2 (CH), 97.2 (CH), 83.1 – 82.9 (CH), 79.8 (C), 77.0 (CH), 70.9 – 70.0 (C), 68.6 (CH2), 





oxo-1,2-dihydropyrimidin-4-yl)carbamate (34). The synthetic method described above gave a 
white powder (5.1 mg, 11.3 μmol, 99 % yield); Rf = 0.40 (5 % methanol in DCM). 1H NMR (601 
MHz, MeOH) δ 8.31 (d, J = 7.7 Hz, 1H), 7.40 (dd, J = 7.5, 1.3 Hz, 1H), 7.38 – 7.29 (m, 2H), 
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7.11 (d, J = 8.3 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.33 – 6.18 (m, 1H), 5.28 (s, 2H), 4.80 (d, J 
= 2.4 Hz, 2H), 4.36 – 4.24 (m, J = 12.1, 8.8 Hz, 1H), 4.03 – 3.92 (m, 2H), 3.87 – 3.77 (m, 1H), 
2.94 (t, J = 2.4 Hz, 1H). 13C NMR (151 MHz, MeOH) δ 165.6 (C), 157.6 (C), 157.3 (C), 155.3 
(C), 145.8 (CH), 131.2 (CH), 131.1 (C), 125.8 (CH), 124.5 (CH), 124.1 - 122.5 (CH), 113.6 
(CH), 97.2 (CH), 83.0 – 82.9 (CH), 79.8 (C), 77.1 (CH), 70.9 – 69.9 (JC-F = 24.2 Hz CH), 64.4 
(CH2), 60.4 (CH2), 57.2 (CH2). HRMS (m/z): [M+Na]+ calcd for C20H19O7N3F2+Na23 474.1083 
found 474.1105 
 
Synthesis of carbonate protected gemcitabine prodrugs. Triethylamine (33 μL, 33 μmol) was 
added dropwise to a solution of gemcitabine HCl (50 mg, 0.17 μmol) in anhydrous DMF (1 mL) 
and stirred rapidly for 10 min. The p-nitrophenyl carbonate moiety (120 mg, 33 μmol) was 
added and the reaction monitored by TLC (10 % methanol in DCM) at t = 1 hr, 6 hr and 24 hr 
monitoring for formation of product at Rf = 0.13 (10 % methanol in DCM). After 24 hr, the 
reaction was concentrated in vacuo, and the crude was purified via flash chromatography (0 




propargyloxybenzyl) carbonate (35) The synthetic method described above using p-
nitrophenyl-p-propargyloxybenzyl carbonate gave a pale yellow oil (17.2 mg, 38.1 μmol, 23 % 
yield); Rf = 0.26 (10 % methanol in DCM). 1H NMR (500 MHz, MeOD) δ 8.30 (d, J = 7.7 Hz, 
1H), 7.39 – 7.36 (m, 2H), 7.35 (d, J = 7.7 Hz, 1H), 7.02 – 6.96 (m, 2H), 6.30 – 6.19 (m, 1H), 
5.17 (s, 2H), 4.73 (d, J = 2.4 Hz, 2H), 4.34 – 4.24 (m, J = 20.7, 12.1 Hz, 1H), 4.02 – 3.93 (m, 
2H), 3.81 (dd, J = 12.6, 3.1 Hz, 1H), 2.93 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 
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165.6 (C), 159.5 (C), 157.6 (C), 154.7 (C), 145.8 (CH), 131.3 (CH), 130.0 (C), 124.1 (t, JC-F = 
258.0 Hz C), 116.2 (CH), 97.2 (CH), 87.0 – 86.1 (CH), 83.2 – 82.6 (CH), 79.8 (C), 77.0 (CH), 
70.7 – 70.0 (CH), 68.6 (CH2), 60.4 (CH2), 57.8 (CH2). HRMS (m/z): [M+Na]+ calcd for 




propargyloxybenzyl) carbonate (36) The synthetic method described above using p-
nitrophenyl-2-propargyloxybenzyl) carbonate gave a pale yellow oil (15.5 mg, 34.3 μmol, 20 % 
yield); Rf = 0.13 (10 % methanol in DCM). 1H NMR (500 MHz, MeOD) δ 8.30 (d, J = 7.7 Hz, 
1H), 7.39 (d, J = 7.5 Hz, 1H), 7.37 – 7.31 (m, 2H), 7.11 (d, J = 8.3 Hz, 1H), 7.00 (t, J = 7.5 Hz, 
1H), 6.30 – 6.18 (m, 1H), 5.27 (s, 2H), 4.79 (d, J = 2.3 Hz, 2H), 4.37 – 4.25 (m, J = 12.1, 8.8 
Hz, 1H), 4.01 – 3.92 (m, 2H), 3.81 (dd, J = 12.7, 3.1 Hz, 1H), 2.94 (t, J = 2.4 Hz, 1H). 13C NMR 
(126 MHz, MeOD) δ 165.6 (C), 157.6 (C), 157.3 (C), 154.7 (C), 145.7 (CH), 131.2 (CH), 131.1 
(C), 126.0 (C), 125.6 (CH) 124.1 (t, JC-F = 259.1 Hz C), 122.5 (CH), 113.6 (CH), 97.2 (CH), 
86.9 – 86.2 (CH), 83.0 – 82.9 (CH), 79.8 (C), 77.1 (CH), 70.6 – 70.1 (CH), 64.4 (CH2), 60.4 
(CH2), 57.2 (CH2). HRMS (m/z): [M+Na]+ calcd for C20H19O7N3F2+Na23 474.1083 found 
474.1083 
 
7.1.10. Synthesis and characterization of doxorubicin prodrugs 
Synthesis of doxorubicin prodrugs. A solution of the p-nitrophenyl carbonate moiety (1.5 equiv) 
in anhydrous DMF (2 mL) was flushed with nitrogen after stirring for 10 minutes, then syringed 
into a flask containing a solution of doxorubicin HCl (20 mg, 36.8 μmol) and triethylamine (7.5 
μL, 55.2 μmol) in anhydrous DMF under nitrogen at rt. The reaction was monitored by TLC 
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(10 % methanol in DCM) to observe complete consumption of doxorubicin. After 20 hr, the 
reaction was diluted with H2O (50 mL) and extracted with ethyl acetate (4 x 50 mL). The 
combined organic extracts were concentrated down to a volume of ~100 mL, then washed 
successively with saturated NaHCO3 (2 x 50 mL), H2O (2 x 50 mL) and brine (2 x 50 mL), dried 
over MgSO4, concentrated in vacuo with the water bath kept below 40 °C and the crude was 
purified via flash chromatography (0 à 2 % methanol in DCM)  
 
 
N-(p-propargyloxybenzyl) carbamate doxorubicin (42). The synthetic method described using 
p-nitrophenyl-p-propargyloxybenzyl carbonate gave a bright red clumpy powder (17.3 mg, 
23.6 μmol, 64 % yield); Rf = 0.25 (2 % methanol in DCM) 1H NMR (500 MHz, CDCl3) δ 13.96 
(s, 1H), 13.23 (s, 1H), 8.03 (dd, J = 7.7, 1.0 Hz, 1H), 7.81 – 7.76 (m, J = 8.3, 7.8 Hz, 1H), 7.39 
(dd, J = 8.5, 0.7 Hz, 1H), 7.24 (s, 1H), 6.92 (d, J = 8.0 Hz, 2H), 5.49 (d, J = 3.9 Hz, 1H), 5.28 
(s, 1H), 5.10 (d, J = 8.3 Hz, 1H), 4.97 (s, 2H), 4.76 (s, 2H), 4.66 (s, 2H), 4.53 (s, 1H), 4.17 – 
4.10 (m, 1H), 4.08 (s, 3H), 3.91 – 3.80 (m, 1H), 3.66 (s, 1H), 3.27 (dd, J = 18.8, 1.8 Hz, 1H), 
3.05 – 2.97 (m, 2H), 2.49 (t, J = 2.4 Hz, 1H), 2.33 (dt, J = 14.5, 1.8 Hz, 1H), 2.17 (dd, J = 14.7, 
4.0 Hz, 1H), 1.93 (d, J = 4.2 Hz, 1H), 1.87 (dd, J = 13.5, 4.8 Hz, 1H), 1.76 (td, J = 13.3, 4.2 Hz, 
1H), 1.28 (d, J = 6.6 Hz, 3H), 1.25 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 214.0 (C), 187.3 (C), 
186.9 (C), 161.2 (C), 157.6 (C), 156.3 (C), 155.8 (C), 157.7 (C), 135.9 (CH), 135.7 (C), 133.7 
(C), 134.0 (C), 130.1 (CH), 129.6 (C), 121.1 (C), 120.0 (CH), 118.6 (CH), 115.1 (C), 111.8 (C), 
111.8 (C), 100.9 (CH), 78.6 (CH), 77.4 (CH), 76.8 (C), 75.7 (C), 69.8 (CH), 69.7 (CH), 67.4 
(CH), 66.6 (CH), 65.7 (CH2), 56.8 (CH3), 55.9 (CH2), 47.1 (CH), 35.8 (CH2), 34.2 (CH2), 30.0 





N-(o-propargyloxybenzyl carbamate) doxorubicin (43). The synthetic method described using 
p-nitrophenyl-o-propargyloxybenzyl carbonate gave a dark red clumpy powder (12.1 mg, 16.5 
μmol, 45 % yield); Rf = 0.25 (2 % methanol in DCM). 1H NMR (500 MHz, CDCl3) δ 13.98 (s, 
1H), 13.25 (s, 1H), 8.04 (dd, J = 7.7, 1.0 Hz, 1H), 7.82 – 7.75 (m, J = 8.4, 7.8 Hz, 1H), 7.39 
(dd, J = 8.5, 0.7 Hz, 1H), 7.33 – 7.27 (m, 1H), 7.01 – 6.93 (m, 2H), 5.51 (d, J = 3.9 Hz, 1H), 
5.33 – 5.27 (m, 1H), 5.15 – 5.08 (m, 3H), 4.76 (s, 2H), 4.70 (s, 2H), 4.55 (s, 1H), 4.14 (dd, J = 
12.3, 6.2 Hz, 1H), 4.08 (s, 3H), 3.92 – 3.82 (m, 1H), 3.68 (s, 1H), 3.28 (dd, J = 18.8, 1.5 Hz, 
1H), 3.03 (d, J = 18.8 Hz, 2H), 2.48 (s, 1H), 2.34 (d, J = 14.7 Hz, 1H), 2.17 (dd, J = 14.7, 4.0 
Hz, 1H), 1.88 (dd, J = 13.5, 5.0 Hz, 1H), 1.77 (td, J = 13.3, 4.2 Hz, 2H), 1.29 (d, J = 6.6 Hz, 
3H), 1.25 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 214.0 (C), 187.3 (C), 186.9 (C), 161.2 (C), 
156.3 (C), 155.9 (C) 155.9 (C), 155.6 (C), 135.9 (CH), 135.7 (C), 133.7 (C), 130.0 (CH), 129.5 
(CH), 125.6 (CH), 121.6 (C), 121.1 (CH), 120.0 (CH), 118.6 (CH), 112.3 (C), 111.8 (C), 111.6 
(C), 111.5 (CH), 100.9 (CH), 78.7 (C), 77.4 (CH), 76.8 (C), 75.7 (C), 69.8 (CH), 69.7 (CH), 
67.4 (CH), 65.7 (CH), 62.2 (CH2), 56.9 (CH3), 56.3 (CH2), 47.1 (CH), 35.8 (CH2), 34.2 (CH2), 






N-(carboxybenzyl) doxorubicin (44). The synthetic method described using p-nitrophenyl-
benzyl carbonate gave a dark red powder (17.3 mg, 25.5 μmol, 94 % yield); Rf = 0.25 (2 % 
methanol in DCM). 1H NMR (500 MHz, CDCl3) δ 13.96 (s, 1H), 13.23 (s, 1H), 8.03 (dd, J = 7.7, 
1.0 Hz, 1H), 7.78 (dd, J = 8.3, 7.9 Hz, 1H), 7.39 (dd, J = 8.6, 0.7 Hz, 1H), 7.34 – 7.26 (m, 5H), 
5.50 (d, J = 3.9 Hz, 1H), 5.28 (s, 1H), 5.14 (d, J = 8.4 Hz, 1H), 5.03 (s, 2H), 4.82 – 4.70 (m, 
2H), 4.54 (s, 1H), 4.14 (dd, J = 13.6, 7.2 Hz, 1H), 4.08 (s, 3H), 3.92 – 3.82 (m, 1H), 3.67 (s, 
1H), 3.27 (dd, J = 18.8, 1.9 Hz, 1H), 3.00 (d, J = 18.8 Hz, 2H), 2.33 (d, J = 14.7 Hz, 1H), 2.19 
– 2.14 (m, 1H), 1.88 (dd, J = 13.5, 4.8 Hz, 1H), 1.77 (td, J = 13.2, 4.1 Hz, 1H), 1.29 (d, J = 6.6 
Hz, 3H), 1.25 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 214.0 (C), 187.3 (C), 186.9 (C), 161.2 (C), 
156.3 (C), 155.8 (C), 155.7 (C), 136.5 (C), 135.9 (CH), 135.7 (C), 133.7 (C), 128.7 (C), 128.3 
(CH), 121.0 (C), 120.0 (CH), 118.6 (CH), 111.8 (C), 111.6 (C), 100.9 (CH), 77.4 (C), 76.8 (CH), 
69.8 (CH), 69.7 (CH), 67.4 (CH), 66.9 (CH), 65.7 (CH2), 56.8 (CH3), 47.1 (CH), 35.8 (CH2), 






N-propargyloxy carbamate doxorubicin (45). The synthetic method described using p-
nitrophenyl-propargyloxy carbonate gave a dark red powder (12.4 mg, 19.8 μmol, 73 % yield); 
Rf = 0.25 (2 % methanol in DCM). 1H NMR (500 MHz, CDCl3) δ 13.96 (s, 1H), 13.21 (s, 1H), 
8.03 (dd, J = 7.7, 1.0 Hz, 1H), 7.81 – 7.74 (m, 1H), 7.39 (d, J = 8.0 Hz, 1H), 5.50 (d, J = 3.8 
Hz, 1H), 5.28 (s, 1H), 5.21 (d, J = 8.5 Hz, 1H), 4.76 (d, J = 1.8 Hz, 2H), 4.61 (d, J = 2.2 Hz, 
2H), 4.51 (s, 1H), 4.14 (q, J = 6.3 Hz, 1H), 4.08 (s, 3H), 3.91 – 3.83 (m, 1H), 3.67 (s, 1H), 3.26 
(dd, J = 18.8, 1.7 Hz, 1H), 2.99 (d, J = 18.8 Hz, 2H), 2.42 (d, J = 2.1 Hz, 1H), 2.33 (d, J = 14.7 
Hz, 1H), 2.17 (dd, J = 14.7, 4.1 Hz, 1H), 1.88 (dd, J = 13.5, 5.1 Hz, 1H), 1.78 (td, J = 13.3, 4.2 
Hz, 1H), 1.29 (d, J = 6.6 Hz, 3H), 1.25 (s, 1H).13C NMR (126 MHz, CDCl3) δ 214.0 (C), 187.3 
(C), 186.8 (C), 161.2 (C), 156.3 (C), 155.8 (C), 154.8 (C), 135.9 (CH), 135.7 (C), 133.7 (C), 
121.0 (C), 120.0 (C), 118.6 (CH), 111.8 (C), 111.6 (C), 100.8 (CH), 78.2 (CH), 77.4 (CH), 76.8 
(C), 74.8 (C), 69.8 (CH), 69.7 (CH), 67.4 (CH), 65.7 (CH2), 56.8 (CH3), 52.7 (CH2), 47.3 (CH), 
35.8 (CH2), 34.2 (CH2), 30.5 (CH2), 17.0 (CH3). HRMS (m/z): [M+Na]+ calcd for 





o-bis-propargyloxybenzyl) carbamate doxorubicin (50) The synthetic method described using 
p-nitrophenyl-o-bis-propargyloxybenzyl- carbonate gave a crude powder that was then further 
purified by semi-prep HPLC to afford a dark red clumpy powder (14 mg, 11 μmol, 30 % yield); 
Rf = 0.52 (2 % methanol in DCM). 1H NMR (500 MHz, CDCl3) δ 13.97 (s, 1H), 13.26 (s, 1H), 
8.05 (d, J = 7.7 Hz, 1H), 7.79 (t, J = 8.1 Hz, 1H), 7.39 (d, J = 8.5 Hz, 2H), 7.24 (s, 1H), 6.70 
(d, J = 5.5 Hz, 2H), 5.50 (d, J = 3.3 Hz, 1H), 5.30 (s, 1H), 5.25 – 5.14 (m, 2H), 5.03 – 4.92 (m, 
2H), 4.76 (s, 2H), 4.69 (s, 4H), 4.13 (s, 1H), 4.08 (s, 3H), 3.88 (s, 1H), 3.70 (s, 1H), 3.16 (dd, 
J = 126.2, 18.6 Hz, 2H), 2.46 (s, 2H), 2.25 (dd, J = 88.8, 14.5 Hz, 2H), 1.79 (ddd, J = 27.8, 
16.8, 7.2 Hz, 2H), 1.31 – 1.24 (m, 3H).13C NMR (126 MHz, CDCl3) δ 214.0 (C), 187.1 (C), 
187.0 (C), 161.1 (C), 157.5 (C), 156.2 (C), 155.9 (C), 155.7 (C), 135.7 (CH), 135.6 (C), 133.7 
(C), 133.6 (C), 130.1 (CH), 121.0 (C), 119.9 (CH), 118.5 (CH), 114.0 (C), 111.7 (C), 111.5 (C), 
106.3 (CH), 100.7 (CH), 78.5 (CH), 77.2 (CH), 76.6 (C), 75.6 (C), 69.5 (CH), 69.5 (CH), 67.3 
(CH), 65.6 (CH2), 56.7 (CH3), 56.5 (CH2), 56.2 (CH2), 47.0 (CH), 35.7 (CH2), 34.1 (CH2), 30.2 




7.2 Biology Methods 
7.2.1 Cell culture 
Cell lines were grown in culture media supplemented with 10 % Fetal Bovine Serum (FBS) 
and 2 mM L-glutamine, then incubated in a tissue culture incubator at 37 °C and 5 % CO2. 
Human adenocarcinomic alveolar basal epithelial A549 cells (a gift from Dr. Simon Wilkinson), 
human prostate cancer DU145 cells (a gift from Dr. Neil Carragher), human glioblastoma 
multiforme U87 cells (a gift from Dr. Noor Gamon), human glioblastoma multiforme T98 cells 
(a gift from Dr. Margaret Frame), human pancreatic carcinoma MiaPaCa-2 cells (a gift from 
Dr. Simon Wilkinson) and human colorectal carcinoma HCT116 cells (a gift from Dr Van 
Schaeybroeck) were cultured in Dulbecco’s modified Eagle’s media (DMEM). Human 
pancreas adenocarcinoma BxPC-3 cells (a gift from Dr Mark Duxbury) were cultured in 
Roswell Park Memorial Institute (RPMI) media.  
 
7.2.2 Non Biological Pd0 mediated Conversion Study 
All stock drug samples (100 mM in DMSO) were dissolved in PBS (1 mL) for a final 
concentration of 100 μM with 1 mg of 30 μm or 150 μm Pd0 beads and shaken at 1200 rpm, 
37 °C in a Thermomixer. 50 µL aliquots were removed at reported time intervals and monitored 
by analytical UPLC using a UV detector. Ultra-performance liquid chromatography (UPLC) 
was performed using a Waters Acquity UPLC PDA with a 50 x 2.4 mm Waters BEH C18 1.7 
µm column, with compounds detected using an evaporative light scattering detector (ELSD) 
and UV detector. All solvents used were HPLC grade. Method: eluent A, H2O and formic acid 
(0.1 %); eluent B, acetonitrile; A/B = 95 : 5 to 20 : 80 in 8 min, 95 : 5 in 8.5 minutes. 
 
7.2.3 Bioorthogonal Comparative Study of Prodrug to Parental Drug  
Cells were seeded in a 96 well plate format at the appropriate cell concentration (2000 
cells/well for DU145 cells and U87 cells, 1,000 cells/well for MiaPaCa-2 cells, 3000 cells/well 
for HCT116 cells and T98 cells and 2500 cells/well for A549 and BxPC-3 cells), and incubated 
-	184	-	
	
for 48 hr before treatment. Each well was then replaced with fresh media containing drug or 
prodrug and incubated for 5 days. Untreated cells were incubated with DMSO (0.1 % v/v). 
PrestoBlue® cell viability reagent (10 % v/v) was added to each well and the plate incubated 
for 1 hr. Fluorescence emission was detected using a PerkinElmer Victor2 multilabel reader 
(excitation filter at 540 nm and emissions filter at 590 nm). All conditions were normalized to 
the untreated cells (100 %) and curves fitted with GraphPad Prism 5 using a sigmoidal variable 
slope curve.  
 
7.2.4 Pd0-Mediated Dealkylation of Prodrugs in Cell Culture 
Cells were plated as described and incubated for 48 hr prior to treatment. Wells were then 
replaced with fresh media containing Pd0-beads. For 130 μm diameter Pd0 bead studies, 
appropriate wells were replaced containing 0.67 mg/mL – (BxPC3 cells) or 1 mg/mL – (DU145 
cells, U87 cells, MiaPaCa2 cells and HCT116 cells) with DMSO (0.1 % v/v). For 30 μm 
diameter Pd0 bead studies, appropriate wells was replaced with fresh media containing 0.6 
mg/mL – (DU145 cells, U87 cells) with DMSO (0.1 % v/v). For doxorubicin assays; wells were 
replaced with media containing prodrugs 42 – 45, 50 (30 - 3000 nM) with DMSO (0.1 % v/v); 
doxorubicin 37 (30 - 3000 nM) with DMSO (0.1 % v/v); or a combination of Pd0 beads and 
prodrugs 42 – 45, 50 (30 - 3000 nM) with DMSO (0.1 % v/v). Untreated cells were incubated 
with Pd0 beads and DMSO (0.1 % v/v), and DMSO (0.1 % v/v) alone. For gemcitabine assays; 
wells were replaced with media containing prodrugs 24 – 26, 33 - 36 (3 - 300 nM) with DMSO 
(0.1 % v/v); gemcitabine 16 (3 - 300 nM) with DMSO (0.1 % v/v); or a combination of Pd0 beads 
and prodrugs 24 – 26, 33 - 36 (3 - 300 nM) with DMSO (0.1 % v/v). Untreated cells were 
incubated with Pd0 beads and DMSO (0.1 % v/v), and DMSO (0.1 % v/v) alone. For 5-
fluorouracil assays; wells were replaced with media containing prodrug 2 (30 - 3000 nM) with 
DMSO (0.1 % v/v); 5FU 1 (30 - 3000 nM) with DMSO (0.1 % v/v); or a combination of Pd0 
beads and prodrug (2) (30 - 3000 nM) with DMSO (0.1 % v/v). Untreated cells were incubated 
with Pd0 beads and DMSO (0.1 % v/v), and DMSO (0.1 % v/v) alone. All cells were incubated 
with drugs for 5 days. PrestoBlue® cell viability reagent (10 % v/v) was added to each well 
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and the plate incubated for 1 hr. Fluorescence emission was detected and results normalized 
as described above. 
 
7.2.5 Spontaneous Raman spectroscopy of drug, prodrug and cell pellet 
For drug and prodrug Raman spectrum analysis, a spatula tip of dry powdered 5FU 1 or 
prodrug 2 was spread evenly across a Raman grade CaF2 polished cover slip and mounted 
under the Raman spectrometer laser for signal acquisition. For cell pellet preparation, the 
adenocarcinomic human alveolar basal epithelial (A549) cell line was maintained in 
Dulbecco's Modified Eagle's Medium (DMEM, Sigma-Aldrich), supplemented with 2 mM L-
glutamine and 10 % FBS (Thermo Fisher Scientific) at 37 °C in a humidified atmosphere 
containing 5 % CO2. A549 cells were grown to confluence in a T75 flask, trypsinated and 
centrifuged into a cell pellet of ~ 1 mm in diameter. Supernatant was removed and the cell 
pellet bathed in 1 or 2 (1 mL of a 500 μM solution in 0.1 % DMSO) for 15 minutes. The cell 
pellet was snap frozen in liquid nitrogen, re-thawed to rt after 1 hr then gently pipetted across 
a Raman grade CaF2 polished cover slip and mounted under the Raman spectrometer laser 
for signal acquisition. The spontaneous Raman spectra were acquired using a confocal 
Raman spectrometer (inVia Raman microscope, Renishaw) at rt. A 200 mW 532 nm laser 
excitation source was used to excite the sample through a 20 x objective, N.A. 0.75 objective 
(Leica Biosystems). The recorded spectral range for grating 1200 g mm-1 was 100 – 3500 cm-
1. The total data acquisition was performed during 10 s for drug and prodrug powder analysis, 
and 60 s for cell pellet analysis, both recorded at λex = 532 nm without background correction 
using WiRE 4.1 software.  
 
7.2.6 Spheroid Assay 
A suspension of freshly trypsinated cells was dispensed as 10,000 cells in 50 µL aliquots into 
wells of a 96 Corning ULA® U-bottom plate at 4 °C. Pd0 bead(s) in fresh media were dispensed 
into required wells in 50 µL aliquots. A solution of Matrigel® in cold media was made up and 
dispensed into the wells for a final concentration of 2 % in Matrigel® in 200 µL media. The 
Corning ULA® U-bottom plate was inserted into a pre-chilled 4 °C centrifuge and spun at 1000 
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G for 10 minutes. Cells were then incubated at 37 °C for 72 hr and viewed under microscope 
to confirm spheroid formation. Wells were replaced with media containing prodrug 43 100 μM) 
with DMSO (0.1 % v/v) or doxorubicin (100 μM) with DMSO (0.1% v/v). Untreated cells were 
incubated with DMSO alone (0.1 % v/v). 2 μL of a 0.3 mM stock solution of DRAQ7™ live 
imaging apoptosis staining solution was added to each well, and the plate was incubated for 
5 days. Microscopy at day 5 was carried out with an ImageXpress micro XLS widefield 
microscope (Molecular Devices) at 4 x magnification, imaged with transmitted light and a Cy5 
far-red filter (excitation 628 +/- 40 nm, emission 692 +/- 40 nm). Images were taken as a Z-
stack at multiple focal planes and processed into a single image using the manufacturer's 
maximum intensity projection routine. Transmitted light images and Cy5 images were merged 
using ImageJ. 
 
7.2.7 Zebrafish Assay 
All zebrafish work presented in this study has been performed in accordance with the UK legal 
requirements for the protection of animals used for experimental or other scientific research 
under the European Directive 2010/63/EU and the Animal (Scientific Procedures) Act 1986 
amended in 2013. All experiments were performed under the Home Office Project License 
70/8000 to EEP. Zebrafish welfare and husbandry were closely monitored by the MRC Human 
Genetics Unit Zebrafish Facility staff. 
Zebrafish (AB line) were raised and maintained as previously described303. Embryos were 
generated by natural pair-wise mating and were kept and handled for all experiments in E3 
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4). Manually 
dechorionated embryos were incubated between 24 hpf and 120 hpf304 in E3 medium 
containing either doxorubicin (Cambridge Biosciences) or prodrug 43 at the following 
concentrations (50 μM, 100 μM, 150 μM and 200 μM). Embryos were soaked in DMSO (0.1 %) 
and E3 media as a control. Embryos were kept in 6-well plates (15 embryos / well; 2 wells / 
condition) at 28.5 °C with dead embryos removed daily. Three experimental replicates were 
performed with n = 30 (15 x 2) embryos per condition and 2 replicates per condition. Pericardial 
edema and body surface was estimated using the area measurement tool in Fiji software. 
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Results were obtained by randomly taking > 10 embryos per condition, then determining 
cardiac/body ratios as previously described273. Statistical analyses were performed using 
Prism GraphPad5 software. Data were subjected to an ordinary one-way ANOVA test. All 
pictures (fluorescent images included) were taken at the same resolution and magnification 
using an AZ100 upright macroscope (Nikon) with a Plan Apochromat 2 x / 0.45 lens equipped 
with a Retiga Exi camera (Qimaging) camera. Images were analyzed and processed with 
Micro-Manager and Fiji software. Embryos were mounted laterally in 1.5 % Low Melting Point 
Agarose (Thermo Scientific) and kept in a 0.02 % w/v MS222 (Thermo scientific) solution in 
E3 medium and culled after imaging in an overdose of MS222 at the end of each experiment. 
 
7.2.8 In vivo / ex vivo Mouse Assays 
All murine experiments were approved by the Animal Welfare and Ethical Review Board at the 
University of Glasgow. The human prostate cancer cell line DU145 was purchased from ATCC, 
authenticated by LCG standards and grown in RPMI (Gibco) containing 10 % (v/v) serum 
supplement and 2 mM L-glutamine at a temperature of 37 C° with 5 % CO2. Nude athymic 
mice were purchased from XimBio. 
Intra-prostatic cancer cell implantation 
Mice were anesthetized by intraperitoneal injection of 0.5 mg / 1 g body weight NembutalR, 3 
µL / 1 g body weight of Ketamine/Xylazine/PBS mixture and subcutaneous Morphene was 
administered subcutaneously at the injection site. The mouse was then placed in an induction 
chamber with 2 % isoflurane / 98 % oxygen, and kept under anaesthesia through continuous 
nose cone flow during surgery. Mouse was positioned supine, and a midline incision provided 
access to the prostate gland. A 50 µL cell suspension containing 5 x 104 DU145 cells was 
injected into the prostate, and the round was appropriately closed with metal clips, before the 
mouse was transferred for recovering and monitoring. 
Intra-tumoural cancer cell implantation 
Mice identified as having produced tumours from initial cancer cell culture implantation were 
anaesthetized as above and positioned supine on a mounted platform within a Visual Sonics 
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Vevo 2100 Imaging Station. A solution of 2 mg 30 µm Pd0 beads in 25 µL was suspended in 
sterile PBS and injected into the mouse prostate using an insulin syringe/needle. Sterile 
surgical jelly was applied to the injection site, and the needle was appropriately positioned into 
the plane of ultrasound observation in the prostate tumour. Injection was completed over 30 
seconds, and was observed using the enhanced abdominal measurement package in the B-
mode setting. Once the needle was removed, mice were transferred for recovery and 
monitoring. 
Tumour resection  
Mice were euthanized according to an IACUC approved method (CO2 asphyxiation), and an 
abdominal incision provided access to the prostate. Prostate tumours were excised with 
scissors, photographed, sliced longitudinally using a rate brain slicer instrument into 1 mm 
sections and affixed to the bottom of a 24 well plate using 1 - 3 spots of tissue glue at the 
perimeter of each sample. Tumour slices were soaked in 2 mL of RPMI media containing 10 % 
(v/v) serum supplement and 2 mM L-glutamine, and 0.1 % (v/v) DMSO dissolving 100 uM of 
each treatment compound. Wells containing drug or prodrug were treated additionally with 2 
µL of DAPI. 
Fluorescent Imaging 
Imaging was performed using the NIKON A1R confocal microscope. Excitation and Emission; 
The 403.1 nm laser was used to excite DAPI, laser power was set at 3 %, emission was 
detected at 450 nm with PMT voltage set at 83 V and offset at -3 V. The 488 nm laser was 
used to excite Rhodamine 110, laser power set at 6 %. Emission was detected with at 525 nm 
with PMT voltage set at 102 V and offset at -4 V. The 560.8 nm laser was used to excite the 
Doxorubicin drug/prodrug, laser power set at 3 %. Emission was detected at 595 nm with PMT 
voltage set at 112 V and offset at -9. In addition DIC images were captured simultaneously. 




Scanning system and acquisition; The microscope stage is enclosed in a perspex “cage” which 
is heated to 37 °C and CO2 bubbled through water into the tissue enclosure to maintain tissue 
viability. The high resolution, non-resonant galvano scanner was used, with a scan size of 512 
x 512 pixels at a speed of 1 frame/second and no line averaging. All images were take over a 
period of 63 hrs with a image taken every 3 hours from t = 0 giving 22 time-points for each 
position. For each well/condition at least two positions were imaged each time, most 
wells/conditions had three positions imaged however a few tissue sections were too small to 
allow for this. The positions were kept exact overtime by use of the perfect focus function of 
the NIKON A1R, which ensures the focus is maintained at each position overtime. 
Standard vs. Xylene Free Fixation Method 
Each tissue slice was processed conventionally (with xylene) or by the xylene-free 
method along with the daily routine material at the Department of Histology at the 
Beatson Institute Glasgow. The processing methods were those in use at the respective 
laboratories at the time of the experimentation, and found in detail in the reference 
included305. All paraffin blocks were then sectioned by one person in a working day 
using one microtome, with the embedding process illustrated. Automatic tissue 
processors utilized during this experiment were those in routine use at the the Beatson 
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BIOORTHOGONAL COMPOUNDS AND METHODS [SUMMARY EXCERPT] 
 
Field of the Invention 
The present invention relates to bioorthogonal deprotection methods, and to compounds for 
use in such methods, including prodrug forms of active agents that can be converted to the 
active agent in situ by palladium catalysis. 
 
Background of the Invention 
 
Bioorthogonal chemistry  
As reported by Bertozzi, et al. in the early 2000's (Bertozzi, C. R. et al. Science, 2000, 287, 
2007-2010 and Bertozzi, C.R. et al. J. Am. Chem. Soc. 2004, 126, 15046-15047), artificial 
synthetic chemistry can be conducted in a biological environment without adverse biological 
effects using highly chemospecific reactive partners. Such reactions which proceed in a 
biological environment without adverse biological consequences are now commonly referred 
to as being "bioorthogonal".   
 
Initial bioorthogonal studies focussed on the development of labelling strategies based on the 
selective conjugation of two biologically-inert functional groups. This development has since 
enabled the real-time study of a wide range of biomolecules in their native environs (see, e.g. 
Bertozzi, C.R. Ace Chem Res. 2011, 44, 651-653).  
 
Transition metal catalysed reactions 
Transition metal catalysed reactions are an extremely powerful tool in organic synthesis as 
they provide chemospecific reaction profiles and facilitate a wide range of chemical 
transformations.  From a bioorthogonal synthetic perspective, it is therefore desirable to 
develop bioorthogonal transition metal catalysed reactions that can perform efficiently in a 
biological environment to provide the biosynthetic chemist with more synthetic flexibility. 
  
A large variety of transition metal catalysed reactions have been reported in the literature. 
However, there has been limited success in the application of such reactions in a biological 
environment. This is potentially due to a large number of reported reaction conditions being 
simply incompatible with a biological environment, e.g. requiring organic solvents and/or high 
temperatures, etc. For instance, the palladium-mediated cleavage of propargyl protecting 
groups from aryl amines requires biologically incompatible temperatures of at least 80 °C (see, 
e.g. Pal, M. et ot., Org. Lett. 2003, 5(3), 349-352). 
  
Certain non-biological transition metal-catalysed reactions have however been shown to be 
promising candidates for use in bioorthogonal synthesis (e.g. Unciti-Broceta, A. et al. Nature 
Protocols, 2012, 7, 1207-1218 and Meggers, E. et al. Chem Commun. 2013, 49, 1581-1587). 
Such bioorthogonal organometallic (BOOM) reactions are biocompatible and involve 
chemospecific transformations undertaken usually by synthetic materials and mediated by a 
non-biotic metal source as described below.  
 
In 2006, Meggers et al. described the application of a water-soluble ruthenium-based catalyst 
to carry out Allyl carbamate (Alloc) deprotection of bis-N,N'-allyloxycarbonyl rhodamine 110 
inside human cells without adversely affecting cell viability (Meggers, E. et al., Angew. Chem. 
Int. Ed. 2006, 45, 5645-5648).  The use of Pd0-functionalized microspheres as a 
heterogeneous catalyst medium for promoting BOOM chemistry inside cells has also been 
reported (Bradley, M. et al., Nat. Chem. 2011, 3, 239-243 and Unciti-Broceta, A. et al. Nature 
Protocols, 2012, 7, 1207-1218).  The palladium-functionalized microspheres were shown to 
be able to enter cells in vitro and catalyse Alloc deprotection and Suzuki-Miyaura cross-
coupling in the cell cytoplasm without any observed cytotoxicity.   
 
Biomedical applications 
In biomedicine, bioorthogonal deprotection methods could be utilised to transform a 
bioorthogonal chemical into a bioactive material.  Prodrugs, for example, are active agent 
precursors that are converted to the active agent following administration to a patient, typically 
by chemical rearrangement of the prodrug and/or by cleavage of a pro-moiety by natural 
biological metabolism.  Typically, prodrugs are based on active agents that have been 
protected with a cleavable protecting group or pro-moiety. By providing an active agent 
precursor that produces the active agent within the body, compounds can be produced that 
exhibit improved pharmacokinetic properties compared to the active drug, such as greater oral 
bioavailability and sustained release profiles.  
 
For safety and simplicity, it is desirable to provide prodrugs that do not exhibit biological activity 
themselves.  The activity profile of the prodrug is then entirely dependent on the metabolic 
conversion of the prodrug to the active agent, providing a greater degree of predictability of 
biological activity in vivo. 
 
Typically, prodrugs are converted to the respective active agents in the gut (for orally 
administered drugs), and/or by general cellular and/or plasma-based metabolic pathways. 
Conventional prodrugs are thus converted to the active agent in a non-bioselective manner, 
leading to general systemic exposure of the body cells to the active agent, which may result 
in undesirable side effects.  
 
It is therefore desirable from a toxicological perspective to be able to deliver active agents 
specifically to the relevant target/disease site, and to prevent the active agent acting on the 
rest of the body cells. 
 
Accordingly, it is one object of the present invention to provide a method of delivering an active 
agent to a target site without substantially exposing the body cells outside of the target site to 
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Bioorthogonal uncaging of a structurally diverse selection of cytotoxic precursors is
achieved by heterogeneous gold catalysis, allowing safe activation of therapeutics
by nonbiological chemical stimuli. In their Communication (DOI: 10.1002/
anie.201705609), J. Santamar!a and A. Unciti-Broceta et al. report gold-catalyzed
bioorthogonal uncaging of clinically approved anticancer drugs in cancer cell
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